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Abstract 
Birt Hogg Dubé (BHD) syndrome is an inherited cancer susceptibility syndrome 
characterised by the development of fibrofolliculomas on the face and upper torso, and 
increased risk of lung cysts, spontaneous pneumothorax and renal cancer.  The findings 
presented in this thesis advance knowledge into how the mutations in the FLCN gene 
cause the phenotypes associated with BHD syndrome, and provides novel insights into 
the functions of folliculin within the cell.  The results presented provide further evidence 
of the association between BHD syndrome and increased risk of colorectal cancer in a 
subset of BHD syndrome families, and suggest that this association appears restricted to 
those patients with an exon 11 mononucleotide tract mutation.  Evolutionary conservation 
analysis across the FLCN sequence suggests that pathogenic mutations could be expected 
throughout the gene, and identifies a region between codons 100-230 of increased 
evolutionary significance.  The experiments undertaken demonstrate a practical strategy 
for determining the pathogenicity of non-truncating folliculin variants in vitro, and 
indicate that loss of protein stability is the main mechanism of pathogenicity for the 
previously reported non-truncating mutations within FLCN.  Finally, this thesis reports 
the first identification of p0071 as a folliculin interacting protein.  Folliculin deficiency 
exerts a functional impact on previously reported p0071 functions inducing RhoA 
signalling upregulation, mitotic defects and disruption of cell junctions.  These results 
demonstrate the potential efficacy of using inhibitors downstream of RhoA as therapeutic 
targets in BHD tumours with dyregulated RhoA signaling, and provide novel directions 
for research into BHD syndrome.          
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Chapter 1 Introduction 
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1.1 The post-genome era for cancer research 
The field of cancer genetics has been transformed in the past decade.  In the time 
previous to the sequencing of the human genome in 2001, and the subsequent burst of 
next generation genetic technologies becoming available, the major field limiting factor 
was the identification of genetic variants responsible for disease phenotype.  The ‘next 
generation genetics’ undertaken within recent years has provided us with the tools to 
assess the complete diseased cancer genome in comparison with the normal genome, 
providing novel insights into the pathogenic landscape of cancer and cancer related 
syndromes.   
However, the promise of new targeted therapies, believed by many to accompany these 
technological advances, has fallen into the next stumbling block; the incredible 
complexity of the cancer genome.  The major field limiting factor is no longer that of 
variant identification, but in elucidating the precise role of these variants in the pathology 
of disease. 
It has been suggested that there are around 80 DNA mutations that alter amino acids in a 
typical cancer, but that less than 15 are likely to be responsible for driving tumour 
initiation and the progressive pathway to metastasis (Wood, et al., 2007).  Specific gene 
mutations are likely to occur infrequently, even among cancers of the same organ.  This 
paints a depressing picture of the impact of genetic advances in eventual translation to the 
clinic.  However, it appears logical for huge numbers of different proteins to become 
mutated in distinct cancer genomes, but that these alterations are likely involved in a far 
more manageable number of intracellular signalling pathways.  There are six well 
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characterised hallmarks of cancer; sustained proliferative signalling, evasion of growth 
suppressors, induction of angiogenesis, resistance of cell death, replicative immortality 
and the activation of invasive and metastatic pathways (Hanahan and Weinberg, 2011).  
Functioning within these hallmark capabilities of a cancer cell, it is believed that not 
more than 20 signalling pathways are deregulated by the enormous number of potential 
driving mutations identified in next generation cancer genomic studies (Wood, et al., 
2007).  This represents a far more manageable and realistic aim of tailoring therapy 
against the specific signalling pathways disrupted in a given cancer, rather than against 
individual genes. 
We are now therefore at the next stage in the road to personalised cancer therapy, namely 
the characterisation of the precise functional roles of genes mutated in cancer in the 
physiological setting, and the impact of their inactivation by mutation.  It is in elucidating 
the molecular and biochemical processes associated with cancer causing mutations, that 
the daunting power of next generation genetics can be harnessed, with hope for 
revolutionising the efficacy of targeted cancer therapeutics in the near future. 
I would argue that research into rare genetic cancer syndromes is a crucial component of 
these investigations.  Rare cancer syndromes provide unequivocal evidence of a specific 
gene (or number of genes) with causative involvement in a particular pathology, often 
also reflected in sporadic forms of the disease.  Research into the role of rare, syndrome 
associated proteins in pathogenesis of disease also informs potentially crucial aspects of 
cellular pathways, yet unidentified by traditional molecular biological methods and often 
overlooked by the broad brush of current genetic technologies (For example 
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identification of the role of the tumour suppressor protein VHL in regulation of hypoxia 
inducible factor (HIF) (Maxwell, et al., 1999)).      
This thesis investigates the link between mutations in the FLCN gene, and the 
relationship with the phenotypes observed in the rare cancer susceptibility disorder Birt 
Hogg Dubé Syndrome (BHD).  The study provides evidence of a potential genotype-
phenotype correlation for a specific BHD phenotype, the probable mechanism of 
pathogenicity of most pathogenic FLCN variants and a novel function for the folliculin 
protein in a potentially drug sensitive, cancer related signalling pathway. 
 
1.2 Genetics of familial renal cancers 
The following section discusses a selection of rare cancer syndromes (with particular 
attention to hereditary renal cancers), and the impact the basic research into these 
syndromes has had on general cancer biology and therapeutics.  The genetics of familial 
renal cancers is of strong relevance to this thesis, increased risk of renal cell carcinoma 
(RCC) being the most clinically problematic manifestation of BHD syndrome, and 
folliculin having a yet fully elucidated role in RCC pathogenesis. 
Annually, kidney cancers account for close to 150,000 new cancer diagnoses and 78,000 
cancer deaths worldwide (Maher, 2011).  The most common renal malignancy is renal 
cell carcinoma (RCC) representing around 95% of all renal tumours (Hagenkord, et al., 
2011).  75% of renal cancers are clear cell RCC (ccRCC), 10% papillary RCC (pRCC) 
and 5% chromophobe RCC (chRCC).  The remaining 5% of kidney cancers observed are 
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oncocytoma (OC), a benign neoplasm (Hagenkord, et al., 2011).  Only around 3% of 
renal malignancies are familial, however study into the familial cases has influenced and 
improved clinical practise for these at risk kindreds also providing important insights into 
sporadic forms of the disease.  Inherited RCC is characterised by an earlier age at 
diagnosis compared with sporadic cases and is often bilateral and multicentric (Maher, 
2011).  
While most patients presenting with renal epithelial tumours have a good prognosis, the 
clinical manifestations can often remain hidden in early stages of disease resulting in 
around 30% presenting with metastasis at the time of initial diagnosis (Sadler, et al., 
2007).  Treatment of advanced kidney cancer with traditional therapies has a far reduced 
prognosis, and it is hoped that investigation of Medelian single gene cancer syndromes 
such as Von-Hippel-Lindau (VHL), hereditary papillary renal cell carcinoma (HPRCC), 
hereditary leiomyomatosis renal cell carcinoma (HLRCC) and Birt Hogg Dubé (BHD) 
syndrome can provide the key to developing pathway-specific therapies for renal cell 
caricinoma (Rosner, et al., 2009). 
 
1.2.1 Classification of Renal Cell Carcinoma 
1.2.1.1 Clear Cell Renal Carcinoma (ccRCC) 
Clear cell renal cell caricinoma (ccRCC) is the most commonly presented renal cancer 
which accounts for around 75% of cases (Kovacs, et al., 1997).  It is thought to originate 
from the proximal tubule of the nephron.  ccRCC have a compact-alveolar or acinar cell 
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growth pattern.  Cells display a clear cytoplasm, commonly filled with glycogen and 
lipids which dissolve upon processing for histologic analysis (Hagenkord, et al., 2011).   
 
1.2.1.2 Papillary Renal Cell Carcinoma (pRCC) 
pRCCs are less frequently observed, making up around 10% of renal cell carcinomas, and 
are morphologically subdivided into small (type 1) and large (type 2) cell tumours.  Type 
1 pRCC are typically of lower stage and grade than type 2 tumours  (Hagenkord, et al., 
2011).  
 
1.2.1.3 Chromophobe Renal Cell Carcinoma (chRCC) 
chRCC comprises approximately 5% of renal epithelial tumours.  Tumour cells are large, 
polygonal and have prominent cell membranes and a clear cytoplasm (Stec, et al., 2009).   
 
1.2.1.4 Oncocytoma (OC) 
The final major group of renal tumours observed is oncocytoma, a benign neoplasm 
accounting for between 3 and 7% of all renal tumours.  Oncocytoma tumour cells display 
abundant, granular eosinophilic cytoplasms, reflecting an abundance of mitochondria 
(Hagenkord, et al., 2011).   
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Figure 1.1. Morphology of the most common renal epithelial tumours -  Adapted 
from (Hagenkord, et al., 2011)   
 
1.2.2 Von Hippel-Lindau disease  
Research into the Von Hippel-Lindau syndrome and elucidation of the functions of the 
VHL tumour suppressor gene function has provided important insights into the 
mechanism of pathogenesis of pVHL deficient renal cell carcinomas.  Discoveries made 
in the last decade are now at the stage of translation into informing therapeutic strategies 
Clear Cell RCC Papillary RCC 
Chromophobe RCC Oncocytoma 
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for treating ccRCC.  Understanding of the molecular mechanisms of the VHL protein 
(pVHL) is arguably a decade further forward than that of BHD syndrome, and thus VHL 
research provides an important template and realistic aim for the BHD syndrome field to 
achieve in the years to come.     
 
1.2.2.1 Genetics of VHL 
Von Hippel-Lindau is the most frequently identified familial RCC and is inherited in an 
autosomal dominant manner.  VHL has a prevalence of approximately 1 in 36,000 live 
births (Maher, et al., 1991).  Patients with VHL are at a greater than 70% lifetime risk of 
developing ccRCC, and also display increased risk of retinal and cerebral 
haemangioblastomas, phaeochromocytomas and pancreatic, renal and epididymal cysts 
(Maher, 2004). 
The cloning and characterisation of the VHL tumour suppressor gene (VHL) (Latif, et al., 
1993) has facilitated early diagnosis of VHL increasing the chances of successful 
treatment and allowing targeted surveillance of RCC and other VHL associated 
manifestations in mutation carriers.  The VHL gene is made up of 3 exons encoding two 
VHL proteins; a full length, 213 amino acid protein and a VHL protein lacking the first 
53 amino acids, both believed to have very similar functional effects (Iliopoulos, et al., 
1998).  A wide range of mutations in VHL have been reported in over 900 VHL disease 
kindreds identified to date (Nordstrom-O'Brien, et al., 2010).  The most common group 
of VHL mutations are deletions (0.5-250kb) that remove at least 1 VHL exon, mainly 
caused by Alu-mediated recombination (Franke, et al., 2009).  The remaining mutations 
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are either non-truncating missense changes or mutations predicted to truncate the 
encoded protein product (nonsense, frameshift and splicesite mutations) (Maher, et al., 
2011).  Complex genotype-phenotype correlations have been described for VHL; for 
example, VHL truncation mutations are associated with a low risk of 
phaeochromocytoma, which is conversely associated with certain missense mutations 
(Ong, et al., 2007).  While the nature of the mutation identified in a VHL patient may 
therefore provide an indication of the likely risk of a VHL manifestation, the inter-
familial variation in phenotype means there is little clinical impact on the management of 
VHL patients depending on mutation type.  However the genotype-phenotype 
correlations described have informed research investigating the mechanisms of 
tumourigenesis in patients with VHL mutations (Maher, 2011).   
The VHL gene is a classical tumour suppressor, with the identification of inactivation of 
the wildtype VHL allele in tumours from VHL patients.  Reintroduction of wildtype 
pVHL into a VHL-null RCC cell line inhibited the ability of the cells to form tumours in 
nude mice (Iliopoulos, et al., 1995).  The second hit can result from deletion of the 
wildtype VHL gene (3p loss is regularly reported in RCC), point mutations or 
hypermethylation of the VHL promoter region (Cheng, et al., 2009).  While some cases of 
non-VHL related familial ccRCC have been reported due to chromosomal translocations 
of 3p and BHD syndrome (see section 1.2.6), a large number of patients with a familial 
risk of ccRCC have no known genetic cause (Woodward, et al., 2008). 
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Sporadic ccRCCs also display somatic inactivation and loss resulting in the loss of both 
copies of VHL, often due to deletion of the short arm of chromosome 3 (81-100% of 
cases) (Hagenkord, et al., 2011; Receveur, et al., 2005). 
 
1.2.2.2 Function of the VHL protein pVHL 
In the years since the identification of pVHL as a tumour suppressor, the protein has been 
reported to have multiple functions and influence numerous cellular pathways.  The best 
defined function is the role of VHL in regulating proteolytic degredation of the α-subunit 
of the HIF-1 and HIF-2 transcription factors.  A number of hypoxia-inducible mRNAs 
are regulated by the HIF-1 and HIF-2, heterodimeric transcription factors.  Both HIF-1 
and HIF-2 consist of a constitutively expressed β subunit, and a degradable α subunit  
(Woodward and Maher, 2006). Under normoxic conditions, the HIF-α subunits are 
rapidly degraded by the VHL containing, ubiquitin ligase protein complex (Maxwell, et 
al., 1999).  Oxygen is essential for facilitating the binding of pVHL to HIF-α, thus in 
hypoxic conditions HIF-1 and HIF-2 are stabilised and activate between approximately 
100 and 200 target genes, many involved in angiogeneisis, apoptosis, proliferation and 
metabolism (Kaelin, 2009).    These effects are mirrored by the loss of active pVHL by 
either deletion or mutational inactivation (Maher, et al., 2011).  VHL tumours are highly 
vascular and display uncharacteristically high production of hypoxia-inducible mRNAs 
such as vascular endothelial growth factor (VEGF) (Woodward and Maher, 2006).  The 
regulation of HIF-α subunits by VHL is displayed in Figure 1.1. 
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.   
Figure 1.1 Regulation of HIF-α subunits by pVHL  
(Woodward and Maher, 2006) 
VHL mutation mimics the effects of hypoxia on HIF-α stabilisation, resulting in the 
activation of HIF target gene transcription.  A: In normoxia, pVHL binds to the HIF-α 
subunits causing polyubiquitination and subsequent proteasomal degredation.  B: When 
VHL is mutated and nonfunctional, HIF-α becomes stabilised and is able to bind HIF-β 
resulting in the activation of hypoxia inducible genes C:This is mimicked in hypoxia 
where two crucial proline residues in the HIF-α subunit are not hydroxylated, thus 
disrupting binding of pVHL to HIF-α.  Hence hypoxia inducible genes are again 
activated 
(VHL – Von-Hippel-Lindau gene,pVHL – Von-Hippel-Lindau tumour suppressor protein 
HIF – Hypoxia inducible factor)  
 [12] 
 
 
Research into the role of pVHL in renal tumourigenesis has provided the foundations for 
the development of targeted therapies for patients with advanced kidney cancer.  Surgical 
excision is curative in the majority of ccRCC cases, but close to 30% of patients without 
detectable metastasis at the time of surgery, develop them after nephrectomy (Motzer, et 
al., 1996).   
 
1.2.2.3 The impact of VHL research in the development of therapeutics for ccRCC 
Understanding the role of pVHL in mediating the expression of HIF target genes has 
provided the opportunity for the development of many drugs targeted specifically against 
HIF gene targets.  Sorafenib is a small-molecule protein kinase inhibitor that has more 
than one target (multikinase inhibitor) including the VEGF receptors, VEGFR-2 and 
VEGFR-3, and was approved in 2005 for treatment of metastatic ccRCC (Escudier, et al., 
2007a).  Sunitinib, an oral multikinase inhibitor that block activity of VEGF and PDGF 
receptors, has been associated with increased progression free survival and a 35% 
response rate in patients with advanced RCC over interferon.  Bevacizumab is a 
humanised, recombinant anti-VEGF antibody that binds and neutralises the activity of all 
types of VEGF-A isoforms (Presta, et al., 1997).  The most recent phase III trial of 
bevacizumab, examined treatment with either bevacizumab or placebo in combination 
with IFN-α in a study of 641 patients with metastatic clear cell RCC.  Bevacizumab 
treated patients had a significantly longer progression-free survival and higher objective 
tumour response rate, compared with placebo treated controls (Escudier, et al., 2007b).  
Pazopanib, another multiple kinase inhibitor, with a broader spectrum of targets including 
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all VEGFRs, was approved in 2009 (Sternberg, et al., 2010).  However despite the 
significant effects on progression free survival and quality of life associated with these 
drugs compared to placebo or interferon therapy, disease progression eventually occurs 
(Costa and Drabkin, 2007).  The challenge is now to identify the factors which lead to 
resistance to anti-VEGF therapy by identifying informative biomarkers so the patients 
where these therapies will be most effective can be selected (Hagenkord, et al., 2011).  
These initial targeted therapeutic approaches, directly spawning from research into VHL, 
demonstrate the efficacy of targeting the VHL pathway in VHL deficient RCCs and 
provide scope for improving targeted therapies for RCC in the future. 
 
1.2.3 Hereditary leiomyomatosis and renal cell cancer (HLRCC) 
HLRCC is a rare, autosomal dominant syndrome caused by germline mutations in the 
fumarate hydratase gene (FH).  Fumerate hydratase is a key enzyme functioning in the 
Krebs cycle catalysing the conversion from fumarate to malate (Tomlinson, et al., 2002).  
The disease is characterised by benign, cutaneous leiomyomas and also multiple uterine 
leiomyomas in women, developing at a young age (Tomlinson, et al., 2002).  Only a 
minority of FH mutation carriers develop RCC, typically papillary RCC or collecting 
duct tumours, however they are particularly aggressive and require surgery as soon as 
they are detected (Maher, 2011).  Age of onset is usually between 30-50 years of age, but 
cases as young as 11 years old have been described therefore renal screening from a 
young age is key to the clinical management of HLRCC patients (Morrison, et al., 2010). 
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1.2.4 Succinate dehydrogenase mutations and renal cancer 
Succinate dehydrogenase is a complex made up of SDHA, SDHB, SDHC and SDHD 
subunits, and is bound to the inner mitochondrial membrane where it plays a crucial role 
in cellular energy metabolism by functioning in the Krebs cycle and as mitochondrial 
complex 2 in the electron transport chain (Maher, 2011).  Germline SDHB mutations 
have been described in up to 5% of patients with inherited RCC susceptibility but no 
known causative syndrome (Ricketts, et al., 2008) with a lifetime risk of around 15% in 
SDHB mutation carriers (Ricketts, et al., 2010).  
Interestingly, renal tumours derived from patients with FH or SDHB mutations also show 
upregulation of HIF-1 and HIF-2.  This is hypothesised to be due to high levels of 
fumerate and succinate inhibiting hydroxylation of key proline residues on HIFα 
subunits.  This prevents the binding of pVHL and thus HIF-1 and HIF-2 are not targeted 
for degradation and can activate hypoxic response genes, mimicking the response of VHL 
gene mutations (Isaacs, et al., 2005; Selak, et al., 2005).  Therefore research into the 
molecular mechanisms of tumourigenesis in FH and SDHB mutation carriers has allowed 
the possibility of treating these patients with similar targeted therapies against HIF 
targets, described above in the treatment of metastatic RCC.    
   
1.2.5 Hereditary papillary RCC and germline MET mutations (HPRCC) 
HPRCC is a very rare (incidence of 1 in 10 million), autosomal dominant hereditary 
cancer syndrome.  It is caused by germline missense mutations in the c-MET proto-
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oncogene, first cloned in 1997 (Schmidt, et al., 1997).  Affected individuals are at an 
increased risk of developing bilateral, multifocal pRCC (Rosner, et al., 2009).  c-MET 
gain of function mutations promote cell proliferation, increase cell motility and neo-
vascularisation (Hagenkord, et al., 2011).  c-MET encodes the cell surface receptor for 
hepatocyte growth factor (HGF) and contains a tyrosine kinase domain (Bottaro, et al., 
1991).  Pathogenic mutations in c-MET constitutively activate the tyrosine kinase domain 
(Linehan, et al., 2009). Basic research into HPRCC has informed a number of approaches 
to target the MET pathway, which are currently in progress.  One approach is to target the 
tyrosine kinase domain of MET using tyrosin kinase inhibitors (TKI’s).  Another is to 
produce antibodies that target HGF, the ligand of the MET cell surface receptor or the 
extracellular domain of MET itself to inactivate its receptor function (Linehan, et al., 
2009).   
 c-MET mutations have also been reported in patients with sporadic type 1 pRCC 
(Linehan, et al., 2009).  Both type 1 and type 2 pRCC characteristically display whole 
chromosome gains, often trisomy 7 (including the HGF and MET genes) and trisomy 17 
(Kim, et al., 2009; Kovacs, et al., 1991).  
 
1.2.6 Familial RCC caused by constitutional chromosome 3 translocations 
Familial RCC can be caused by dominantly inherited chromosome 3 translocations, of 
which 12 have been described previously (Woodward, et al., 2010).  In some cases, the 
translocations have been shown to have breakpoints within candidate tumour suppressor 
genes (eg. LSAMP, FHIT, TRC8, and NORE1), that have been demonstrated to be 
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deregulated, mutated or epigenetically inactivated in various sporadic RCCs and RCC 
cell models (Chen, et al., 2003; Gemmill, et al., 2002; Gemmill, et al., 1998; Ohta, et al., 
1996).  In contrast, other RCC associated translocations have been shown not to disrupt 
candidate genes and hence a “three hit” model has been proposed in such cases.  In these 
cases it is proposed that the translocation is associated with chromosomal instability 
leading to loss of a derivative chromosome containing VHL, and somatic mutation of the 
remaining VHL allele (Schmidt, et al., 1995).    
 
1.2.7 Tuberous sclerosis complex  
Tuberous sclerosis complex (TSC) is a rare genetic disease caused by germline mutations 
in the TSC1 or TSC2 genes (1993; Borkowska, et al., 2011; van Slegtenhorst, et al., 
1997).  TSC can impact nearly every organ system in the body, with the most clinically 
problematic manifestations affecting the brain, heart, lung and kidney.  The tumours in 
TSC are classified as harmatomas (similarly to fibrofolliculomas in BHD syndrome), 
which are benign and consist of a disorganised mass of cells and tissues normally found 
in the area of the body where the growth occurs.  Regarding renal manifestations, TSC 
patients can develop RCC (in less than 3% of cases), and more usually benign 
angiomyolipoma in the kidney (~50% of cases) (Neuman and Henske, 2011).  TSC is of 
relevance to BHD syndrome research as the proteins encoded by TSC1 and TSC2 
(harmatin and tuberin respectively), function as part of the mammalian target of 
rapamycin (mTOR) signalling pathway (a pathway in which folliculin also functions), by 
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inhbiting Rheb upstream of mTORC1 (see sections 1.3.5.5 and 1.3.6.1) (Neuman and 
Henske, 2011).   
 
1.3 Birt Hogg Dubé syndrome 
The following section reviews the knowledge of Birt Hogg Dubé (BHD) syndrome as of 
2008, at the start of this project.  Research published in the in the last four years are 
discussed in relevant thesis chapters.  
 
1.3.1 Introduction 
BHD is an autosomal, dominantly inherited familial cancer syndrome characterised by 
the development of benign skin tumours on the face and upper torso, called 
fibrofolliculomas (Birt, et al., 1977).  The syndrome also causes pre-disposition to kidney 
tumours, with clear cell, chromophobe or oncocytic features, pulmonary cysts and 
spontaneous pneumothorax (collapsed lung) (Schmidt, et al., 2005).  The syndrome was 
first described in 1977 (Birt, et al., 1977), and the responsible gene, FLCN, identified in 
2002 (Nickerson, et al., 2002).  This marked a key discovery in BHD syndrome research, 
and has been the major driving force in studies trying to define the function of the FLCN 
encoded protein, folliculin, which has been shown to act as a tumour suppressor (Vocke, 
et al., 2005).  In 2008, close to 200 BHD syndrome families had been identified (Toro, et 
al., 2008), although the syndrome is likely under-diagnosed due to the wide variability of 
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clinical symptoms, and this number is likely to increase as clinicians become more 
familiar with BHD syndrome and it manifestations.  
 
1.3.2 Clinical manifestations of the Birt Hogg Dubé syndrome 
1.3.2.1 Fibrofolliculomas 
The appearance of benign hair follicule tumours on the head and upper torso, called 
fibrofolliculomas, are the characteristic phenotype of BHD syndrome, and develop after 
the age of 20.  However, an estimated 25% of BHD patients do not manifest skin lesions 
(Schmidt, et al., 2005; Toro, et al., 2008).  Fibrofolliculomas appear as dome-shaped, 
white pauples and are displayed in Figure 1.2.  The number of fibrofolliculomas a patient 
develops is highly variable, ranging from under 10 to over 100 (Toro, et al., 1999).     
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Figure 1.2 Fibrofolliculomas on the face of a BHD patient  
(Menko et al 2009) 
 
 
1.3.2.2 Kidney cancer 
Individuals with BHD syndrome are also at increased risk of developing RCC (Toro, et 
al., 1999; Zbar, et al., 2002).  The histology of BHD associated renal tumours is diverse, 
in contrast to the other familial kidney cancer syndromes described previously, for which 
a specific subtype of RCC was characteristic.  Clear cell, chromophobe and papillary 
renal cell carcinoma, as well as oncocytoma have been described in BHD syndrome 
patients.  Most common is a hybrid chromophobe and oncocytic renal tumour, occurring 
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in around half the cases of RCC in BHD syndrome (Pavlovich, et al., 2002).  
Chromophobe RCC presents in 33% of BHD patients, and renal oncocytoma in 5% 
(Hagenkord, et al., 2011).  It is therefore likely that folliculin might play a universal role 
in the pathogenesis of RCC.  Metastasis has also been reported in BHD renal tumours, all 
of papillary or clear cell histology (Claessens, et al., 2010b; Pavlovich, et al., 2005; Toro, 
et al., 2008).   
The risk of developing kidney cancer in BHD patients is believed to be around seven-
times increased compared with the general population (Zbar, et al., 2002). In one study, 
34 of 124 (27%) individuals with BHD syndrome has renal tumours at a mean age of 
50.4 years (Pavlovich, et al., 2005), and in another, 30 of 89 (34%) BHD patients had 
developed kidney tumours (Toro, et al., 2008).  BHD patients often present bilateral renal 
tumours (60% reported frequency) (Pavlovich, et al., 2002).  The earliest reported age of 
kidney tumour diagnosis in BHD patients is 20 years (Khoo, et al., 2002).     
Folliculin loss is rare in sporadic RCCs (da Silva, et al., 2003; Khoo, et al., 2003) when 
compared with the frequency of VHL loss in sporadic ccRCC for example.  However a 
low frequency of nonsense, frameshift and splice site mutations have been identified in 
sporadic chromophobe RCC and oncocytoma (Gad, et al., 2007).  It is therefore likely 
that disruption of folliculin function does contribute to renal carcinogenesis, and that in 
some cases where FLCN is not mutated, folliculin related pathways are likely to be 
affected.        
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1.3.2.3 Spontaneous pneumothorax and pulmonary cysts 
The presence of lung cysts in BHD patients was identified in 1999, and is now known to 
be the most common BHD manifestation, observed in up to 90% of patients (Zbar, et al., 
2002).  The same study reported a 50-times increase in the risk of pneumothorax in BHD 
patients, likely related to the presence of lung cysts (Toro, et al., 2007; Zbar, et al., 2002).  
Following an initial primary spontaneous pneumothorax (PSP), subsequent recurrent 
events are more common (Toro, et al., 2007).  Pneumothorax has been reported to 
manifest in BHD patients as young as 7 and 16 years of age (Bessis, et al., 2006; Gunji, et 
al., 2007).  
Patients with multiple pulmonary cysts and recurrent pneumothorax but no other BHD 
manifestations, have been found to harbour FLCN mutations (Gunji, et al., 2007), 
suggesting BHD syndrome should be considered in cases of multiple lung cysts even 
when other BHD symptoms are not present. 
FLCN mutations have also been identified in patients with dominantly inherited PSP.  A 
genome wide scan of a Finnish family with a dominant risk of PSP identified 17p11 as 
the candidate region.  A 4-bp deletion in FLCN was identified, which was associated with 
bullous lung lesions and PSP displaying 100% penetrance (Painter, et al., 2005).  While 
this family presented no other BHD associated phenotypes, the close connection between 
these conditions means such families are also monitored for renal/skin manifestations 
(Painter, et al., 2005).     
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1.3.2.4 Other clinical findings 
As well as the widely accepted BHD phenotypes affecting the lungs, kidneys and skin, a 
small number of other clinical manifestations have been suggested to be associated with 
BHD syndrome.   
Early studies suggested an increased risk of colorectal neoplasia to be part of the BHD 
phenotype, although this association has been subject to much debate (Khoo, et al., 2002; 
Rongioletti, et al., 1989; Zbar, et al., 2002).  The risk of colorectal cancer and polyps in 
BHD patients is further investigated in Chapter 3. 
BHD patients have also been reported with a range of tumours, both benign and 
malignant, however so far no causative association between BHD syndrome and 
increased risk of any tumour (but RCC) has been proven.  These cases include the benign 
tumours, parotid-gland adenoma and oncocytoma, colorectal polyp and adenoma, 
multinodular goiter, neural-tissue tumour, connective-tissue nevus, trichoblastoma, focal-
cutaneous mucinosis, lipoma, cutaneous leiomyoma and angiolipoma (Menko, et al., 
2009).  Malignant tumours include colorectal cancer, breast cancer tonisillar cancer, 
sarcoma of the leg, lung cancer, melanoma, dermatofibrosarcoma protuberans, basal and 
squamous-cell skin cancer and cutaneous leiomyosarcoma (Menko, et al., 2009).  
However it is likely that most of these cases represent sporadic cancers occurring by 
chance in BHD patients at the time of presentation, and further work is required to 
determine which, if any of these are causally linked to BHD syndrome.  As well as these 
cancerous reports in BHD patients, a number of other abornormalites have been reported 
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including congenital cystic lung soft tissue mass, chorioretinopathy, internal carotid-
artery aplasia and congenital chest deformation (Menko, et al., 2009).      
 
1.3.3 FLCN and the molecular genetics of BHD syndrome  
The field of BHD syndrome research was transformed with the identification of the 
causative gene FLCN in 2002 (Nickerson, et al., 2002).  This discovery has provided the 
basis for all subsequent genetic and functional investigations into the syndrome in the 
past six years. 
 
1.3.3.1 The mapping of FLCN 
The BHD gene was mapped to the short arm of chromosome 17(17p11.2) by Khoo et al. 
(2001) and Schmidt et al. (2001).  Khoo et al. (2001) used a genome wide scan on 17 
individuals of a Swedish pedigree to identify the susceptibility locus of BHD.  Using two-
point LOD score linkage analysis, the group found a maximum LOD score between the 
disease locus and the microsatellite marker D1781852.  Haplotype analysis showed a 
recombination event between D1781852 and D1781824, thus providing evidence for 
BHD to be located within a 35.5cM region on chromosome 17p12-q11.2 (Khoo, et al., 
2001).  
Schmidt et al. (2001) performed an initial genome wide scan on a three-generation family 
with 18 BHD affected members and, by linkage analysis, located the BHD locus to 
 [24] 
 
 
region 17p.  Further linkage analysis on another 8 BHD affected families produced a 
maximum LOD score of 16.06 for the most informative marker D17S2196.  Haplotype 
analysis was used to narrow the minimal region of non-recombination to the location 
between D17S1857 and D17S805 (less than 4cM), which is within chromosomal band 
17p11.2 (Schmidt, et al., 2001). 
Subsequently Nickerson et al. (2002) used recombination mapping to, further narrow the 
BHD region to a 700kb section on 17p11.2.  Within this region, the authors identified a 
novel candidate gene harbouring protein truncating mutations in BHD syndrome patients, 
named BHD (now named FLCN) (Nickerson, et al., 2002). 
 
1.3.3.2 FLCN mutation spectrum 
The FLCN gene is made up of 14 exons, with exons 4 to 14 being translated to the 
folliculin protein (Nickerson, et al., 2002).  Since the cloning of the FLCN gene in 2002, 
numerous FLCN mutations have been identified, the vast majority of which prematurely 
truncate the protein product (Schmidt, et al., 2005).  A mutation hotspot has been 
identified in the mononucleotide tract of 8 cytosine residues, in exon 11, with cytosine 
insertion or deletion thought to be responsible for close to 50% of the mutations within 
FLCN (Schmidt, et al., 2005).    An in depth discussion and experimental investigation of 
the effects of FLCN mutations on folliculin function is located in Chapter 4. 
The two-hit hypothesis proposed by Alfred G. Knudson suggested that two mutational 
events (within tumour suppressor genes) were necessary to cause cancer.  In the 
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hereditary form, the initial mutation is inherited in the germline and the second occurs in 
somatic cells, thus increasing the risk of cancer in that individual.  In the sporadic form, 
both mutations must occur in the same somatic cell thus reducing the risk of a specific 
cancer (Knudson, 1971).  BHD syndrome patients harbour a mutation in one copy of the 
FLCN gene, inherited through the germline.  Somatic mutations in the second, wild-type 
(WT) copy of the FLCN gene, or a loss of the WT region has been identified in the renal 
tumours of BHD patients, hence suggesting a role for FLCN as a tumour suppressor 
(Vocke, et al., 2005).  However the role of FLCN in the skin phenotype seems to be more 
complex.  In a study of five BHD patients, no evidence of loss of heterozygosity (LOH) 
or somatic mutations were found in fibrofolliculomas suggesting haplo-insufficiency may 
be enough to cause the formation of skin lesions (van Steensel, et al., 2007).  In 
agreement, FLCN mRNA has also been reported to be strongly expressed in 
fibrofolliculomas (Warren, et al., 2004).         
   
1.3.4 Functions and associations of the folliculin protein 
1.3.4.1 Folliculin 
The FLCN encoded protein produces a 579 amino acid protein, folliculin (FLCN), with a 
molecular weight of 64kDa (Nickerson, et al., 2002).  The protein has no major 
homology to any other human protein, but is strongly evolutionarily conserved (Menko, 
et al., 2009).  Two additional folliculin isoforms are predicted, which lack the C-terminal 
(342 and 197 encoded amino acids respectively) (Nickerson, et al., 2002).  FLCN mRNA 
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expression was investigated by fluorescent in situ hybridisation techniques, displaying 
expression in a number of tissues including the skin, the kidney and lung.  As 
aforementioned, fibrofolliculomas displayed strong FLCN mRNA expression, however 
mRNA was severely reduced in renal tumours derived from a patient with VHL disease, 
hereditary pRCC and BHD syndrome (regardless of tumour histology) (Warren, et al., 
2004).   
 
1.3.4.2 Folliculin interacting proteins 
The folliculin protein has no known function, and the amino acid sequence of folliculin 
provides few clues as to potential function, with no transmembrane domains or organelle 
localisation signals identified with the folliculin sequence (Warren, et al., 2004).  The 
identification of interacting proteins is likely to provide important insights into the 
function of the folliculin protein.  Thus far, only two folliculin interacting proteins have 
been identified, FNIP1 and FNIP2/FNIPL, suggesting a link between folliculin and the 
mTOR signalling pathway (Baba, et al., 2006; Hasumi, et al., 2008; Takagi, et al., 2008).  
 
FNIP1/AMPK 
A fundamental study by Baba et al. (2006) made a number of key discoveries and the 
first insights into the role of folliculin in the cell.  The first protein found to interact with 
folliculin was FNIP1, identified by immunoprecipitation and mass spectrometry.  FNIP1 
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also binds to AMP-activated protein kinase (AMPK), a negative regulator of mammalian 
target of rapamycin (mTOR) signalling with a role in energy sensing (Baba, et al., 2006). 
The proteins were shown to interact in vitro by co-immunoprecipitation, and also 
displayed a co-localised, reticular pattern by immunofluorescence of co-expressed 
folliculin and FNIP1 in Hela Cells.  Folliculin also showed a strong nuclear signal 
whereas FNIP1 was absent from the nucleus (Baba, et al., 2006).  
 A functional relationship between folliculin and AMPK/mTOR signalling was 
demonstrated by folliculin and FNIP1 being phosphorylated by AMPK.  Folliculin 
phosphorylation was diminished by rapamycin and amino acid starvation suggesting 
folliculin may act downstream of mTOR and AMPK.  Folliculin phosphorylation was 
also dependent on FNIP1 expression levels, leading the authors to hypothesise that 
FNIP1 may act as a scaffold regulator of folliculin (Baba, et al., 2006).  Folliuclin 
phosphorylation was reported to be both AMPK and mTOR dependent, however the 
functional relevance of folliculin phosphorylation is yet to be elucidated.  In an 
investigation into the effects of FLCN knockdown on mTOR activation, the authors 
found that under amino-acid starvation, phosphorylation of ribosomal protein S6 kinase 
beta-1 (S6K1) (Thr389) was suppressed in BHD null cells but not in cells where 
folliculin had been stably re-expressed.  Conversely, under serum starved conditions, 
pS6K1 was upregulated in BHD null cells but not those in which folliculin was re-
expressed (Baba, et al., 2006).  Further work into the role of folliculin in mTOR 
signalling is discussed in sections 1.3.6.1 and 6.2.3.  
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FNIP2/FNIPL 
Two years after the identification of FNIP1 as a folliculin binding protein, a second 
closely related protein, FNIP2 (also reported as FNIPL) was identified by sequence 
homology (Hasumi, et al., 2008; Takagi, et al., 2008).  FNIP2 is homologous to FNIP1 
with a 49% identity and 74% similarity (Hasumi, et al., 2008).  The protein was identified 
by bioinformatic searching of proteins closely related to FNIP1.  Similarly to FNIP1, 
FNIP2 is reasonably conserved throughout evolution, although it contains no known 
functional domains.  Like FNIP1, folliculin and FNIP2 co-localise in a reticular pattern in 
the cytoplasm but not in the nucleus (Takagi, et al., 2008).  By subcellular fractionation 
analysis in Hela cells, FNIP1 and FNIP2 were enriched in the membrane fraction, 
similarly to folliculin.  Interestingly, folliculin was also significantly located in the 
cytoskeletal fraction (Takagi, et al., 2008).  Takagi et al. (2008) reported folliculin/FNIP1 
and folliculin/FNIP2 to positively regulate S6K1 phosphorylation, with phosphorylation 
of S6K and mTOR reduced when FNIP1 or FNIP2 was knocked down by siRNA 
(Takagi, et al., 2008).    
Studies into the binding of FNIP1 and FNIP2 to folliculin have also mapped the region of 
interaction by immunoprecipitation of various deletion constructs of each protein.  The 
C-terminus of folliculin is required for binding to FNIP1, with deletion of 63 amino acids 
from the C-terminus enough to disrupt FNIP1 binding.  The full FNIP1 protein is 
required for optimal binding to folliculin, although there is still (albeit severely reduced) 
interaction when the first 300 amino acids in FNIP1 are deleted.  This suggests that 
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optimal folliculin-FNIP1 interaction requires at least amino acids 300-1166 of FNIP1, 
likely required to form proper conformation of the protein (Baba, et al., 2006).  
In respect of FNIP2-folliculin interaction, Takagi et al. (2008) reported that the C 
terminal of FNIP2 was required for folliculin binding, with deletion of 203 amino acids 
(of 1114) from the C terminal sufficient to disrupt FLCN-FNIP2 binding (Takagi, et al., 
2008).  The authors also reported that, like its interaction with FNIP1, the C terminus of 
folliculin was required for binding to FNIP2, with deletion of 217 amino acids from the C 
terminus enough to disrupt folliculin-FNIP2 binding (Takagi, et al., 2008).  This finding 
was confirmed by Hasumi et al (2008), who reported that deletion of 63 amino acids 
from the folliculin C-terminus disrupted FNIP1 binding (Hasumi, et al., 2008).  It is of 
interest that the C-terminal region of folliculin is required for FNIP1/FNIP2 binding as 
this is a region lost as a result of the vast majority of FLCN mutations, which prematurely 
truncate the protein.  However it is currently unclear whether nonsense mediated decay 
mechanisms would result in absence of the full FLCN product in these cases, or produce 
a translated truncated protein.  A broad schematic of the regions of binding for folliculin 
to FNIP1 and FNIP2 is displayed below. 
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Figure 1.3 Schematic summary of FLCN-FNIP1/2 binding regions 
 
 
 
 
1.3.5  Animal models of BHD syndrome 
1.3.5.1 BHD syndrome mouse models 
At the start of this project, two mouse models of BHD syndrome had been reported 
(Baba, et al., 2008; Chen, et al., 2008).  Homozygous deletion of FLCN is embryonically 
lethal to the mouse, mutants dying between 3.5 and 8.5 days post conception (Chen, et 
al., 2008), therefore two conditional FLCN-knockout mouse were developed.  The first 
was created using a cre-lox system, facilitating inactivation of FLCN specifically in the 
kidney by deleting exons 3 and 4 (Chen, et al., 2008).  The second also used cre 
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technology to create conditional knockout in the kidney by deleting FLCN exon 7 (Baba, 
et al., 2008). 
Baba et al. (2008) reported that BHD-knockout mice developed large, polycystic kidneys 
and died from renal failure at age 3 weeks (Baba, et al., 2008).  The same results were 
confirmed in the mouse model developed by Chen et al. (2008).  Both studies also 
reported up-regulation of mTOR signalling in the knockout mice, describing that 
rapamycin (mTOR inhibitor) had an ameliorating effect on kidney phenotype and 
extended mouse survival (Baba, et al., 2008; Chen, et al., 2008).  Staining of BHD-
inactivated kidneys also displayed elevated levels of phospho-c-Raf (Ser338), and 
downstream targets MEK1/2 and Erk1/2 in one study (Baba, et al., 2008).  
    
1.3.5.2 Rat model of BHD syndrome 
The ‘Nihon’ rat model of BHD is a naturally occurring model of mendelian, dominantly 
inherited, renal carcinoma susceptibility (Okimoto, et al., 2004a).  It was found to 
harbour a germline frameshift mutation in the rat FLCN gene, and is thus an excellent 
model for studying BHD syndrome in the rat (Okimoto, et al., 2004b).  Similar to the 
mouse models described, homozygous mutant rats are embryonically lethal; however in 
heterozygotes renal carcinomas develop at as early as 3 weeks of age.  These carcinomas 
showed LOH at the FLCN locus or second hit mutation fitting the Knudson two hit model 
of FLCN as a tumour suppressor and confirming inactivation of FLCN as responsible for 
the “Nihon rat” phenotype (Okimoto, et al., 2004b).  Further characterisation of the role 
of FLCN as a tumour suppressor in the Nihon rat was provided by Togashi et al. (2006), 
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who reported rescue of embryonic lethality in homozygote and suppression of renal 
carcinogenesis in heterozygote rats upon introduction of wildtype FLCN (Togashi, et al., 
2006).  
 
1.3.5.3 Canine model of BHD syndrome 
First described in 1985, hereditary multifocal renal cystadenocarcinoma and nodular 
dermatofibrosis (RCND) is a kidney cancer susceptibility syndrome occurring naturally 
in dogs.  The syndrome is characterised by nodules within the skin and bilateral, 
multifocal kidney tumours (Lium and Moe, 1985), displaying similar phenotype to BHD 
syndrome in humans.  A causative FLCN mutation (H255R) was identified in exon 7 of 
canine FLCN in 2003, and similar to the rat and mouse models, homozygous inactivation 
of FLCN was embryonically lethal (Lingaas, et al., 2003).  LOH was subsequently 
identified in renal cysts and tumours in both juvenile and adult dogs confirming the 
tumour suppressor function of FLCN in this BHD model (Bonsdorff, et al., 2008; 
Bonsdorff, et al., 2009). 
 
1.3.5.4 Drosophila model of BHD syndrome 
BHD syndrome has also been investigated in the fly model of Drosophila melanogaster.  
RNA interference was used to decrease the expression of the FLCN homologue in the fly 
(DBHD).  DBHD was demonstrated to be required for male germline stem cell 
maintenance in the testis of the fly (Singh, et al., 2006).  Reducing the DBHD activity in 
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the fly testis caused a loss of germline stem cells.  DBHD was also linked to JAK/STAT 
and Decapentaplegic (DPP) signalling discussed in section 1.3.6.3.  
 
1.3.5.5 Yeast model of BHD syndrome 
The FLCN homologue in Schizosaccharomyces pombe (fission yeast) SPBC24C6.08c
+
 
(BHD+, now called LST7), was identified in 2007 (van Slegtenhorst, et al., 2007).  
Homologous recombination was used to generate a strain of yeast in which BHD+ had 
been deleted.  The authors were interested to see if knocking out BHD+ in S. Pombe 
produced similar effects to knocking down the tuberous sclerosis complex (TSC) 
homologues in yeast.  TSC shares many clinical hallmarks of BHD in humans including 
skin hamartomas, lung cysts, pneumothorax and renal tumours, and it is thus likely they 
function in similar pathways.  Mutations in the two TSC genes, TSC1 and TSC2, inhibit 
mTOR via the small GTPase RHEB, a mechanism conserved in S.Pombe (van 
Slegtenhorst, et al., 2007).  Interestingly, expression profiling in the BHD deleted strain 
showed an opposite profile compared to TSC1/2 deleted strains, and the authors 
concluded that BHD+ activates TOR2 (homologous mTOR protein in yeast) (van 
Slegtenhorst, et al., 2007).  If this finding is replicated in human or mouse tissue, it would 
contrast with the studies of Chen et al. (2008) and Baba et al. (2008), who found 
folliculin loss to upregulate mTOR signalling (Baba, et al., 2008; Chen, et al., 2008).   
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1.3.6 FLCN signalling pathways 
1.3.6.1 mTOR signalling, cancer and folliculin 
In the non-cancerous cell, mTOR signalling is involved in regulating cell growth in 
response to extracellular growth factors and nutrients (Sabatini, 2006).  mTOR functions 
in two complexes; the first and best understood, mTOR complex 1 (mTORC1), is a 
protein kinase which consists of the mTOR catalytic subunit and raptor and mLST8.  The 
role of mTORC1 in controlling cell growth is achieved through modulating protein 
synthesis, autophagy and ribosome biogenesis (Sabatini, 2006).  mTORC1 is activated in 
a high proportion of cancers.  The TSC1-TSC2 (tuberous sclerosis 1-tuberin) tumour 
suppressor complex has been found to be the key upstream, negative regulator of 
mTORC1 (Gao, et al., 2002; Tapon, et al., 2001).  This complex is a GTP-ase activating 
protein for the small GTPase Rheb which functions in activating mTORC1 (Garami, et 
al., 2003; Tee, et al., 2003).  Inhibition of TSC1-TSC2 is responsible for the deregulation 
of mTOR signalling that occurs when cancer cells lose PTEN, LKB1, NF1 or p53 tumour 
suppressors (Sabatini, 2006), for example the loss if LKB1 suppresses AMPK, which is 
required for mediating the phosphorylation, and hence activation, of TSC1-TSC2 (Inoki, 
et al., 2003) see Figure 1.4.   
mTORC1 controls cell growth through various downstream effectors, including S6K1  
and 4EBP1 (eukaryotic translation initiation factor 4E binding protein 1) (Hay and 
Sonenberg, 2004).  Upregulation of S6K1 promotes protein synthesis, but also represses 
the PI3K-Akt pathway by inhibiting the cellular levels of IRS1 (insulin receptor substrate 
1) and IRS2, creating cross-talk between the two mTOR complexes (Shah, et al., 2004). 
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mTOR complex 2 (mTORC2) is less well characterised, but is known to contain mLST8, 
rictor and mSin1 as well at mTOR (Sabatini, 2006).  The complex functions as part of the 
PI3K-Akt signalling pathway, directly phosphorylating AKT (Sarbassov, et al., 2005).  
Normally active AKT regulates cell survival, metabolism and proliferation by 
phosphorylating targets such as MDM2 and GSK3β (Vivanco and Sawyers, 2002).  
Activation of AKT in the cancer setting is thought responsible for cellular transformation 
and apoptotic resistance by promoting growth, proliferation and survival while also 
inhibiting apoptotic pathways (Guertin and Sabatini, 2005). 
As mentioned previously, folliculin has been linked to the regulation of mTOR signalling 
through its interaction with FNIP1/FNIP2 and indirect interaction with AMPK (Baba, et 
al., 2006; Takagi, et al., 2008).  Although the exact role of folliculin in mTOR signalling 
is yet unknown, kidney specific knockout of folliculin in mice resulted in an increase in 
phosphorylated S6R (Baba, et al., 2008; Chen, et al., 2008), suggesting a role for 
folliculin in the downregulation of mTORC1 signalling.  Activation of the PI3K-AKT-
mTOR pathway was also observed in folliculin null kidneys, suggesting a role for 
folliculin in the mTORC2 branch of mTOR signalling (Baba, et al., 2008).   However, the 
yeast model of BHD and different cell models showed opposite results, with mTOR 
signalling reported as being downregulated in the absence of folliculin (Takagi, et al., 
2008; van Slegtenhorst, et al., 2007).   Recent insights published during the period of 
current research, into the potential role of folliculin in mTOR signalling suggest a 
complex, context dependent role and are discussed in full in the discussion sections of 
this thesis.  The predicted position of folliculin in the context of the mTORC1 and 
mTORC2 pathways is displayed in Figure 1.4. 
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Figure 1.4 Schematic diagram of mTOR/PI3K signaling detailing possible position of FLCN 
– adapted from (Sabatini, 2006)
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1.3.6.2 Raf-MEK-Erk signalling 
The Raf-MEK-Erk signalling cascade relays signals from cell surface receptors through 
the RAS GTPase switch, to transcription factors, thus regulating gene expression 
(Schubbert, et al., 2007).  The pathway functions in regulating cell proliferation and is 
frequently activated in clinical cancers (Roberts and Der, 2007).  Activation of Raf-
MEK-Erk is also a marker of poor prognosis (McCubrey, et al., 2007).  The mouse model 
of BHD syndrome created by Baba et al. (2008) displayed upregulation of Raf-MEK-Erk 
signalling in folliculin null kidneys.  The authors hypothesised that, as PI3K-AKT-mTOR 
was also activated, folliculin loss might be activating a common upstream effector of 
Raf-MEK-Erk and PI3K-AKT-mTOR (Baba, et al., 2008).   
 
1.3.6.3 JAK/STAT signalling 
Singh et al. (2006) demonstrated that in Drosophila Melanogaster, the folliculin 
homologue DBHD regulates male germline stem cell maintenance and functions 
downstream, or in parallel with the JAK/STAT and Dpp signal transduction pathways.  
The authors hypothesised that this may be due to both signalling pathways synergising on 
downstream targets such as DBHD (Singh, et al., 2006).  The JAK/STAT (Janus 
kinase/signal transducers and activators of transcription) pathway is a critical signalling 
mechanism for a wide range of growth factors and cytokines, and stimulates cell 
proliferation, differentiation, migration and apoptosis (Rawlings, et al., 2004).  
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Constitutive activation of JAK/STAT signalling has been linked to several cancers 
(Valentino and Pierre, 2006).  However, links to this pathway have currently only been 
described in flies, and further research is required to identify possible relevance for the 
human DBHD homologue.   
The studies described above provide a summary of some of the signalling pathways 
affected by folliculin loss, and give some clues as to the function of the folliculin protein.  
However, it is likely that there are numerous facets of folliculin function yet to be 
elucidated, and it can be argued that the causal link between FLCN mutation and BHD 
syndrome phenotype has yet to be identified.  Further investigation into the role of this 
protein in the cell is required, with the ultimate aim to be able to target specific folliculin 
related pathways therapeutically when folliculin is mutated and non-functional.  
 
1.4 Summary and thesis objectives 
Research into rare hereditary renal cancer syndromes has greatly influenced the 
understanding and treatment of renal cell carcinoma.  Birt Hogg Dubé syndrome is 
caused by germline mutations in the FLCN gene, and is characterised by the development 
of benign hair follicule tumours, lung cysts and renal cancer.  Other manifestations have 
been described, including the possible increased risk of colorectal cancer in BHD 
patients.  This association is investigated in Chapter 3. 
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Most FLCN mutations prematurely truncate the encoded protein, although a small 
number of non-truncating mutants have been described.  The mechanism of pathogenicity 
of these mutants is currently unknown, and is investigated in Chapter 4. 
The function of the folliculin protein is currently not well elucidated. Studies have linked 
folliculin to mTOR signalling through its association with FNIP1 and FNIP2 although a 
reliable functional consequence of these associations is currently unclear.  It is possible 
that folliculin may bind to other proteins, exerting functional impact on yet unidentified 
pathways.  The identification of a novel folliculin binding partner and signalling pathway 
is described in 0.   
The identification of FLCN mutations in BHD syndrome patients, and loss of 
heterozygosity in BHD renal tumours highlights an important role for folliculin loss in 
renal tumourigenesis.  The ultimate aim of research into BHD syndrome is to identify the 
physiological functions of the folliculin protein and how loss of this protein contributes to 
renal tumourigenesis.  Elucidation of these functions may reveal mechanisms for 
potential therapeutics for BHD syndrome patients and could also provide important 
insights into the pathways deregulated in sporadic renal cancer.    
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Chapter 2 Materials and Methods 
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2.1  Sequencing analysis 
2.1.1 DNA samples 
2.1.2 Polymerase chain reaction 
The Polymerase Chain Reaction (PCR) was used to amplify all coding exons and 
intron/exon boundaries in FLCN.  Ten primer pairs were designed for the 11 coding 
exons of FLCN (exons 12 and 13 are encompassed by one reaction) using primer 3 
software (Rozen and Skaletsky, 2000).  Primers used for amplifying the mononucleotide 
tract sequences in IGF2R, TGFBR2 and MSH6 were designed in a similar way.  The 
primers used are given in Table 2.3 and Table 2.4 (Alta Bioscience) and reagents and 
volumes for each reaction are displayed in Table 2.2 (Roche).  A negative control 
reaction containing water in replacement of DNA was run in parallel for each PCR to 
confirm no DNA contamination in the PCR reagents.  The thermal cycling profile of the 
PCR reaction is given in Table 2.1. 
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Step Temperature  Time Number of Cycles 
Initial Melting 
 
95
o
C 4 minutes 1 
Melting 95
o
C 30 seconds  
35 Annealing 58
o
C 30 seconds 
Extension 72
o
C 45 seconds 
 
Final Extension 
 
72
o
C 
 
7 minutes 
 
1 
Table 2.1 PCR conditions for FLCN exon amplification 
 
The extension time was calculated based on the length of PCR product and rate of 
extension of Taq Polymerase. 
 
Reagent Volume (µl) 
Faststart Taq DNA Polymerase (5 units/µl) 0.2 
10x PCR buffer  5 
MgCl2 (2nM) 4 
dNTP mix (25 mM per dNTP) 1 
Template DNA (100 ng/µl) 1 
Forward Primer (20 pmol/µl) 1 
Reverse Primer (20 pmol/µl) 1 
Nuclease Free Water 36.8 
Total 50 
Table 2.2 PCR reagents and volumes 
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Exon Forward Primer (5’-3’) Reverse Primer (3’-5’) 
4 GCAGGAAGTCCATGGCACC CCTGAGAAGCAGTCTGTGTC 
5 GCTTGAGTTTTCCGAGCTCAG CCTGTGCTGTGCTGATCTGC 
6 GCTGATTTGTGCCAGCTGAC GCAAGCAAACACGGCTAAGG 
7 GGACTGATCCTCCAGGAGTC GCAAGCAAACACGGCTAAGG 
8 GCTGGGTGAGCGTCAGGTTTGC CGTTCTGGGCTGATTCAGAGC 
9 CCATGAAGTATCTTGGGCTG GCTGTCAGTCACTTCCTGC 
10 CGCCTCCCTGAGAAGATAAG CACAGCGGTTCTGTGCTG 
11 ACAAGCTGGTGTGTGACTGG TCCACAACCCATGACAGAGA 
12+13 CACGGTGGGCTAGCGCAG CAGCTCCAGGTTTTCTCCAGG 
14 GGTGTGGATTCCAGCTCTGC CCTTGCTGGGACACAGCTCC 
Table 2.3 FLCN genomic primers  
 
Gene Forward Primer Reverse Primer 
IGF2R  
(exon 27) 
 
CCCGAACCAAACCTTGTTTA 
 
ATATGATCCCAGCAGCCTGA 
TGFBR2 
(exon 3) 
 
CCTCGCTTCCAATGAATCTC 
 
TGCACTCATCAGAGCTACAGG 
MSH6 
(exon 5) 
 
CTGATAAAACCCCCAAACGA 
 
TAGGCTTTGCCATTTTCCTG 
FLCN 
(exon 11) 
 
TCCTCCTCAGACCATGCTTC 
 
GGTTCCACTTTGGGCCTGA 
Table 2.4 Mononucleotide tract amplifying primers 
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2.1.3 Agarose gel electrophoresis 
Amplified PCR products were resolved on an agarose gel to confirm successful, specific 
amplification.  A 1.5% (w/v) agarose gel was made by dissolving 2.25 g agarose in 150 
ml 1x TBE buffer (89 mM Tris Borate pH8.3, 2mM Na2EDTA (Geneflow Ltd)) and 10 
ng/ml ethidium bromide.  Typically 8 µl of PCR product was mixed with 2 µl of 5x DNA 
loading buffer (33% (v/v) glycerol, 0.1% (w/v) orange G, in ddH2O) and loaded onto the 
gel.  To determine the size of amplified products, a 100 base pair ladder (Invitrogen) was 
also loaded for comparison.  Electrophoresis was carried out at 180 volts for 20 minutes.  
Products were viewed under UV light and imaged using an Ingenius Syngene Bioimaging 
machine. 
  
2.1.4 Exosap/Clean up reaction 
Successfully amplified PCR products were cleaned using the Exosap reaction in order to 
remove unwanted primers by exonuclease and unwanted dNTP’s by Antarctic 
phosphatase.  The reaction mixture, displayed in Table 2.5, was heated at 37
o
C for 30 
minutes then at 80
o
C for 20 minutes in PCR machine (G storm).  Reagents were 
purchased from New England Biolabs. 
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Reagent Volume (µl) 
Antarctic phosphatase 1 
Antarctic phosphatase buffer 1 
Exonuclease 0.25 
H20 1.75 
PCR product 6 
Table 2.5 Exosap reagents and volumes 
 
2.1.5 Sequencing 
Exosap cleaned PCR products were sequenced directly by dideoxy termination 
sequencing.  Each product was sequenced in both forward and reverse directions, for 
confirmation of any alterations observed.  The sequencing reaction mixture is displayed 
in Table 2.6, reagents purchased from Applied Biosystems. 
 
Reagent Volume (µl) 
Big Dye 0.75  
5x Big Dye buffer  2 
Primer (20 pmol/µl) 1 
Nuclease free water 2.25 
PCR product 4 
Table 2.6 Sequencing reaction reagents and volumes 
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Sequencing reaction conditions are displayed in Table 2.7 
 
Temperature Time 
95
o
C 30 secs 
50
o
C 30 secs 
60
o
C 4 minutes 
Table 2.7 Sequencing reaction conditions 
 
2.1.6 Ethanol precipitation 
After completion of the sequencing reaction, the DNA was purified by ethanol 
precipitation.  DNA was precipitated by addition of 1 µl of 250 mM ETDA and 35 µl of 
100% ethanol.  Samples were centrifuged at 2254 x g for 30 minutes at 4
o
C to pellet 
DNA, and residual ethanol removed by centrifuging plates upside down on filter paper at 
20 x gfor 1 minute.  The DNA pellet was washed with 200 µl of 70% (v/v) ethanol, and 
the DNA re-pelleted at 2254 x g for a further 20 minutes at 4
o
C.  The ethanol was 
removed as before, and the DNA mixed with 10 µl of HiDi formamide (Applied 
Biosystems).  The DNA was denatured at 95
o
C for 5 minutes, and then cooled on ice.  
Samples were then loaded onto an ABI 3730 capillary sequencer (Applied Biosystems). 
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2.1.7 Mutation detection 
DNA sequences were analysed using the BioEdit Sequence alignment program 
(http://www.mbio.ncsu.edu/bioedit/page2.html) to compare patient sequence with a 
reference sequence.  Traces were also checked by eye to identify heterozygous changes 
not detected by the alignment program.  In the case of an identified variant, a second 
repeat of the PCR-Sequencing process was completed from the original DNA for 
confirmation of the result.  Novel mutations were checked for absence in SNP databases 
(dbSNP, Ensembl, Exome variant server) and tested for absence in the sequence of more 
than 200 control chromosomes. 
 
2.1.8 DNA extraction from culture cells and tumour tissue 
DNA was extracted from cells adnd tissue using the DNA isolation kit for cells and 
tissues (Roche).  For DNA isolation from tissue, the tissue was initially ground into a 
powder under liquid nitrogen.  10 ml Cellular lysis buffer was added to each 400 mg of 
ground tissue and mixed.  6.1 µl of proteinase K solution was added and the mixture 
incubated at 65
o
C for 1 hour.  After incubation, 400 µl of RNase solution (10 mg/ml) was 
added to degrade unwanted RNA, and the sample placed at 37
o
C for 15 minutes.  To 
precipitate unwanted protein, 4.2 ml protein precipitation solution was added and the 
sample incubated on ice for 15 minutes.  The DNA was the collected by centrifugation at 
15600 x g for 20 minutes.  The DNA was precipitated by addition of isopropanol and a 
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10 minute centrifugation at 500 x g, and washed with 10 ml of 70 % (v/v) ethanol.  The 
DNA pellet was collected by centrifugation and resuspended in nuclease free water.   
The same method was used for DNA extraction from cells in culture (see below for 
trypsinisation and preparation of cell pellet), with proportionally smaller volumes of 
reagent added depending on quantity of cells to be extracted from.          
 
2.2  Cell Culture 
2.2.1 Cell lines and growth conditions 
2.2.1.1 Cell lines used 
FTC-133 cells, derived from lymph node metastasis of a follicular thyroid carcinoma, 
were purchased from ECACC.  The cell line is mutant for FLCN (p.His429ProfsX27) and 
produces no translated folliculin protein.  FTC-133 cells were maintained in Dulbecco’s 
modified Eagle’s medium (DMEM) and Ham’s F12 (vol:vol = 1:1), 10% (v/v) foetal 
bovine serum (FBS), 2mM L-glutamine and 1x penicillin-streptomycin.  FTC-133 cell 
with stable transfection were grown in the same media supplemented with 500µg/ml 
G418 solution (PAA).  ACHN cells with stable knockdown of FLCN (by shRNA) and a 
stable, scrambled control were kindly donated by Professor Arnim Pause (McGill 
University, Montreal, Canada) and have been described in (Hudon, et al., 2010).  These 
cells were grown in DMEM, 10% (v/v) foetal bovine serum (FBS) and 2mM L-glutamine 
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supplemented with 1µg/ml puromycin.  MCF-7, HaCat, IMCD-3 and Hela cells were 
grown in DMEM (PAA) and Hek293 DMEM (Sigma), in addition to 10% (v/v) foetal 
bovine serum (FBS) and 2mM L-glutamine, all without selective antibiotic.  All cell 
culture reagents were purchased from Sigma-Aldrich unless otherwise stated.  Cell 
culture vessels were purchased from BD Falcon or Corning.     
 
2.2.1.2 Cell maintenance 
When the cells had grown to confluency, or were required for a specific experiment, the 
media was aspirated, and the cells washed with 5 mls of pre-warmed phosphate buffered 
saline (PBS) (1 PBS tablet per 100 ml ddH2O, Gibco).  The PBS was aspirated and 
replaced with 1 ml of trypsin (Gibco) (for a T75 flask), and the flasks placed in a 37
o
C 
incubator for ~ 5 minutes.  Once the cells were completely detached, they were 
resuspended in 9 mls of media and either re-seeded at a suitable dilution (1/4 – 1/10) back 
into a T75 flask.  If a specific cell seeding density was required, the trypsinised cells were 
place in a 15 ml falcon tube and centrifuged at 280 x g for 3 minutes.  They were then re-
suspended in 5 mls of media and counted using a haemacytometer, and the required 
dilution calculated before seeding.  
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2.2.1.3 Cryopreserving cells 
Cells were trypsinised as described above then centrifuged at 280 x g for 3 minutes.  
Media was aspirated, the cell pellet resuspended in cold PBS and the cells re-centrifuged 
for a further 3 minutes at 280 x g.  Cell pellets taken from a confluent T-75 flask, were 
resuspended in 4 mls of FBS containing 10% (v/v) dimethyl sulphoxide (DMSO, Sigma).  
Each 1 ml of cells was transferred into a 2 ml cryovial, placed in a Mr Frostie freezing 
container (Sigma) and left at -80
o
C overnight.  Frozen cryovials were kept at -80
o
C or in 
liquid nitrogen for longer term storage. 
 
2.2.2 Serum starvation of cells 
Cells were serum starved in this project to determine basal levels of RhoA and mTOR 
signaling, and also to inhibit cell growth when testing the migratory ability of cells.  Cells 
for serum starvation were first washed in serum free media, and then incubated in PBS 
for 10 minutes.  The PBS was then replaced with serum free media and left over night.   
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2.2.3 Transfection 
2.2.3.1 Transient transfection 
Fugene HD 
The majority of transfections within this project were undertaken using the Fugene HD 
method.  Cells were plated the day before transfection at between 3 x 10
5
 and 5 x 10
5
 per 
well of a 6 well plate depending on the rate of growth of the cell line in question, to 
achieve a cell density of greater than 80% at the time of transfection.  On the day of 
transfection, fresh media was placed on the cells.  2 µg of plasmid DNA was diluted in 
100 µl of serum-free medium (Opt-MEM 1 - Invitrogen), and the transfection complex 
formed by adding 7 µl of Fugene HD transfection reagent (Roche, West Sussex, UK).  
The optimum ratio of plasmid to Fugene volume was determined by titration.  The 
complex was mixed and incubated for 15 minutes at room temperature, before being 
added to the cells dropwise.  The media was changed after 24 hours and transfection 
confirmed by western blot after 48 hours. 
 
Calcium phosphate precipitation 
Transfection by calcium phosphate precipitation was used to co-express the venus vectors 
into Hela cells as part of the bimolecular fluorescence complementation (BiFC) analysis 
of the interaction between folliculin and p0071 (see section 2.7.1).  Hela cells were plated 
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on the day before transfection at 7.5 x 10
4
 per ml, to reach close to 50% confluence by 
the time of transfection.  On the day of transfection, 4 µg of each plasmid for co-
transfection was diluted in 85.5 ml of nuclease free water.  12.5 µl of 2 M CaCl2 was 
added to the diluted plasmids, and the transfection complex formed by adding 2xPP (50 
mM Hepes pH7.05, 1.5 mM Na2HPO4, 10 mM KCl, 280 mM NaCl, 12 mM glucose) 
dropwise to a gently swirling tube.  The mixture was then incubated at room temperature 
for 20 minutes, before being added dropwise to the cells.  After 6 hours of incubation at 
37
o
C, the media was aspirated and the cells washed once in serum free media.  The cells 
were then “shocked” by addition of glycerol to maximise transfection efficiency.  500 µl 
of glycerol mixture (150 µl Glycerol, 100 µl ddH20, 250 µl 2xPP) was added to each 
well, and incubated for exactly 2 minutes.  After removal of the glycerol, the cells were 
washed 3 times in serum free media and finally left in normal serum media overnight.  
Transfection was confirmed by cell fixation and immunofluorescence analysis after 24 
hours.      
 
Lipofectamine 2000 
Transfection using Lipofectamine 2000 reagent (Invitrogen) was used to co-express flag-
tagged folliculin and dsRED-tagged p0071 constructs for exogenous co-expression, 
immunofluorescence analysis in Hela, HaCat, MCF-7, FTC-133 and ACHN cells.  
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Cells were seeded into 6 well plates with coverslips, at 3.75 x 10
5
 cells per ml the day 
before transfection, to reach 95% confluence at the time of transfection.  For each 
transfection sample, 2 µg of each DNA construct were pooled and diluted into 250 µl 
serum free media.  At the same time, 10 µl of Lipofectamine 2000 were was diluted into 
a separate tube of 250 µl serum free media, and incubated for 5 minutes at room 
temperature.  After this time, the diluted DNA and Lipofectamine 2000 tubes were 
pooled, mixed gently and incubated for 20 minutes at room temperature.  After 
incubation, the mixture was added dropwise to a single well of a 6 well plate and 
incubated at 37
o
C for 6 hours.  Media was replaced after 6 hours, and transfection 
confirmed by co-staining and immunofluorescence analysis after 24 hours. 
 
2.2.3.2 Transfection of stable mixed populations 
For transfection of a stable expressing pool of mixed clones, the initial transfection 
procedure was as described above using Fugene HD transfection reagent.  After 48 hours, 
the media was aspirated, and replaced with media containing 500 µg/ml G418 solution 
(PAA), which was used to select for cells expressing neomycin resistance gene, an 
indication of plasmid incorporation into the genome.  An untransfected control well was 
also grown in G418 containing media to confirm a lack of resistance to G418 in the 
general cell population.  Cells which stably expressed neomycin resistance gene were 
grown until confluent in a T75 flask and cryopreserved for future experiments. 
 [54] 
 
2.2.4 Short interfering RNA transfection 
Short interfering RNA (siRNA) transfection was used to transiently silence specific genes 
by degrading the encoded mRNA and thus reducing protein synthesis.  For each well the 
required concentration of siRNA was diluted in 200 µl of Opt-MEM 1 Reduced Serum 
Media (Invitrogen) and the transfection mixture formed by adding 10 µl of INTERFERin 
transfection reagent (Polyplus).  The mixture was then homogenized for 10 seconds and 
incubated at room temperature for 10 minutes.  The transfection mixture was placed 
dropwise into each well of a 6 well plate.  Cells were trypsinised, counted and seeded 
directly onto the siRNA transfection mixture at between 30-50% confluency (~1x10
5
 
cells/ml).  The cells were incubated for 72 hours at 37
o
C, and gene silencing measured by 
western blotting and densitometry or TaqMan Real Time qPCR in comparison with 
luciferase siRNA transfected controls. 
siRNA sequences were purchased from Applied Biosystems.  Human flcn siRNA 
sequence was GGAAGGUGGCAUUCAGAUG.  Mouse flcn siRNA sequence was 
CCUCAGCAAGUAUGAG, and mouse p0071 siRNA sequence was 
CAGACAGCAUUGUAUCGC.          
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2.3 RNA analysis 
2.3.1 Extraction of RNA 
RNA was extracted from cells and tissue using the TRIzol Plus RNA Purification Kit 
(Ambion).  Cells were trypsinised and pelleted by centrifugation at 280 x g at room 
temperature as described in the cryopreservation section. Lysis was achieved by 
resuspending the cell pellet in TRIzol Reagent and incubating the lysate at room 
temperature for 5 minutes.  The amount of TRIzol Reagent added was based on the 
culturing dish area (1 ml per 10 cm
2
).  0.2 mL of chloroform was added, mixed by 
shaking the tube for 15 seconds and incubated at room temperature for 3 minutes.  The 
samples were then centrifuged at 12000 x g for 15 minutes at 4
o
C, after which the 
mixture had separated into a lower, red phenol-chloroform phase, an interphase and a 
colourless upper phase (which contained the RNA).  The RNA containing phase was 
removed, mixed with an equal volume of 70% ethanol, vortexed, and added to a spin 
column.  Tubes were centrifuged at 12000 x g for 15 seconds to bind RNA to the 
collection column.  The column was washed and then centrifuged with 700 µl wash 
buffer I followed by two washes with wash buffer II.  RNA was then eluted by addition 
of 30 µl nuclease free water, a 1 minute incubation and a centrifugation step of 12000 x g 
for 2 minutes.  RNA was eluted 3 times to maximize the amount of RNA extracted and 
the 3 elutions pooled.  Concentration and quality was determined using a Nanodrop 
spectrophotometer (NanoDrop Technologies, Wilmington, USA). 
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2.3.2 cDNA synthesis 
For cDNA synthesis, 1 µg of total RNA was reverse transcribed using SUPERSCRIPT 
III reverse transcriptase (Invitrogen).  2 µl of 50uM random primers were added to 1 µg 
RNA and 1 µl 10mM dNTP mix (final volume 13 µl), mixed well and heated to 65
o
C for 
5 minutes to destroy all secondary structure of mRNA.  After this incubation, 4 µl 5x 
First-strand Buffer, 1 µl of 0.l M DTT, 1 µl RNaseOUT inhibitor (40 units/ µl) and 1 µl 
SUPERSCRIPT II RT (200 units/ µl) were added to the mixture (final volume 20 µl), and 
mixed well in a PCR tube.  The tubes were then incubated at 55
o
C for 90 minutes and 
heated to 70
o
C for 15 minutes to inactivate the enzyme.  Finally the amount of cDNA 
was measured with a Nanodrop spectrophotometer and a working concentration of 
200ng/ µl diluted using nuclease free water.  Reagents were purchased from Invitrogen. 
 
2.3.3 TaqMan quantitative real time PCR reaction 
The TaqMan assay was used to determine gene expression by quantifying the amount of 
cDNA present in a given sample.  It works based on the 5’ nuclease activity of Taq DNA 
polymerase.  Predesigned TaqMan probes hybridise to target DNA between two designed 
PCR primers (which span between different exons to inhibit amplification of genomic 
DNA).  Fluorescent signal from the probe is quenched by the non-fluorescent quencher 
on its 3’ end.  When the PCR cycling commences, Taq polymerase extends the DNA 
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from each primer.  When extension reaches the TaqMan probe, it cleaves the FAM dye 
from the quencher, thus releasing a fluorescent signal.  With each cycle of PCR more dye 
is released exponentially, which is then detected in real-time by the qPCR machine.  The 
amount of fluorescence detected can therefore be used to determine the amount of cDNA 
and hence mRNA in the original sample.  
For each gene analysed, a TaqMan gene expression assay containing a pair of specific 
primers and MGB probes was ordered from Applied Biosystems. For each gene 
amplified, a plate of standard DNA concentrations was prepared at 100 ng, 250 ng, 500 
ng, 650 ng, 850 ng and 1 µg, to determine a suitable concentration of cDNA to add to the 
reaction.  Each concentration was carried out in duplicate.  The reaction mixture is 
displayed in Table 2.8 and the reaction conditions given in Table 2.9.  Reactions were run 
on an IQ5 multicolor real-time PCR machine (BioRad). 
 
Reagent Volume per reaction (µl) 
TaqMan universal PCR master mix (2x) 10 
20x gene expression assay Mix 1 
cDNA (100ng/ µl) + water 
Total 
9 (of differing cDNA concentrations) 
20 
Table 2.8 TaqMan reaction reagents and volumes  
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Step Temperature (
o
C) Time Number of Cycles 
Initial Melting 95 10 minutes 
 
 
1 
Melting 
 
Annealing/elongation 
95 
 
60 
15 seconds 
 
1 minute 
 
40 
Table 2.9 Quantitative real-time PCR reaction conditions  
 
An input cDNA concentration which produced quantitative amplification was determined 
from the standard curve, and that concentration used in subsequent assays. 
Each assay consisted of amplification of the gene of interest and of GAPDH acting as an 
internal control for normalisation.  The mRNA levels of the gene of interest in 
comparable samples were determined by the amount of cDNA amplification of the gene 
normalized by GAPDH control for each sample.   
 
2.4 Protein analysis 
2.4.1 Protein extraction 
To extract protein for immunoblotting, the cells were first washed in PBS and scraped 
into 200 µl of RIPA lysis buffer (Tris pH7.4, NaCL 150mM, EDTA 0.5 mM, 1% Triton 
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(v/v) and protease inhibitor cocktail (Roche Applied Sciences)).  For co-
immunoprecipitation experiments, the same buffer was used, although to maximise the 
quantity of cell lysate produced, a T75 flask was scraped with 500 µl of lysis buffer.  
Protein extraction for G-LISA RhoA activation assay is described in detail in section 
2.8.2.2.  The cells were then centrifuged at 13300 x g and 4
o
C for 20 minutes and the 
supernatant transferred to a new tube for protein quantification.  Cell lysates were stored 
at -20
o
C 
 
2.4.2 Total cellular protein quantification 
The concentration of protein within the lysate was determined using the DC Protein 
Assay Kit (BioRad).  5 µl of each sample in duplicate, and a standard curve with a serial 
dilution of bovine serum album (BSA) and lysis buffer (0 mg/ml to 2 mg/ml) were added 
to the wells of a 96 well plate.  20 µl of buffer S was mixed with 1 ml of reagent A to 
make reagent A’ and 25 µl added to each well followed by 200 µl of reagent B.  The 
plate was incubated at room temperature for 10 minutes before absorbance was measured 
using a Victor X3 Multilabel plate reader (PerkinElmer). The protein concentration was 
then determined using the standard curve as reference for each sample. 
For western blot of total cellular lysate, equal concentrations of each sample were 
calculated and mixed with an appropriate volume of 5x protein loading buffer (250mM 
Tris HCl (pH6.8), 10% SDS (w/v), 0.5% Bromophenol Blue (w/v), 50% Glycerol (v/v), 
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5% DTT (v/v)).  Samples were boiled for 5 minutes (>95
o
C) before being loaded onto 
SDS-PAGE gels for electrophoresis.   
 
2.4.3 Co-immunoprecipitation 
Co-immunoprecipitation using Dynabeads was used to confirm the interaction of 
folliculin and p0071 in vitro (see 0).  The procedure used Dynabeads Protein G 
(Invitrogen), which are superparamagnetic polymer beads, covalently coupled to Protein 
G which binds to the Fc part of a wide range of immunoglobulins (Igs).  The dynabeads 
were mixed with antibody, which bound to the Dynabeads protein G (protein G has been 
shown to have a strong affinity with both mouse IgG and rabbit IgG antibodies used in 
these experiments).  The antibodies were covalently cross-linked to the beads to 
minimize heavy and light chain contamination.  Finally the antibody conjugated 
dynabeads were incubated with protein lysate to pull down the specific antibody binding 
protein and also other proteins bound as part of a complex.  As the dynabeads are 
magnetic, they can be separated from solution using a magnet, minimising contamination 
of unbound protein.  Mixing steps were carried out at room temperature away from the 
magnet, and liquids removed from the beads after 30 seconds exposure to the magnet.  
Incubations were carried out using end-over mixing apparatus.     
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Figure 2.1 Principle of co-immunoprecipitation with using Dynabeads Protein G 
 
2.4.3.1 Antibody conjugation to beads 
Dynabeads were resuspended and 20 µl of beads placed on the magnet per co-
immunoprecipitation.  Beads were washed twice with 500 µl citrate phosphate buffer 
(24.5 mM citric acid and 51.7 mM dibasic sodium phosphate, pH 5.0) and mixed with 4 
µg of the required antibody diluted in 20 µls of PBS (see Table 2.10), and incubated for 
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an hour at room temperature (except in the case of anti-FLCN rabbit monoclonal 
antibody, Cell Signaling, where 0.5 µg was used).  After a further 3 washes with 500 µl 
citrate phosphate buffer, the beads were washed 3 times in 500 µl 0.2 M triethanolamine 
(Sigma).  Antibodies and beads were cross linked by incubation with 20 mM dimethyl 
pimelimidate (Sigma - dissolved in 0.2 M triethanolamine) for 30 minutes at room 
temperature.  After removal of the dimethyl pimelimidate, the reaction was quenched by 
incubation with 1 ml of 50 mM Tris pH 7.5 for 15 minutes at room temperature.  The 
antibody conjugated beads were washed 3 times with PBST (PBS and 0.1% tween) and 
re-suspended in 20 µl PBST. 
 
2.4.3.2 Immunoprecipitation 
Dynabeads were first washed 3 times in citrate phosphate buffer and then resuspended in 
RIPA lysis buffer.  For semi-exogenous co-immunoprecipitation 200 µg and for 
endogenous co-immunoprecipitation 250 µg of total cellular protein were added to 20 µl 
of antibody bound dynabeads and incubated at 4
o
C for 3 hours.  The lysates were then 
placed on the magnet and the supernatant removed as unbound fragment.  The beads 
were washed 3 times with 500 µl RIPA buffer (Tris pH 7.4, NaCl 300 mM, EDTA 0.5 
mM, 1% (v/v) Trition-X-100, protease inhibitor cocktail (Roche)).  Beads were 
resuspended in 20 µl of 2x Laemmi sample buffer (Sigma) and transferred to a fresh 
eppendorf tube.  Pulled down proteins were eluted by boiling for 10 minutes, and were 
then loaded onto 8% (w/v) SDS-PAGE gels for analysis.  
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2.4.4  Western blotting 
2.4.4.1 SDS-PAGE electrophoresis 
Proteins were resolved by SDS-PAGE electrophoresis.  Gels were made up of 8 mls 
resolving gel and 2 mls stacking gel cast between two glass plates (1.5 mm).  Gels of 6%, 
8.5%, 10% and 12.5% (w/v) were used depending on the size of the protein of interest.  
Initially the resolving gel was poured and 1 ml of ddH2O added to ensure a straight edge 
to the gel.  Once the resolving gel was set, the ddH20 was removed and 2 mls of stacking 
gel added on top of the resolving gel.  In most instances a 15 well comb (occasionally a 
10 well comb) was inserted into the stacking gel pre-setting to provide wells for lysate 
loading.  Once set, gels were placed into an electrophoresis tank part filled with 1x SDS 
running buffer (25 mM Tris, 192 mM Glycine, 0.1% (w/v) SDS pH 8.3), and proteins 
separated using 150 Volts for one hour.  5 µl prestained protein marker (Fermentas) was 
loaded in the first and last lanes as a reference of protein size, and to separate 
experiments when more than one were run per gel. 
     
2.4.4.2 Transfer to nitrocellulose membrane 
The proteins separated by gel electrophoresis were then transferred onto PVDF 
(polyvinylidene difluoride) membrane (GE Healthcare), which was initially activated by 
1 minute incubation in methanol.  The transfer apparatus was set up as described in 
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Figure 2.2, and run in 1x transfer buffer (Geneflow) at 100V for 1.5 hours, with an ice 
pack.     
 
 
 ANODE 
 
 
       Direction     
             Of     
       Transfer                
CATHODE 
Figure 2.2 Diagram of transfer apparatus 
 
 
2.4.4.3 Immunoblotting 
Membranes were initially calibrated in PBST for five minutes, before being blocked with 
5% (w/v) milk (5g powdered milk (Marvel) dissolved in 100 mls PBST) at room 
temperature for one hour.  After blocking, the membrane was placed on a rocker in PBST 
for three 5 minute washes.  Blocked membranes (proteins facing inwards) were left 
rolling in a 50 ml falcon containing 5 mls of diluted antibody overnight at 4
o
C.  Primary 
Sponge 
Filter paper 
PVDF membrane 
Gel 
Filter paper 
Sponge 
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antibodies were diluted as described in Table 2.10.  After incubation in primary antibody 
the membrane was washed three times with PBST for 5 minutes each time, before being 
incubated (on a roller) with corresponding secondary antibody for 1 hour at room 
temperature.  Secondary antibodies had been conjugated to horse radish peroxidase to 
allow for their detection using autoradiography film (described in Table 2.11).  After 3 
final washes in PBST for 5 minutes, the membrane was incubated for 1 minute in 
enhanced chemiluminescence (ECL) reagent, and proteins detected using BioMax XAR 
film (Kodak).  
 
2.4.4.4 Striping and re-probing of membranes 
In order to detect another protein of similar size to the protein initially detected, 
membranes were stripped and re-probed with an alternate primary antibody.  ECL 
reagent was washed from the membranes by incubation with PBST on a rocker for five 
minutes.  Proteins were incubated in ddH2O for a further 5 minutes before being left in a 
beaker of boiling ddH2O for 10 minutes.  After stripping, membranes were incubated in 
PBST for 5 minutes before being blocked in 5% milk as before.  They were then 
immunoblotted as described above as for the initial antibody. 
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2.4.4.5 Densitometry 
Western Blots were quantified by densitometry using the Genetools, Sycgene program.  
Blots were scanned as TIFF files and imported into the Syngene program 
(http://www.syngene.com/genetools/).  Identical boxes were constructed around each 
band of interest, and one representing the background signal of the film.  The intensity of 
signal within each box was calculated by the Sycgene program.  Using Microsoft Excel, 
the intensity of each band was calculated minus background signal, and normalized either 
to the corresponding loading control or, in the case of bicistronic vector, to the GFP 
transfection control.  
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Antibody Company Species Concentration Application 
FLCN monoclonal Cell 
Signalling 
Rabbit 1 in 5000 Western Blot 
FLCN monoclonal Cell 
Signalling 
Rabbit 0.5 µg Immunoprecipitation 
FLCN monoclonal Cell 
Signalling 
Rabbit 1 in 400 Immunofluorescence 
FLCN polyclonal Abnova Mouse 1 in 2000 Western Blot 
GFP monoclonal Clontech Mouse 1 in 5000 Western Blot 
GFP monoclonal Clontech Mouse 1 in 200 Immunofluorescence 
p0071 (clone 7.7.9) 
monoclonal 
Progen Mouse 1 in 20 Western Blot 
p0071 (clone 7.7.9) 
monoclonal 
Progen Mouse 4 µg Immunoprecipitation 
p0071 monoclonal (Wolf et al 
2006) 
Guinea 
Pig 
1 in 100 Immunofluorescence 
Flag monoclonal Sigma Mouse 1 in 1000 Western Blot 
Flag monoclonal Sigma Mouse 4 µg Immunoprecipitation 
Flag monoclonal Sigma Mouse 1 in 1000 Immunofluorescence 
β actin monclonal Sigma Mouse 1 in 5000 Western Blot 
α Tubulin monoclonal Sigma Mouse 1 in 5000 Immunofluorescence 
HA monoclonal Roche Rat 1 in 500 Immunofluorescence 
Table 2.10 Primary antibodies used 
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Antibody Company Species Concentration Application 
HRP conjugated anti-mouse Dako Rabbit 1 in 1000 Western Blot 
HRP conjugated anti-rabbit Dako Goat 1 in 1000 Western Blot 
anti-rabbit Alexa 594 Invitrogen Goat 1 in 1000 Immunofluorescence 
anti-mouse Alexa 488 Invitrogen Goat 1 in 1000 Immunofluorescence 
anti-mouse Dylight 649 Jackson  Donkey 1 in 250 Immunofluorescence 
anti-rabbit Dylight 649 Jackson  Donkey 1 in 250 Immunofluorescence 
anti-mouse Dylight 488  Jackson  Donkey 1 in 300 Immunofluorescence 
anti-Guinea Pig Dylight 488 Jackson  Donkey 1 in 300 Immunofluorescence 
anti-rabbit Dylight 488 Jackson  Donkey 1 in 400 Immunofluorescence 
anti rabbit Cy3 Jackson  Donkey 1 in 400 Immunofluorescence 
anti-mouse Cy3 Jackson  Donkey 1 in 300 Immunofluorescence 
anti-Guinea Pig Cy3 Jackson  Donkey 1 in 400 Immunofluorescence 
Table 2.11 Secondary antibodies used 
 
2.5  Cloning 
Plasmid cloning was used in two sections of this project.  Initially FLCN cDNA was 
subcloned from the p.FLAG-CMV vector into the p.IRES2-acGFP1 vector, and patient 
mutations modeled in FLCN cDNA using site-directed mutagenesis. 
FLCN was also cloned from human cDNA into the Venus vectors used in bimolecular 
fluorescence complementation analysis, to make fusion proteins of folliculin with each 
half of YFP, in both orientations (see section 2.7.1).  
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2.5.1 Proofreading PCR 
To amplify the FLCN open reading frame from human cDNA, primers were designed 
which incorporated EcoR1 and BamH1 sites at the 5’ and 3’ end of FLCN respectively.  
It was confirmed by sequence analysis that FLCN contained no sites of recognition for 
these restriction endonucleases within its sequence.  The primers were designed to 
include the restriction enzyme sites so that they were in frame with the preceding tag 
sequence and where appropriate the proceeding Venus fusion protein.  A cap of GCAG 
was added to the start of each primer to aid restriction digest.  Primer sequences used for 
cloning FLCN into the Venus constructs are given in Table 2.14.   The PCR reaction 
mixture and reaction profile are given in tables Table 2.12 and Table 2.13 respectively.  
Pfu enzyme was purchased from Stratagene, other PCR reagents were the same as used 
for PCR described in section 2.1.2. 
Reagent Volume per reaction (µl) 
10x PCR buffer (2 mM Mg) 5 
dNTP mix (25 µM/µl per dNTP) 2.5 
Forward primer (20 pmol/µl) 1 
Reverse primer (20 pmol/µl) 1 
Pfu polymerase (5 units/µl) 1 
DNA template 3 
Nuclease free H2O 37.5 
Total 50 
Table 2.12 Proofreading PCR reagents and volumes 
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Step Temperature (
o
C) Time Number of Cycles 
Initial melting 
 
95 5 minutes 1 
Melting 95 30 seconds  
35 Annealing 56 30 seconds 
Extension 72 60 seconds 
 
Final extension 
 
72 
 
7 minutes 
 
1 
Table 2.13 Proofreading PCR reaction conditions 
 
 
Primer Sequence 
FLCN forward GCAGGAATTCATGAATGCCATCGTGGCTCT 
FLCN reverse STOP GCAGGGATCCTCAGTTCCGAGACTCCGAGG 
FLCN reverse no STOP GCAGGGATCCGTTCCGAGACTCCGAGGCTG 
Table 2.14 Primers used for FLCN cloning into Venus vectors 
FLCN Forward was used as the forward primer for all vectors.  FLCN reverse STOP was 
used as the reverse primer for p.Ven2-HA-C and p.Ven1-Flag-C and FLCN reverse no 
STOP used for p.Ven1-Flag-N and p.Ven2-HA-N 
 
2.5.2 Gel extraction 
The amplified PCR products were electrophoresed on a 1% (w/v) agarose gel as in 
section 2.1.3, using a 1 kb DNA ladder (New England Biolabs) for a DNA fragment size 
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reference.  The gel was visualised under UV light, and the correct sized band excised 
using a clean scalpel.  To purify the DNA, the surrounding gel was digested using the 
QIAGEN QIA quick spin kit.  The gel slice was weighed and 3 volumes of QG buffer 
added per 1 volume of gel (100 µl per 100 mg gel), and the tubes incubated at 50
o
C for 
10 minutes until the gel was completely dissolved.  1 gel volume of isopropanol was 
added to the sample to maximize DNA yield, the sampled added to a collection column 
and centrifuged at 15600 x g for 1 minute at room temperature.  To remove all traces of 
agarose, the DNA bound to the collection column was washed by addition and 
centrifugation of 0.5 ml buffer QG.  To wash the DNA 0.75 ml of buffer PE was added, 
incubated for 3 minutes then centrifuged.  Flow through was discarded, and the column 
re-centrifuged at 15600 x g to remove residual PE buffer.  Finally the DNA was eluted by 
addition of 30 µl of nuclease free water to the centre of the column, incubation for 1 
minute and centrifugation at 15600 x g for 1 minute.     
  
2.5.3 Restriction digest 
Gel extracted PCR products and corresponding vectors were digested with restriction 
enzymes EcoR1 and BamH1, respectively, to create complimentary, cohesive ends on 
both.  Digestion mixtures were set up as in Table 2.15 and incubated at 37
o
C for 4 hours.  
Reagents were purchased from Promega.   
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Reagent Volume per Digest (µl) 
10 x Buffer E 2 
BSA 0.2 
BamH1 0.5 
EcoR1 0.7 
DNA Volume for 1 µg 
Nuclease free water Up to 20 
Total 20 
Table 2.15 Restriction digest reagents and volumes 
 
Digested products were then loaded in full onto a 1% (w/v) agarose gel and 
electrophroresed and gel extracted as described previously.  Estimation of the quantity of 
DNA digested was determined by comparison with a 1kb DNA ladder. 
 
2.5.4 Ligation 
To ligate the digested insert into the digested plasmid, the following reaction mixture was 
prepared and incubated at room temperature over night.  Reagents were purchased from 
Promega. 
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Reagent Volume per Ligation (µl) 
2x ligation buffer 5 
T4 DNA ligase (3 units/ µl) 1 
Insert digested DNA 3 
Vector digested DNA 1 
Total 10 
Table 2.16 Ligation reaction reagents and volumes  
 
2.5.5 Transformation 
The ligated plasmids were then transformed into E. Coli for propagation.  7 µl plasmid 
was added to 30 µl competent E. Coli cells, and the mixture incubated on ice for 30 
minutes.  The bacteria were heat-shocked at 42
o
C for 45 seconds and immediately cooled 
back on ice.  500 µl of SOC medium (Invitrogen) was added to each transformation 
mixture, and the cells incubated at 37
o
C for 90 minutes with 220 rpm shaking, to allow 
antibiotic resistance genes located in the plasmids to be expressed.  Cells then were 
collected in a pellet by centrifugation at 2254 x g for 3 minutes, and the pellet 
resuspended in 100 µl of SOC medium (Invitrogen).  The bacteria containing medium 
was then transferred to LB agar plates containing either 100 µg/ml of ampicillin or 50 
µg/ml of kanamycin, and the plated incubated over night at 37
o
C.  
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2.5.6 Purification of plasmid DNA 
2.5.6.1 Screening of colonies 
Only bacteria which had been transformed were able to grow on the selective bacterial 
plates.  Single colonies were picked and transferred into 5 ml of LB broth containing the 
same concentration of appropriate antibiotic.  The cultures were left to propergate 
overnight at 37
o
C in a shaking incubator (220 rpm).  After > 16 hours of growth, the cells 
were collected by centrifugation and the plasmid purified by either miniprep (small scale) 
or maxiprep (large scale).   
 
2.5.6.2 Miniprep 
Minipreps were carried out using a QIAGEN miniprep kit.  Cells were pelleted by 
centrifugation at 6000 x g for 15 minutes at 4
o
C.  The cell pellet was resuspended in 250 
µl of buffer P1, and cells lysed in 250 µl of buffer P2.  The lysis reaction was neutralized 
by addition of 350 µl of buffer N3.  Cells were then centrifuged for 10 minutes at 13,000 
rpm to separate the cell debris.  The plasmid containing supernatant was transferred to a 
spin column and the DNA bound by centrifugation.  The DNA was washed initially with 
500 µl of Buffer PB and then 750 µl of Buffer PE, with a 1 minute, 15600 x g 
centrifugation step after each wash.  The column was then transferred to a clean tube and 
50 µl of nuclease free water added to the column.  After 2 minute incubation, the DNA 
was eluted by centrifugation at 15600 x g for 1 minute.   
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A restriction digest was set up as before for 5 µl of the DNA, and the digested product 
run on a 1% (w/v) agarose gel to check for which plasmids had ligated the correct sized 
insert.  When a correctly ligated plasmid was identified the minipreped DNA was then 
sequenced directly for the complete FLCN sequence including primers covering the 
boundaries between insert and vector.  Primers are given in Table 2.17, and the reaction 
profile and ethanol precipitation was the same as for genomic DNA sequencing.  If the 
plasmid was proved by sequencing to include the insert in frame, and un-mutated, the 
DNA was propagated in large bacterial cultures and purified by maxiprep for use in cell 
transfections.       
 
2.5.6.3 Maxiprep 
For the large scale preparation of plasmid DNA, the Genopure Plasmid Maxi Kit (Roche 
Applied Science) was used.  Colonies were initially picked and grown in 5 mls of LB 
broth containing the appropriate antibiotic for 6 hours in a shaking incubator at 37
o
C.  
This culture was then added to 100 ml of the same LB broth, and grown over night with 
the same conditions.  The following day, the cells were centrifuged at 1400 x g for 5 
minutes and the supernatant disposed of.  The pellet was resuspended in 12 mls of 
suspension buffer and the cells lysed by addition of 12 mls of lysis buffer and incubation 
for 3 minutes.  The lysis was neutralised by addition of 12 mls of neutralisation buffer 
and mixing inverting the tube 6-8 times until a homogenous suspension had formed.  The 
tube was then incubated for 5 minutes on ice.  The lysate was cleared of SDS precipitates 
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by filtration, and the filtered solution loaded onto a pre-equilibrated column.  The lysate 
was allowed to run through the column by gravity flow, and the flowthrough discarded.  
The column was then washed twice with 16 ml of wash buffer and the flowthrough 
discarded.  To maximize yield the plasmid was eluted into a fresh tube by addition of 15 
ml of pre-warmed elution buffer (50
o
C) to the column.  The eluted plasmid DNA was 
then precipitated by addition of 11 ml of isopropanol, and collected by centrifugation at 
1400 x g for 30 minutes at 4
o
C.  The DNA pellet was then washed with 4 mls of ice cold 
70% ethanol and re-centrifuged for 10 minutes at 1400 x g.  After removal of the 70% 
ethanol by pipette, the DNA pellet was allowed to air dry for 10 minutes, before being 
dissolved in 200 µl of nuclease free water.       
After both plasmid preparation procedures, the DNA concentration was measured using a 
nanodrop spectrophotometer and the quality of DNA can be determined by ratio of 
absorbance at 260mm vs 280mm. 
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Primer Sequence 
EcoR1 GCGAATTCAATGAATGCCATCGTGGCTCTCTGC 
Primer1 GCACCCGGGATATATCAGCCATG 
Primer2 AGCGTGCTCAGAGGATGAACACAG 
Primer3 TCTTCAAGTCCCTCCGGCACATG 
Primer4 GCTCAGCAAGTACGAGTTTGTG 
BamH1 Reverse GATGGATCCTCAGTTCCGAGACTCCGAGGC 
EcoR1 Reverse GCGCACGCATCCGACTGTTCATCT 
Table 2.17 Primers used for FLCN ORF sequencing 
EcoR1 primer designed from the EcoR1 site encompassing the FLCN ATG start site 
BamH1 reverse primer designer from the reverse BamH1 site encompassing the FLCN 
stop codon  
EcoR1 reverse primer designed to sequence from within FLCN back into the vector 
 
 
2.5.7 Site directed mutagenesis 
Site-directed mutagenesis using the QuikChange Lightning Site-Directed Mutagenesis 
Kit (Stratagene) was used to introduce a number of patient mutations into FLCN cDNA 
for expression in FTC-133 cells.  FLCN had been previously cloned into the pFLAG-
CMV vector by Dr Anne Reiman, which acted as a template for construction of the 
FLCN mutants.  Primers for site-directed mutagenesis are displayed in Table 7.1.  Mutant 
constructs were subsequently sub-cloned into the p.IRES2-AcGFP1 vector described in 
Appendix 7.1.   
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Complimentary primers were designed according to the manufacturer’s instructions to 
contain the appropriate mutation surrounded by between 15 and 20 base pairs of wild 
type sequence in each direction.  A proofreading PCR was carried out to synthesis the 
mutant DNA.  Reaction components are given in Table 2.18, reaction thermal profile 
given in Table 2.19.  
 
Reagent Volume (µl) 
10 x Reaction Buffer 2.5 
dsDNA template (100ng) 2.8 
Primer 1 (50 ng/µl) 0.5 
Primer 2 (50 ng/µl) 0.5 
dNTP mix 0.5 
Quiksolution reagent 0.75 
Nuclease free water 16.95 
QuikChange lightning enzyme 0.5 
Total 25 
Table 2.18 Site-Directed mutagenesis reaction reagents and volumes 
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Step Temperature  Time Number of Cycles 
Initial melting 
 
95
o
C 2 minutes 1 
Melting 95
o
C 20 seconds  
18 Annealing 60
o
C 10 seconds 
Extension 68
o
C 4 minutes 
 
Final Extension 
 
68
o
C 
 
5 minutes 
 
1 
Table 2.19 Site-Directed mutagenesis reaction PCR conditions 
 
After completion of the PCR reaction, 2ul of Dpn 1 restriction enzyme was added to each 
amplification reaction to digest the methylated, non-mutated parental DNA (DNA 
isolated from almost all E. coli strains is dam methylated and therefore susceptible to 
Dpn I digestion), but leaving the PCR amplified (mutant DNA) intact.  The mixture was 
then spun down, and incubated at 37
o
C for 5 minutes.  
Transformation was achieved using XL10-Gold ultra competent cells as described in 
section 2.5.5, and colonies processed and sequenced as described previously.   
Plasmids used in this project are given in Appendix 7.1. 
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2.6 Soft Agar Colony Formation Assay 
The soft agar colony formation assay tests the ability of cells to grow unadhered to a 
surface suspended in soft agar, which measures cell proliferation in a semisolid culture 
media.  The assay is considered a simple yet stringent assay for detecting malignant 
transformation in vitro and was used in this project to test the potential tumour suppressor 
function of a number of mutant folliculin constructs. 
Firstly 1 x DMEM and 2 x DMEM solutions were made up as described in Table 2.20 
and Table 2.21. 
 
Reagent Volume (mls) 
Fetal calf serum 50 
Pen/strep solution 5 
L-Glutamine 5 
10 x DMEM 50 
7.5% Sodium bicarbonate 25 
Sterile nuclease free water 115 
Total 250 
Table 2.20 2 x DMEM reagents and volumes 
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Reagent Volume (mls) 
Fetal calf serum 20 
Pen/strep solution 2 
L-glutamine 2 
10 x DMEM 20 
7.5% sodium bicarbonate 10 
Sterile nuclease free water 146 
Total 200 
Table 2.21 1 x DMEM reagents and volumes 
 
1.4% (w/v) noble agar  was dissolved in sterile, distilled water and mixed with the 
DMEM mixtures as described in Table 2.22 and Table 2.23, to form 0.7% (v/v) DMEM 
agar and 0.35% (v/v) DMEM agar. 
 
 
Reagent Volume (mls) 
2 x DMEM 150 
1.4 % Agar 150 
Total 300 
Table 2.22  0.7% (v/v) DMEM agar constituents 
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Reagent Volume (mls) 
1 x DMEM 40 
2 x DMEM 20 
1.4 % agar 20 
Total 80 
Table 2.23 0.35% (v/v) DMEM agar constituents 
 
Both DMEM agar mixtures were kept at 42
o
C to maintain a liquid state.  2 mls of 0.7% 
DMEM agar was added to each well of a 6 well plate to make the base agar level, and 
was left to set at room temperature.  FTC-133 cells expressing various FLCN mutants as 
stable mixed populations were released from flasks using trypsin as described in section 
2.2.1, and were counted.  Per well, 3 x 10
4
 cells were combined with 1 ml of 0.35% agar 
and laid on top of the 0.7% base layer.  This layer was then left to set at room 
temperature.  Finally a further 2 mls of 0.7% agar was place on top of the cells and left to 
set at room temperature.  The plates were left in and incubator for up to four weeks, with 
200 µl of G418 selective media added per well twice weekly.  At day 27 the plates were 
blinded and colonies over 100 microns in size were counted (indicative of loss of growth 
suppression).  Experiments were carried out in 6 wells for each construct.   Reagents 
were purchased from Sigma unless otherwise stated. 
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2.7  Immunofluorescence Microscopy 
Immunofluorescence microscopy was used to determine if apparent non-pathogenic 
FLCN variants might be influencing the cellular distribution of folliculin and also to 
define the cellular context of the interaction between folliculin and p0071. 
Cells were grown on poly-L-Lysine covered cover slips for at least 24 hours before 
fixation.  Media was aspirated and the cells washed 3 times with ice cold PBS.  To fix the 
cells, ice cold 3.7% (w/v) formaldehyde (dissolved in PBS pH 7.0) was added to each 
well and the plate left for 10 minutes on ice.  After this time, formaldehyde was aspirated 
and the slides washed a further 3 times with ice cold PBS.  To permeabilise cell 
membranes, 1 ml of 0.5% Triton-X-100 (Sigma) diluted in PBS was added to each well, 
and incubated on ice for 15 minutes.  The cells were then blocked to prevent non-specific 
antibody binding, by incubating with pre-centrifuged 1% (w/v) milk (diluted in PBS) at 
4
o
C for 2 hours. 
After blocking, the coverslips were washed 3 times with PBS, and placed upturned onto a 
50 µl drop of primary antibody diluted in milk for 1 hour at room temperature.  After 
incubation with primary antibody, the coverslips were washed three times in PBS and 
placed onto a 50 µl drop of corresponding, fluorophore conjugated secondary antibody, 
and incubated in the dark also for 1 hour at room temperature. Antibodies and 
concentrations used are given in Table 2.10 and Table 2.11.  Finally, coverslips were 
washed twice in PBS, once in distilled water and once in 70% ethanol before being left to 
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dry in the dark.  Coverslips were mounted onto glass microscopy slides using ProLong 
Gold Antifade Reagent with DAPI (4',6-diamidino-2-phenylindole) (Invitrogen).    
2.7.1  Bimolecular fluorescence complementation analysis 
Bimolecular fluorescence complementation analysis enabled the direct visualization of 
the interaction between folliulin and p0071 in living cells.  The principles of the assay in 
the context of this thesis are discussed in section 5.3.2.1.      
Full length FLCN was amplified from human cDNA by PCR, and cloned into both Venus 
1 and Venus 2 BiFC vectors, in both N-terminal fusion and C-terminal fusion orientation 
respectively (For plasmid maps for Venus constructs see Appendix 7.1).  Venus 
constructs expressing p0071 fused to both the N terminal half (Venus 1 - amino acids 1-
115) and C terminal half (Venus 2 - amino acids 115-238) of YFP respectively, were co-
expressed with FLCN constructs cloned into the complimentary Venus vector.   
All various combinations of FLCN and p0071 complimentary Venus constructs were co-
transfected into Hela cells using calcium phosphate precipitation (see section 2.2.3.1).  
After 24 hours, the cells were fixed using formaldehyde fixation at 4
o
C, and were stained 
for HA, Flag and DAPI.  Cells in which both FLCN and p0071 Venus-fusion constructs 
were expressed at close to endogenous levels (identified by HA and Flag staining), were 
imaged using a Nikon Eclipse 600 microscope.  BiFC signal was detected at 495 
nanometers, and it was determined that the combination of pVen1-Flag-p0071 and 
p.Ven2-HA-FLCN produced the most easily detectable signal.  To determine potential 
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interaction at cytokinesis, α-tubulin was stained instead of Flag so that midbodies could 
be identified.  Folliculin was predicted by yeast-2-hybrid to bind to the head domain of 
p0071, so a p.Ven1-Flag-p0071 repeats fusion of only the armadillo repeats of p0071 
(head domain of p0071 lacking) was used as a negative control. 
          
2.8 G-LISA RhoA activation assay 
2.8.1 Assay principle 
The small GTPase RhoA, is a molecular switch which operates by alternating between an 
active, GTP bound state and an inactive, GDP bound state.  The mechanisms of RhoA 
activation are discussed in detail in Section 5.1.3.2.  The G-LISA RhoA activation assay 
(cytoskeleton inc.) was used to determine the amounts of active RhoA in various isogenic 
cell models, and hence the differences in the signaling intensity through the RhoA 
pathway.   
The G-LISA kit contains a protein which specifically binds to the GTP-bound form of 
RhoA, linked to the wells of a 96 well plate.  When lysates are added to the plate, only 
active RhoA is bound, and the inactive RhoA removed during washing steps.  The 
amount of GTP-bound RhoA is detected with a RhoA specific antibody, and the signal 
absorbance quantified using a microplate spectrophotometer. 
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2.8.2 Methodology 
2.8.2.1 Cell culture 
Cells were grown in 100 mm dishes for 3 days to reach a confluency of 50-60% by the 
time of harvesting. In experiments including siRNA treatment, cells were seeded on top 
of the siRNA mixture, and left for 3 days to reach the required 50-60% confluency at 
harvesting.  In primary experiments, cells were grown in both normal and serum starved 
media, which had no impact on the experimental outcome.  Subsequent experiments were 
therefore undertaken in normal serum media. 
 
2.8.2.2 Cell lysis 
The binding of RhoA to GTP is a transient occurrence, and is liable to dissociate rapidly 
if exposed to temperatures of greater than 4
o
C for a prolonged period.  Therefore in 
lysing the cells, every effort was made to work as quickly as possible, keeping the cells 
lysates as cold as possible.  Lysate collection was undertaken sequentially to allow rapid 
processing.  After three days of culture, the cells were lysed.  Media was immediately 
aspirated from the 100 mm dish, and the cells rinsed with 10 ml of ice cold PBS.  All 
PBS was carefully removed and 250 µl of ice cold lysis buffer added to the cells.  Lysates 
were harvested with a cell scraper, transferred to an ice-cold 1.5 ml tube and clarified by 
centrifugation at 11180 x g at 4
o
C for 2 minutes.  60 µl of lysate was removed for protein 
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quantification and western analysis, and the remaining lysate snap frozen in liquid 
nitrogen and stored at -80
o
C. 
Equalised protein lysates were immunoblotted for p0071, folliculin, β-actin and RhoA to 
confirm equal loading and successful knockdown where appropriate.   
 
2.8.2.3 G-LISA assay 
Frozen lysates were thawed in a room temperature water bath, and placed on ice once 
thawed.  70 µl of lysate was mixed with an equal volume of binding buffer by vortexing, 
and 50 µl added to duplicate wells of the Rho plate.  A buffer blank negative control and 
1 ng of GTP bound RhoA positive control were also mixed with binding buffer and 
added to duplicate wells.  The plate was then incubated at 4
o
C on an orbital microplate 
shaker (20 g) for 30 minutes.  Lysate was then vigorously removed and the wells washed 
twice with 200 µl of wash buffer.  200 µl of antigen presenting buffer was added to each 
well and incubated at room temperature for 2 minutes.  After 3 more washes with 200 µl 
of wash buffer, the wells were incubated with 50 µl of anti-RhoA primary antibody on a 
microplate shaker for 45 minutes at room temperature.  After incubation, the antibody 
was vigorously removed and the wells washed 3 times in wash buffer, before being 
similarly incubated with 50 µl HRP coupled, secondary antibody for 45 minutes at room 
temperature.  Secondary antibody was removed after the incubation; the wells were 
washed 3 times with wash buffer and 50 µl of HRP detection reagent added to each well.  
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The plate was then left in a 37
o
C incubator for 15 minutes at which point 50 µl HRP stop 
buffer was added to each well to quench the reaction.  The luminescence absorbed from 
each well was immediately measured at 490 nm using a microplate spectrophotometer, 
and the levels of active RhoA calculated in Microsoft Excel according to the G-LISA 
manufacturing instructions.    
 
2.9 In vitro cell scratch migration assay 
The in vitro cell scratch assay was used to study the effects of folliculin loss on cell 
migration.  Cells were grown to full confluency in 6 well plates, and serum starved as 
described in section 2.2.2.  The following day, a scratch in the cell monolayer was made 
with a p200 pipette tip, with a perpendicular scratch for reference.  The cell scratch was 
imaged at the same point (using the perpendicular scratch) at 0 hours and every 24 hours 
until the scratch had healed.  The percentage of scratch healed at each time point was 
determined using ImageJ software.  In the experiments investigating the effects of Rock 
inhibitor Y-27632 (Sigma) on cell migration, 10 µM (dissolved in 20 µl ddH20) was 
added dropwise to each well every 12 hours though out the experiment (media changed 
before each treatment).  In the untreated samples, the same volume of distilled water was 
added to the cells in a similar manner.   
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Chapter 3 Investigations of the FLCN 
gene in familial and sporadic colorectal 
cancer 
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3.1  Introduction and overview 
3.1.1 Colorectal cancer 
Colorectal cancer (CRC) is a major worldwide health risk with over 800,000 new patients 
being diagnosed with colorectal carcinomas each year, making up approximately 8.5% of 
all new cancer cases.  Of these, approximately 30% of patients will have a first or second 
degree relative affected by the cancer (Gatalica and Torlakovic, 2008).  While the 
molecular mechanisms of colorectal tumourigenesis are increasingly well understood, the 
prognosis, particularly for more advanced forms of the disease has not dramatically 
improved (Li and Lai, 2009).  It is crucial to try and catch colorectal cancer as early as 
possible, with over a 90% five year survival rate for those cases caught at Dukes stage A 
(currently only around 9%) (O'Connell, et al., 2004).  This can be achieved by identifying 
groups at increased risk of colorectal cancer (especially if earlier onset), and subsequently 
tailoring their colonoscopy surveillance to this information.  The interaction between a 
person’s genetics and environmental factors play an important role in colorectal 
carcinogenesis, and it is through insights into both these mechanisms that these at risk 
groups can be identified. 
   
3.1.2 The genetic mechanisms of colorectal tumourigenesis 
Colorectal tumorigenesis is a multistep process of genetic alterations that cause the 
progressive transformation from normal colorectal mucosa into benign adenomas and 
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eventually highly malignant carcinomas.  This progression is driven by the accumulation 
of mutations; each one providing a growth advantage to the mutated cells.  The mutated 
cancer cells acquire various advantageous properties including uncontrolled proliferation, 
the loss of intracellular adhesion, the ability to digest the basement membrane, enhanced 
motility and the ability to survive in remote locations (Tejpar and Van Cutsem, 2002). 
E. Fearon and B. Vogelstein proposed the following model for colorectal tumourigenesis.  
It has since been confirmed and expanded, and is considered a classic genetic model of 
tumourigenesis (Fearon and Vogelstein, 1990).    
 
 
 
Figure 3.1  Genetic model of colorectal tumourigenesis 
Adapted from (Tejpar and Van Cutsem, 2002) 
 
 
While more recent studies have confirmed the model proposed by Fearon and Vogelstein, 
there are many additional genes which have been demonstrated to also be involved 
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(Lynch and de la Chapelle, 2003).  Colorectal cancers progress through the accumulation 
of additional genetic instability which drives the accumulation of other cancerous 
mutations.  This instability is achieved either through chromosomal instability (as in 
Familial Adenomatous Polyposis) or microsatellite instability (as in Lynch 
syndrome/HNPCC), observed in both sporadic and familial colorectal cancers andnd is 
discussed in more depth in section 3.1.3.  As a consequence of these molecular 
alterations, tumour suppressor genes can be inactivated (by mutation, deletion or 
epigenetic mechanisms) or proto-oncogenes activated.  
 
3.1.2.1 Inactivation of APC is characteristic of the majority of colorectal cancers  
APC is a tumour suppressor gene that is inactivated in more than 80% of colorectal 
cancers, a common feature of colon cancers driven by chromosomal and microsatellite 
instability.  One of the functions of APC is to prevent the accumulation of catenins that 
can lead to the accumulation of oncogenes c-myc and cyclinD1 (Su, et al., 1993).  The 
cellular levels of β-catenin, a mediator in the wnt/wingless signalling pathway, are 
regulated by the APC gene product.  The wnt signall transduction pathway is a complex 
network of proteins that regulates the transcription of certain genes in response to 
extracellular glycoprotein ligands, often in conjunction with other pathways notably the 
transforming growth factor-B (TGF-B) and fibroblast growth factor (FGF) pathways 
(Tejpar and Van Cutsem, 2002).  A brief summary of Wnt signalling in the physiological 
and cancer setting is displayed in Figure 3.2. 
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3.1.2.2 Wnt signalling and colorectal cancer 
 
 
Figure 3.2 Summary of the Wnt signaling transduction pathway     
(Logan and Nusse, 2004) 
In the absence of Wnt signalling, a cytoplasmic degrading complex including APC, 
glycogen synthase kinase 3B and β-Catenin, causes the phosphorylation of both β-catenin 
and Axin by GSK-3B.  This initialises the interaction of β-catenin with β-TrCP, leading 
to the ubiquitination of β-catenin and hence its degradation in the proteosome.  Therefore 
the Wnt target genes remain off. 
When the Wnt signal is present, it interacts with its co-receptors Frizzled and LRP, which 
causes the modular protein, dishevelled (Dsh), to be activated.  Dsh interacts with Axin to 
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antagonise GSK3, halting the ubiquitination of β-catenin.  Therefore β-catenin 
accumulates in the nucleus, interacts with TCF/LEF transcriptors and leads to the 
activation of Wnt target genes as an essential co-activator of transcription (Alberici and 
Fodde, 2006).  Numerous TCF target genes have been identified and appear to be cell 
type specific, MYC (c-myc) and CCND1 (Cyclin D1) being of major interest for cancer 
research (Clevers, 2006).      
Although this pathway is a normal developmental pathway, its deregulation is a 
fundamental event in the initiation of colorectal cancer.  80% of colorectal adenomas 
have mutations in APC and of the other 20%, half harbour activating CTNNB1 (β-
catenin) mutations (Sparks, et al., 1998).  Other genes encoding key members of the Wnt 
signalling pathway are also altered in colorectal cancer albeit less frequently, e.g. 
mutations in the genes  AXIN1 , AXIN2 and TCF7L2 (T-cell factor 4 a β-catenin binding 
transcription factor) and also the epigenetic silencing of genes such as sFRPs (secreted 
frizzled-related proteins).  Despite the wnt pathway being known to activate alternate 
pathways including activation of Rho GTPase, Jun kinase and calcium dependent 
effectors, and wnt ligands being able to bind to alternate receptors such as Ryk and 
ROR2, activation of the wnt pathways has proved to be the key action for developing 
colorectal cancer cells (Polakis, 2007). 
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3.1.3 The chromosomal and microsatellite instability pathways of colorectal 
tumourigenesis 
The progression to more advanced colorectal cancer occurs by adenoma cells acquiring 
additional genetic instability via either the chromosomal instability pathway or the 
microsatellite instability pathway.     
 
3.1.3.1 Chromosomal instability  
Chromosomal instability (CIN) is found in approximately 90% of colorectal cancers 
(Yim, 2011).  CIN tumours develop gains or losses of whole chromosomes at a rate that 
is up to 100 times higher compared with normal cells.  BUB1 was the first gene reported 
that when mutated, lead to CIN (Cahill, et al., 1998), although loss of function of APC 
itself has been implicated in producing chromosomal instability (Fodde, et al., 2001).  
The progression to invasive colorectal carcinoma is achieved through the deregulation of 
numerous signalling pathways including, Wnt signalling, TGF-β signalling, and the p53 
and K-ras pathways (Tejpar and Van Cutsem, 2002). 
 
3.1.3.2 Microsatellite instability 
Microsatellites are short, repetitive DNA tracts, and are mostly found in non-coding 
sections of the genome.  However certain genes associated with promoting cancer, 
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including APC and K-ras, contain coding microsatellites.  Mutations in one of the main 
mismatch repair (MMR) genes MLH1, MSH2, MSH3 MSH6 (MSH2 and MLH1 are 
responsible for 90% of cases) lead to deficiency in mismatch repair proteins, promoting 
mutations in genes harbouring coding microsatellites (Yim, 2011).  These genes 
accumulate frame-shift mutations and hence become non-functional, fuelling the 
progression of colorectal cancer.  However it is often unclear which microsatellite 
mutations are driving tumourigenesis and which mutations represent background 
microsatellite instability, not contributing to the progression of cancer.  Microsatellite 
instability can be caused by sporadic inactivation of MMR genes, or due to a germline 
mutation in a MMR gene causing Lynch syndrome (discussed below).  Interestingly, 
APC is one of numerous genes at increased risk of mutation in the background of 
mismatch-repair gene deficiency, and thus MMR genes are thought to represent 
“caretaker” genes which increase the mutation rate, whereas APC is believed to be a 
“gatekeeper” where mutation initiates neoplasia directly (Gryfe, 2009).   
 
3.1.4 Hereditary colorectal cancer 
The risk of developing colorectal cancer in the general population is between 5-6%.  
Patients with a familial risk (one or more first or secondary degree relatives with the 
disease) make up around 20% of all colorectal cancer cases, with 5-10% of all cases 
displaying a mendelian pattern of inheritance (Lynch and de la Chapelle, 2003). 
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The fraction of familial cancers related to high penetrance, predisposition alleles is 
relatively modest.  The best understood colorectal syndromes, Familial Adenomatous 
Polyposis (FAP) and Hereditary non-polyposis colorectal cancer (HNPCC or Lynch 
Syndrome), together account for less than 5% of colorectal cancers, the remaining 
familial risks are likely due to lower penetrance alleles (de la Chapelle, 2004).  
Identifying genes associated with familial cancers can help to identify at risk families, 
facilitating early detection, but can also provide important insights into the pathogenesis 
of both the familial and sporadic forms of the disease.  For example, the discovery that 
mutations in the APC gene cause FAP, identified APC as a key gene to be mutated in the 
majority (>80%) of sporadic colorectal cancers (see FAP section below). 
 
3.1.4.1 Lynch syndrome/Hereditary non-polyposis colorectal cancer (HNPCC)  
Lynch syndrome is the most common heritable colon cancer syndrome and is dominantly 
inherited.  Multiple generations are affected with the cancer with an early age of onset 
(mean approximately 45 years).  Lynch syndrome also exhibits accelerated 
carcinogenesis, whereby a small colonic adenoma may become a carcinoma in 2 to 3 
years as opposed to the 8 to 10 years seen in the general population (Lynch and de la 
Chapelle, 2003).   The syndrome is caused by a lack of functional mismatch repair 
proteins due to germline mutations in mismatch repair (MMR) genes MSH2, MLH1, less 
frequently in MSH6 and rarely in PMS2 (Imai and Yamamoto, 2008).  Germline MMR 
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gene mutations are implicated in the development of various cancers, with a penetrance 
of approximately 80% for colorectal cancer, 60% for endometrial cancer and less than 
20% for a number of other organs.  The lack of functional MMR proteins reflects in high 
microsatellite instability and the accumulation of mutations in the exonic microsatellites 
of multiple cancer driving genes (see microsatellite instability section).  Lynch syndrome 
makes up approximately 3-5% of the total cancer burden in the USA (Gatalica and 
Torlakovic, 2008). 
 
3.1.4.2 Familial adenomatous polyposis 
Familial adenomatous polyposis (FAP) is another hereditary colorectal cancer syndrome 
which, like Lynch syndrome, presents autosomal dominant inheritance.  The syndrome is 
characterised by a large number (>100) of adenomatous colorectal polyps usually 
presenting in adolescence (de la Chapelle, 2004).  FAP makes up less than 1% of all new 
colorectal carcinomas observed, and is caused by a germline mutation in the APC gene 
(Kinzler, et al., 1991).  In fully developed cases, the colonic mucosa is carpeted by 
hundreds of polyps, evenly distributed along the whole large bowel.  At mean age of 40, 
second hit mutations/deletions result in adenocarcinoma development in a small 
proportion of these adenomas, with malignant degradation in most patients by the age of 
50 (Lynch and de la Chapelle, 2003). 
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3.1.4.3 MYH associated polyposis 
A second genetic pre-disposition to colorectal adenomatous polyposis and cancer, caused 
by mutations in the MYH gene, was identified in 2002 (Al-Tassan, et al., 2002).  The 
polyposis in MYH mutation carriers is generally less severe that for FAP patients.  MYH 
functions in DNA proofreading (base-excision repair) and inactivation of MYH leads to 
somatic mutations, in particular, a specific G:C to T:A transversion mutation in the APC 
gene.  Thus MYH, similarly to MMR genes, can also be described as a “caretaker” gene 
(Gryfe, 2009).          
 
3.1.5 The possible association between Birt Hogg Dubé Syndrome and increased risk 
of colorectal cancer 
Birt Hogg Dubé syndrome is characterised by the development of fibrofolliculomas on 
the face and upper torso, renal cell carcinoma, lung cysts and pneumothorax, however the 
association with increased risk of colorectal cancer is more controversial. 
Early reports of BHD syndrome described colorectal cancer as being part of the BHD 
phenotype (Birt, et al., 1977; Chung, et al., 1996; Hornstein, 1976; Rongioletti, et al., 
1989; Schachtschabel, et al., 1996; Schulz and Hartschuh, 1999).  However a large study 
of 111 BHD patients by Zbar et al. (2002), found only 3 to have colon cancer compared 
with 0 of the 112 non-BHD-affected control group (p=0.12) and regarding neoplasia, 8 of 
45 BHD-affected persons compared with 7 of 38 non-affected-controls had colon polyps 
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by colonoscopy (p=1.00). The study concluded that colonic neoplasms were not 
associated with BHD syndrome (Zbar, et al., 2002). 
Nevertheless, Khoo et al. (2002) described a large BHD syndrome family in which 6 of 
20 affected family members had developed colonic polyposis and 2 had died of probable 
gastrointestinal cancer.  These observations suggest that the association between BHD 
and colonic neoplasia may only relate to certain BHD families and that the interfamilial 
differences described may relate to allelic heterogeneity or modifier effects (Khoo, et al., 
2002). 
A small number of studies have examined the role of FLCN inactivation in colorectal 
tumourigenesis.  Da Silva et al. (2003) reported a germline missense substitution 
(p.Arg320Gln) and a somatic missense substitution (p.Arg392Gly) in a study of 29 
primary colorectal tumours, although the pathogenicity of these variants is unclear.  Shin 
et al. (2003) identified frameshift mutations in the FLCN exon 11 mononucleotide tract, 
in 5/32 sporadic, microsatellite unstable colorectal tumours.  Kahnoski et al. (2003) 
reported two novel missense variants Ser79Trp and Ala455Thr in 30 microsatellite stable 
CRCs, also of unknown pathogenicity (da Silva, et al., 2003; Kahnoski, et al., 2003; Shin, 
et al., 2003) 
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3.2 Aims and Approaches 
Previously, members of our laboratory had identified unsuspected germinline FLCN 
mutations in ~5% of patients with inherited RCC (familial RCC, multiple tumours or 
early onset) but no know causative syndrome (Woodward, et al., 2008).  To further 
investigate the potential role of folliculin in the pathogenesis of colorectal cancer  it was 
investigated (1) whether individuals with non-syndromic, familial colorectal cancer may 
harbour germline FLCN mutations (and how this compared with mutation rates in a new 
cohort of non-syndromic familial RCC patients), (2) whether there were potential 
genotype-phenotype correlations for CRC in BHD patients and (3) the frequency and 
clinicopathological associations of exon 11 mononucleotide repeat mutations in FLCN, in 
microsatellite unstable CRC. 
 
3.3 Patients and samples 
Four cohorts of patients were used for this study.  (1) Blood DNA samples from 50 
unrelated patients with familial colorectal cancer and no evidence of germline MMR gene 
mutations or FAP, were sequenced for germline FLCN mutations.  FLCN was also 
sequenced in DNA extracted from five colorectal cell lines available in the laboratory 
(HCT-116, DLD-1, SW480, LoVo and HT29).  (2) Similarly blood DNA from 39 
unrelated patients with a familial risk of RCC (2 or more relatives with the disease), but 
no clinical diagnosis of VHL disease, BHD syndrome, familial leiomyomatosis or a 
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germline VHL mutation, and no evidence of a 3p chromosomal translocation were also 
analysed for germline FLCN mutations.  All 11 coding exons and exon/intron boundaries 
were amplified by PCR and sequencing carried out directly from PCR products. (3)  
Clinical data for colorectal neoplasia (colon cancer or adenomatous polyps) was collected 
from 149 BHD syndrome affected patients from 51 families (FLCN mutation positive or 
clinically diagnosed according to European BHD consortium criteria (Menko, et al., 
2009)).  A subset of these patients (15 British and Dutch kindreds harbouring one of two 
recurrent, germline FLCN mutations) were analysed to identify possible genotype 
phenotype correlations for colorectal neoplasia.  (4)  DNA extracted from paraffin 
embedded tumour samples from 30 patients with microsatellite unstable colorectal cancer 
was analysed for somatic mutations in the mutation hotspot, C8 mononucleotide tract in 
FLCN exon 11, and in the mononucleotide tracts in TGFBR2, IGF2R and MSH6 genes.   
Mutations analysis was performed as described in methods 2.1 using the primers in Table 
2.3 and Table 2.4. 
 
 
 
 [103] 
 
3.4  Results 
3.4.1 FLCN mutation analysis in individuals with familial, non-syndromic RCC and 
CRC 
FLCN mutations were identified in 3 of 39 patients with familial RCC (see Figure 3.3).  
The study also included a positive control patient whose FLCN mutation had been 
previously reported.  This mutation was correctly identified in the study.  The p.S386X 
nonsense mutation identified in exon 10 is novel and has not been previously reported.  It 
was not present in 164 normal control DNA samples also tested (Figure 3.3), nor was it 
found to be present in dbSNP (http://www.ncbi.nlm.nih.gov/projects/SNP/) or Exome 
Variant Server (evs.gs.washington.edu).  
No FLCN mutations were detected in the cohort of patients with familial colorectal 
cancer, although one heterozygous variant of unknown significance (p.R362C) was 
identified in the LoVo cell line (Figure 3.3). 
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 Figure 3.3 Summary of FLCN mutations detected  
(A) Diagram of electropherograms displaying three previously unidentified mutations, 
p.S386X in exon 10, p.Y463X in exon 12 and p.Ala204X in exon 6 
(B) Previously identified, control mutation (p.R239C) in exon 7 
(C) Mutation detected in colorectal cell line LoVo 
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3.4.2 Genotype-phenotype correlations for colorectal cancer in BHD patients 
The cohort of 149 BHD patients were analysed for age related risk of colorectal cancer 
and colorectal neoplasia (cancer or neoplastic polyps).  The risk of colorectal cancer and 
colorectal neoplasia are shown in Figure 3.4.  Five members of the cohort had developed 
a CRC (mean age 57.4 years, range 48-64 years) and five patients had been diagnosed 
with colorectal polyps (mean age 52.0 years, range 42-68 years) (Figure 3.4). 
Of this cohort, germline FLCN mutations had been described in 32 of the 51 families 
(104 affected individuals).  Six mutations were found in two or more families, only two 
mutations present in more than 5 patients.  The frameshift mutation c.1285dupC in exon 
11, was present in 37 patients from 9 families and the c.610delGCinsTA nonsense 
mutation in exon 6, was present in 32 patients from 6 families.  5 patients harbouring the 
c.1285dupC mutation developed a colorectal neoplasm (3 of which were malignant) in 
contrast, none of the exon 6 mutation carriers developed a colorectal polyp or cancer.  
Comparison of the risks of colorectal neoplasia in c.1285dupC and c.610delGCinsTA 
mutation carriers displayed a significantly higher risk of colorectal neoplasia in the 
mononucleotide tract mutation carriers (χ2=5.78, p=0.016) (Figure 3.5). 
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Figure 3.4 Age related risk of colorectal cancer (A) and neoplasia (B) in a cohort of 
149 BHD patients from 51 families.  
Error bars represent 95% confidence intervals 
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Figure 3.5 Comparison of the risks of colorectal neoplasia in FLCN c.1285dupC and 
c.610_611delGCinsTA mutation carriers. 
Error bars represent 95% confidence intervals 
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3.4.3 FLCN C8 mononucleotide repeat mutation analysis in sporadic colorectal cancer 
tumours with microsatellite instability 
The genotype-phenotype correlation identified suggested allelic heterogeneity in FLCN 
might be responsible for the differing risks of colorectal neoplasia in BHD patients, 
specifically at the exon 11 mononucelotide tract.  Exonic mononucleotide tracts, such as 
that in FLCN, may be at increased risk of accumulating mutations under microsatellite 
unstable conditions. To test if this region might be mutated in sporadic colorectal cancers, 
the FLCN mononucleotide tract was sequenced in 30 microsatellite unstable colorectal 
tumour DNAs.  Seven of 30 (23%) microsatellite unstable CRCs were identified to have 
heterozygous frameshift mutations within the FLCN mononucleotide repeat region in 
exon 11 (C8).  In five cases, the mutation was a single cytosine deletion (c.1285delC) and 
in two cases a single cytosine insertion (c.1285dupC) (Figure 3.6 ). Mean % (+standard 
deviation) of microsatellite instability (i.e. % of microsatellite markers showing 
instability divided by number of microsatellite markers tested) was similar in FLCN C8 
mutated and non-mutated tumours (83.5 (+8.38) and 64.2 (+5.86) respectively (t=1.57 
P=0.128 – 2 tailed, independent Student’s T Test. The mean % of mononucleotide 
microsatellite instability (tested using BAT25, BAT26 and/or BAT40 (Lynch and de la 
Chapelle, 2003)) was similar for FLCN mutated and non-mutated tumours (77.8 (+16.47) 
and 69.6 (+8.76) respectively (t=0.434 P=0.667 – 2 tailed, independent Student’s T 
Test)).  Results of MSH2 and MLH1 protein expression (by routine 
immunohistochemistry) were available for 26 tumours. The frequency of FLCN C8 
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mutations was significantly higher in tumours that demonstrated loss of MLH1 or MSH2 
protein expression than in those with no loss (43% (6/14) and 0% (0/12) respectively 
(P=0.017 – Fisher’s exact test)) (Table 3.1).  To give an indication of the relative 
frequency of FLCN mutations compared with other known colorectal cancer MSI+ target 
genes, the mononucleotide tracts in TGFBR2, IGF2R and MSH6 were also sequenced in 
the same samples.  All tumours tested demonstrated a mutation within the A10 tract in 
TGFBR2 and 2/30 (7%) harboured a mutation within the G8 tract in IGF2R. The two 
tumours with IGF2R mutations demonstrated instability for all microsatellite markers 
tested (6/6 and 7/7 markers). Immunohistochemistry for MSH2 and MLH1 expression 
was available for one of the IGF2R unstable cancers and loss of MLH1 expression was 
detected. No tumour demonstrated a mutation in both FLCN and IGF2R. MSH6 
mononucleotide tract mutations were detected in 7/30 (23%) of the colorectal cancers 
tested (28.5% and 8% respectively of those with and without MSH2 or MLH1 protein 
expression loss; P=0.17 – Fisher’s exact test) (Table 3.2). 
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Figure 3.6 Schematic diagram of p.His429ThrfsX39 and p.His429ProfsX27. 
Electropherograms showing the two mutations detected in 30 microsatellite unstable 
colorectal cancers, affecting the mononucleotide tract in exon 11 of FLCN 
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Tumour Folliculin MSI Immunohistochemical analysis 
1 no mutation 4 of 4 (3/3BATs) Loss of MLH1 
2 no mutation 4 of 4 (3/3BATs) n/a 
3 no mutation 2 of 4 (1/3BATs) No loss of MLH1/MSH2 
4 mutation 7 of 7 (3/3BATs) Loss of MLH1 
5 no mutation 6 of 6 (3/3BATs) n/a 
6 no mutation 2 of 7 (0/3BATs) No loss of 
MLH1/MSH2/MSH6/PMS2 
7 no mutation 3 of 7 (2/3BATs) No loss of MLH1/MSH2/MSH6 
8 no mutation 2 of 7 (0/3BATs) No loss of MLH1/MSH2 
9 no mutation 4 of 4 (0/0BATs) Loss of MLH1 
10 mutation 4 of 5 (2/2BATs) Loss of MLH1/PMS2 
11 no mutation 3 of 6 (2/2BATs) No loss of MLH1/MSH2 
12 no mutation 2 of 7 (0/3BATs) No loss of MLH1/MSH2 
13 no mutation 3 of 7 (3/3BATs) No loss of MLH1/MSH2 
14 mutation 7 of 7 (3/3BATs) Loss of MSH2 
15 no mutation 7 of 7 (3/3BATs) Loss of MLH1 
16 no mutation 3 of 7 (3/3BATs) Loss of MLH1 
17 no mutation 4 of 6 (3/3BATs) n/a 
18 no mutation 2 of 4 (1/3BATs) No loss of MLH1/MSH2 
19 no mutation 3 of 7 (0/3BATs) No loss of MLH1/MSH2 
20 no mutation 6 of 7 (3/3BATs) Loss of MLH1 
21 no mutation 7 of 7 (3/3BATs) No loss of MLH/MSH2 
22 no mutation 3 of 7 (3/3BATs) No loss of MLH1/MSH2 
23 mutation 3 of 6 (0/3BATs) n/a 
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24 no mutation 5 of 7 (1/3BATs) Loss of MSH2 
25 mutation 5 of 7 (2/3BATs) Loss of MLH1 
26 no mutation 2 of 7 (2/3BATs) No loss of MLH1/MSH2 
27 no mutation 7 of 7 (3/3BATs) Loss of MLH1/PMS2 
28 mutation Unknown Loss of MLH1/PMS2  
29 mutation 7 of 7 (3/3BATs) Loss of MLH1 
30 no mutation 5 of 7 (3/3BATs) Loss of MSH2 
Table 3.1 Details of FLCN mutation status and immunohistochemical status of 
mismatch repair proteins in MSI+ colorectal tumour DNA samples analysed, where 
information available  
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Tumour FLCN  IGF2R MSH6 TGFBR2 
1 - - - + 
2 - - - + 
3 - - - + 
4 + - - + 
5 - + + + 
6 - - - + 
7 - - - + 
8 - - - + 
9 - - + + 
10 + - - + 
11 - - - + 
12 - - - + 
13 - - - + 
14 + - - + 
15 - - - + 
16 - - - + 
17 - - + + 
18 - - - + 
19 - - - + 
20 - - - + 
21 - - + + 
22 - - - + 
23 + - - + 
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24 - - - + 
25 + - + + 
26 - - - + 
27 - + - + 
28 + - - + 
29 + - + + 
30 - - + + 
Table 3.2 Mutation profile of the mononucleotide repeat in four MSI+ target genes in 
30 MSI+ colorectal tumours 
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3.5  Discussion 
Cumulatively, the lifetime risk of developing colorectal cancer in the USA is high, close 
to 6% (Bazensky, et al., 2007).  Assessing the precise tumour risks associated with rare 
familial cancer syndromes is a problem for geneticists, because of the limited number of 
patients available and the possible ascertainment bias associated with this. 
The risks of colorectal neoplasia in this cohort (cohort (3) described in the methods 
section to this chapter) of BHD patients was around 20% and is notably higher than that 
in the general population (~6%) (Jemal, et al., 2002), however much larger numbers of 
patients would be required to obtain statistically significant results.   
The results presented in this chapter differ from that of (Toro, et al., 1999), who found no 
colorectal neoplasms in 152 BHD syndrome patients.  In a subsequent study from the 
same group, 3 colorectal tumours were detected in 111 patients with BHD syndrome, 
which was not statistically different from the number (0) in unaffected members of BHD 
families, leading the authors to conclude that there was no increased risk of colorectal 
neoplasia in BHD syndrome (Zbar, et al., 2002).  Our findings are more similar to those 
of Khoo et al. (2002) who described a large French family with BHD syndrome, and an 
increased risk of colorectal neoplasia. 
Differences in risk of colorectal neoplasia between different studies and BHD families 
may be the result of interfamilial differences in environment, or genetic modifier effects.  
The results presented in this chapter suggest that it is probable the differences observed 
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are due to FLCN allelic heterogeneity; different mutations within FLCN being associated 
with differing risks of colorectal cancer.  This study identified that BHD patients with a 
mutation in the mononucleotide tract in exon 11 had a significantly higher risk of 
colorectal neoplasia than those with a c.610_611delGCinsTA nonsense mutation.  It is 
also interesting to note that the high risk family described by Khoo et al. (2002) also 
affected the same locus (c.1285delC (previously reported as c.1733delC)).  In the absence 
of nonsense mediated decay, exon 11 mononucleotide mutations with a single cytosine 
deletion would be predicted to result in a protein with p.His429ThrfsX39 (lacking 114 
amino acids) and a single cytosine duplication p.His429ProfsX27 (lacking 126 amino 
acids).  A possible explanation for the genotype-phenotype correlation observed is that if 
p.His429ThrfsX39 and p.His429ProfsX27 were produced in colorectal cells, they might 
exert a dominant negative effect on endogenous folliculin function not associated with 
the c.610delGCinsTA mutation (p.Ala204X (lacking 377 amino acids)).  Alternatively, 
the shorter protein produced from the c.610delGCinsTA mutation may have differential 
effects on as yet undetermined folliculin functions (both mutations lack the FNIP1/FNIP2 
binding domain).  However Toro et al. (2008) reported 19 patients with exon 11 
mononucleotide frameshift mutations who did not develop colorectal neoplasia, and 
hence further studies are required to confirm this finding in a larger dataset.  If proven, it 
will be very useful to determine a functional explanation for the genotype-phenotype 
correlation observed, with an overall aim of providing better surveillance for those BHD 
patients at increased risk of CRC, and potentially influencing therapeutic strategies in the 
future.  
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Familial cancer genes are often also somatically inactivated in sporadic forms of the 
disease.  Such examples include the finding of VHL and APC somatic mutations in most 
clear cell RCC and colorectal cancers respectively (Gallou, et al., 1999; Miyoshi, et al., 
1992).  Conversely, genetic studies into FLCN have revealed a low frequency of 
mutations in sporadic colorectal cancer.  Three studies have previously investigated 
FLCN in sporadic colorectal cancer, reporting FLCN heterozygous mutation frequencies 
of 2/30 microsatellite stable CRC (p.Ser79Trp and p.Ala455Thr), 5/32 microsattelite 
unstable CRC, and 2/29 CRC (germline p.Arg320Gln and somatic p.Arg392Gly) (da 
Silva, et al., 2003; Kahnoski, et al., 2003; Shin, et al., 2003) respectively.  The 
pathogenicity of the missense changes is unclear, and having never been reported as 
germline mutations in BHD patients, it is impossible to determine if they represent 
“passenger” mutations or those driving cancer progression. 
Having identified an association between the germline FLCN c.1285dupC mutation and 
colorectal neoplasia, the potential link between colorectal neoplasia and exon 11 
mononucleotide mutations was further investigated by analysing the region for somatic 
mutations in 30 microsatellite unstable (MSI+) CRCs.  As aforementioned, 
mononucleotide repeat regions are known to be hypermutable in MSI+ CRC.  Kahnoski 
et al. (2003) did not detect C8 mutations in 8 MSI+ CRC analysed (Kahnoski, et al., 
2003), however Shin et al. (2003) detected two c.1285dupC, two c.1285delC and one 
c.1285delCC in 32 sporadic MSI+ CRC’s (5/32 = 16%) (Shin, et al., 2003).  In this study, 
FLCN C8 tract mutations were identified in 23% of MSI+ CRC analysed.  In addition to 
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the mutant sequence, WT sequence was also detected (Figure 3.6), suggesting either the 
absence of loss of heterozygosity (no second hit mutation was identified in 4 MSI+ 
tumours for which every exon was sequenced) and a possible dominant negative effect, 
or perhaps the presence of normal tissue in the tumour sample.   
Evolution of tumours to a more advanced and aggressive state (including the 
microsatellite unstable tumourigenesis pathway) is reliant on the selection of mutations 
within genes driving neoplastic growth.   These driver mutations occur in the background 
of a large number of random mutations having no impact on cancer progression.  It was 
therefore important to try and identify if the somatic mutations we observed in FLCN 
were likely to be driver or passenger mutations.  A number of criteria have been 
suggested to distinguish driver mutations in MSI, including (a) a high mutation 
frequency, (b) biallelic inactivation, (c) involvement in a growth suppressor pathway, (d) 
inactivation of the same pathway in MSS tumours and (e) functional studies (Boland, et 
al., 1998).  Despite points (b) and (c) proving controversial (Perucho, 1999), mutation 
frequency and functional studies, are argued to be the simplest parameters for defining 
the likelihood of mutations being drivers (Woerner, et al., 2003).  The functions of FLCN 
beyond its role as a general tumour suppressor are not yet well defined.  We were unable 
to confirm biallelic inactivation in our samples, and so chose to compare the frequency of 
FLCN mutations in our samples to those of other previously reported, functional 
colorectal MSI+ target genes. 
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The frequency of FLCN mutations (23%) was less than that of TGFBR2 (100%), similar 
to that of MSH6 (23%) and greater than that of IGF2R (7%) (Table 3.2).  Somatic 
mutations in IGF2R and MSH6 have been considered to contribute to tumourigenesis in 
MSI+ CRC’s (Malkhosyan, et al., 1996; Souza, et al., 1996), suggesting that the 
frequency of FLCN mononucleotide mutations in MSI+ CRC may be consistent with 
mutations in the gene undergoing selection during tumourigenesis.   
Folliculin has been reported to have a role in mTOR signalling (Baba, et al., 2006) (See 
section 1.3.6.1).  Interestingly, deregulation of the mTOR pathway has been previously 
linked to intestinal tumourigenesis; Cowden syndrome presents a gastrointestinal 
polyposis phenotype (Umemura, et al., 2008) and rapamycin (inhibitor of mTORC1) is 
able to suppress polyp formation in a mouse model of human FAP (Fujishita, et al., 
2008).  However, folliculin is likely to have multiple functions and, thus to properly 
determine the role of FLCN in colorectal cancer, it will first be necessary to better 
characterise the function of the folliculin protein. 
Mutations in FLCN have been previously identified in individuals with non-syndromic 
RCC (Woodward, et al., 2008).  This study reports a comparative frequency of FLCN 
germline mutations identified in a similar group of familial RCC patients (7.7%).  The 
p.S386X, c.1655C>G, is a novel nonsense mutation that has not been previously reported 
in FLCN.  The c.610delGCinsTA is a recurrent mutation in BHD syndrome and this 
study therefore excludes the possibility that a distinct set of FLCN mutations are 
responsible for the “non-syndromic” RCC susceptibility phenotype.  
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In contrast we did not identify any germline mutations in 50 patients with “non-
syndromic” inherited CRC.  The difference between the involvement of FLCN in these 
two situations may have several explanations.  BHD is a rare disorder and familial CRC 
is more frequent than familial RCC, hence it may be necessary to test a larger group of 
familial CRC patients to identify a causative FLCN mutation.  Also, whereas BHD is 
associated with early onset RCC, this study reports the mean age of colorectal cancer to 
be 57.4 years.  As many diagnostic criteria for familial CRC include early onset tumours, 
it is therefore less likely that BHD patients may present in this group.  The missense 
variant (p.Arg362Cys) identified in the colorectal cell line LoVo is of unknown 
significance, and is further investigated in Chapter 4. 
In summary, the identification of a genotype-phenotype correlation for colorectal 
neoplasia risk in BHD is a potential explanation for the heterogeneity reported in the 
literature.  It does appear that the increased risk of colorectal neoplasia is restricted to a 
subset of BHD families.  Further studies are required to confirm this finding, with the 
potential for using FLCN mutation type to determine the need for colonic surveillance in 
BHD patients.   
In light of these findings, it was decided to investigate the mechanism of pathogenicity of 
previously reported germline FLCN mutations, with the aims of providing insights into 
wildtype folliculin function, investigating the cellular effects of pathogenic FLCN 
mutations and trying to elucidate the basis for the genotype-phenotype correlation 
reported in this chapter, at a functional level.   
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Chapter 4 Birt Hogg Dubé syndrome-
associated FLCN mutations disrupt 
protein stability 
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4.1 Introduction 
Twenty four years after the syndrome was first described, the gene locus for Birt Hogg 
Dubé syndrome was localised to chromosome 17p11.2 by linkage analysis (Khoo, et al., 
2001; Schmidt, et al., 2001).  The following year, truncating mutations were identified in 
a novel gene at that locus, FLCN; a gene with an encoded protein product, folliculin, 
which had no known function (Nickerson, et al., 2002).  Subsequently, FLCN mutations 
have been identified in patients with familial primary spontaneous pneumothorax (PSP) 
and in familial renal cell carcinoma patients lacking the other classical BHD 
manifestations (Frohlich, et al., 2008; Graham, et al., 2005; Gunji, et al., 2007; Painter, et 
al., 2005; Ren, et al., 2008; Woodward, et al., 2008). 
The FLCN gene consists of 14 exons (transcription commencing in exon 4) encoding a 
protein of 579 amino acids, folliculin (Nickerson, et al., 2002).  Close to 85% of patients 
with BHD syndrome have been found to harbour germline FLCN mutations (Nickerson, 
et al., 2002; Schmidt, et al., 2005) and recent work by Benhammou et al (2011) has 
identified large intragenic gene duplications and deletions in seven BHD families 
previously found to be FLCN mutation negative by sequencing.  These duplications and 
deletions are thought to account for at least 5% of cases of BHD syndrome (Benhammou, 
et al., 2011).  
In 2010, a FLCN mutation database was collated to identify and pool all previously 
reported FLCN mutations (Lim, et al., 2010).  At the time of writing, 147 unique FLCN 
variants are listed on the database, of which 132 are reported as pathogenic.  Mutations 
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have now been identified in all coding exons, with a mutation hotspot of eight cytosine 
residues in exon 11 where close to 50% of mutations are reported to occur (Schmidt, et 
al., 2005).  Consistent with the putative tumour suppressor function for FLCN, the vast 
majority of pathogenic FLCN mutations are predicted to prematurely truncate the 
encoded product, in the absence of nonsense mediated decay.  The FLCN mutation 
database describes 52.9% frameshift, 20% splice site and 14.3% nonsense mutations 
(Lim, et al., 2010). 
In addition, a small number of potential FLCN non-truncating, missense or in-frame 
deletion mutations have been described (see Table 4.1).  These mutations are of particular 
interest as they could indicate the importance of specific domains within the protein 
which result in BHD syndrome phenotype when disrupted.  However unless a missense 
substitution is detected in a large kindred and shown to segregate with disease status or 
affect protein function, the pathogenicity of rare, non-truncating variants can be difficult 
to determine. 
Most human genetic variation is represented by single nucleotide substitutions, 
accounting for about 90% of sequence differences (Wang and Moult, 2001).  It is 
estimated that 60,000 to 87,600 substitutions occur in coding regions causing an 
alteration of the wildtype amino acid (Cargill, et al., 1999; Livingston, et al., 2004).  
These are most often neutral changes (benign single nucleotide polymorphisms), but in 
rare cases are pathogenic.  In an age of high-throughput sequencing methods, the 
numbers of such reported variants is rapidly increasing and the ability to discriminate 
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between benign and pathogenic variants is therefore of great importance.  An amino acid 
substitution or deletion may disrupt critical sites for the function of the protein, such as 
ligand binding pockets or catalytic residues, causing either a loss or inappropriate gain of 
function (Thusberg and Vihinen, 2009), or more frequently may affect the structure and 
stability of the protein product thereby preventing the protein from functioning correctly 
(Wang and Moult, 2001).  A less frequently observed effect of missense mutations is to 
disrupt the cellular localisation of the mutant protein.  Proteins are normally directed to 
the correct location by short peptide sequences.  Missense changes in the signal peptide 
can lead to alteration of the signal and a pathogenic response through mislocalisation of 
the protein (Laurila and Vihinen, 2009).   
Great efforts are being deployed to develop computer software to accurately predict the 
pathogenicity of non-truncating variants, using structural and/or evolutionary information 
about the mutated sites.  This study utilised 2 computational methods to predict the 
phenotypic effects of the missense variants investigated.  SIFT (Sorting Intolerant From 
Tolerant) is a program which uses evolutionary information to predict tolerance of 
variants, by constructing a multiple sequence alignment (MSA) and mathematically 
considering the position and type of amino acid change (Ng and Henikoff, 2001; 
Thusberg and Vihinen, 2009).  PolyPhen (Polymorphism Phenotyping) uses a 
combination of functional and/or protein structural parameters as well as MSA 
information in making predictions of pathogenicity (Sunyaev, et al., 2001).  The program 
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characterises a given missense variant using multiple other sequence, structure and 
phylogeny based descriptors (Thusberg and Vihinen, 2009).      
To give an indication of domains of particular importance within the folliculin protein 
(where mutations are most likely to be pathogenic), an evolutionary analysis was 
undertaken both at an inter- and intra-gene level.  This is a useful technique, as the 
debilitating effects of mutations create selective pressures which result in sequence 
conservation over evolutionary time.  Thus disease-associated missense/IFD mutations 
occur more often at residues that have been strongly, evolutionarily conserved (Pal, et al., 
2006).     
In this study I have used both computational software and have modelled 10 previously 
described FLCN mutations in vitro, to determine the pathogenicity of these mutations, 
and the effects on folliculin stability and tumour suppressor activity.  
 
 
4.2 Aims and Approaches 
In order to gain insights into potential functional domains of the folliculin protein and 
indicate the pathogenicity of the missense and in frame deletion mutations reported in 
FLCN, the aims of this chapter are to analyse the patterns of evolutionary conservation of 
folliculin and study 10 FLCN mutations in vitro.              
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4.3 Methods 
4.3.1 Evolutionary Conservation of FLCN – Analysis performed by Professor 
Laurence D Hurst, University of Bath 
The patterns of evolutionary conservation of FLCN at both the inter and intra-gene level 
was analysed using computational techniques by Prof Laurence D Hurst.  A summary of 
the methods used is located below.  For complete methodology, see  (Nahorski, et al., 
2011). 
Orthologues of human Folliculin isoform 1 were identified using Homologene at NCBI, 
and the sequences for chicken, cow, dog, mouse, rat, xenopus and chimp extracted from 
GenBank.  The sequences were aligned using Muscle (Edgar, 2004) on the translated 
sequence, with the nucleotide aligned being reconstructed from the aligned protein 
sequences using the program AA2NUC.  Ka and Ks were estimated using the method of 
Li (Li, 1993), and K4 estimated using the Tamura-Nei protocol (Tamura and Nei, 1993). 
Using this data, the overall rate of evolution of the gene was compared with a comparator 
set of previously defined set of 5,056 orthologs (Parmley, et al., 2007).  To look at the 
evolutionary constraints across the FLCN gene, a sliding window analysis was 
undertaken using 102 codon windows and a three codon jump between windows (using 
the program SLIDERKK). 
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4.3.2 Selection of FLCN mutations and variants 
The great majority of reported FLCN mutations are predicted to prematurely truncate the 
encoded protein.  To investigate the consequences of non-truncating FLCN variants, the 
six missense and in-frame-deletion (IFD) mutations that were available in the BHD 
database (www.lovd.nl/flcn) at the start of the study (representing all such changes at the 
time), an unpublished germline variant (p.His255Pro) and a variant detected in the LoVo 
colorectal cell line (p.Arg362Cys – reported in section 3.4) were selected for analysis 
(see Figure 4.1).  In the previous chapter, a genotype-phenotype correlation for colorectal 
cancer risk was reported.  Patients harbouring the c.1285dupC (p.His429ProfsX27) 
mutation were at significantly higher risk of colorectal neoplasia than those with the 
c.610delGCinsTA (p.Ala204X) nonsense mutation.  To continue this investigation, both 
of these mutations were also selected for study.  The location of each mutation studied 
within the FLCN gene is displayed in Figure 4.1, and associated clinical information is 
summarised in Table 4.1. 
 
4.3.3 Characterisation of FLCN mutations in vitro 
FLCN was expressed in vitro by amplifying the coding region of FLCN from human 
cDNA, and cloned into the EcoR1-BamH1 sites of the pFlag-CMV vector (available at 
the start of the study, with thanks to Dr Anne Reiman).  Mutations were introduced into 
FLCN using the Quik-Change Site-Directed Mutagenesis kit (see methods 2.5.7).  The 
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mutant constructs were subsequently subcloned into the pIRES2-AcGFP1 vector (see 
Appendix 7.1) and confirmed by sequencing.  Primer sequences are displayed in table. 
FTC-133 cells with no folliculin expression (Lu, et al., 2011) were transiently transfected 
with the ten mutant constructs as well as wild type FLCN and empty vector expressing 
controls.  Cells were lysed, electrophoresed and blotted as described in methods 2.4.4.  
The cellular levels of exogenous folliculin, transfected GFP (a marker of transfection 
efficiency) and β-actin were determined by densitometry of western blots.  The cellular 
levels of folliculin were divided by that of GFP to give a value of folliculin steady state 
levels for each FLCN construct.  Experiments were carried out in triplicate. 
 
4.3.4 Extraction of DNA and protein from BHD renal tumour 
Tumour and normal tissue from the kidney of a BHD patient was ground into a powder 
under liquid nitrogen.  DNA was extracted using the DNA Isolation Kit for Cells and 
Tissues (Roche) and protein extracted by resuspension of the tissue in RIPA buffer (as for 
protein extraction from culture cells).  FLCN sequence was determined as described 
previously and protein expression determined by western blotting. 
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4.3.5 Soft agar colony formation assay 
Soft agar colony formation assays were carried out to identify if selected FLCN mutants 
had lost their ability to suppress cell growth, in vitro.  Assays were also utilised to 
investigate a potential dominant negative effect, testing whether the p.His429ProfsX27 
mutant disrupted endogenous FLCN function, in a colorectal cancer background.  
Complete methodology is located in methods 2.6. 
 
4.3.6 Immunocytochemistry 
FTC-133 cells transfected were transfected with FLCN mutants which had no impact on 
protein stability, to identify possible alterations to intra-cellular distribution of FLCN.  
Full methodology is located in methods 2.7 
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Figure 4.1 Schematic diagram describing the location of variants analysed within FLCN  
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Table 4.1  Clinical Information for FLCN variants selected 
 
 
Mutation Exon Mutation type BHD syndrome features Reference 
c.469_471delTTC p.Phe157del 6 Inframe deletion PSP Ren et al 2008 
c.610_611delGCinsTA p.Ala204X 6 Nonsense Fibrofolliculomas, PSP, lung cysts, RCC  Toro et al 2008, Leter et al 2008 
c.715C>T p.Arg239Cys 7 Missense RCC Woodward et al 2008  
c.764A>C p.His255Pro 7 Missense Multiple skin lesions (biopsy proven tricodiscoma)  Unpublished 
c.1084C>T p.Arg362Cys 10 Missense Detected in colorectal cell line LoVo Unpublished 
c.1198G>A p.Val400Ile 11 Missense Variant of unknown significance Lim et al 2010 
c.1285dupC p.His429ProfsX27 11 Frameshift Fibrofolliculomas, PSP, lung cysts, RCC  Nickerson et al 2002 
c.1522_1524delAAG p.Lys508del 13 Inframe deletion PSP, fibrofolliculomas So et al 2009 
c.1523A>G p.Lys508Arg 13 Missense RCC Toro et al 2008 
c.1528_1530delGAG p.Glu510del 13 Inframe deletion Fibrofolliculomas, PSP, lung cysts Toro et al 2008 
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4.4 Results 
4.4.1 Evolutionary constraint of FLCN 
By comparing the evolutionary conservation of the complete FLCN gene with over 5000 
other mouse-human orthologues, Professor Hurst found that folliculin is slower evolving 
at the protein level than the average gene (Figure 4.2) and under slightly stronger 
purifying selection compared with the average gene (Figure 4.3).  Analysis within the 
gene identified a domain from approximately codons 100-230 that is both slower 
evolving (Figure 4.3a) and under especially strong purifying selection (Figure 4.3b) 
compared with the rest of the gene.  This finding was repeatable across independent 
comparisons.  Thus, all non-synonymous mutations here are extremely likely to be 
deleterious.  However, given the high level of constraint operating throughout the rest of 
the FLCN sequence, deleterious mutations could be expected anywhere.   
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Figure 4.2 Folliculin is a slower than average evolving gene 
A: Ka of 5057 mouse-human orthologs.  Horizontal line shows the result for folliculin.  Median for all orthologs is 0.04115 (quartiles: 
0.0817-0.0168).  Ka for folliculin = 0.0407.  B: Ka/K4 of 5057 mouse-human orthologs.  Line shows the result for folliculin.  Median 
for all is 0.0932 (quartiles: 0.0414-0.1765).  Ka/K4 for folliculin = 0.0724.  Li’s Ka estimation and Tamura and Nei’s K4 estimation 
were used in this analysis.  
(Analysis was undertaken with thanks to Professor Laurence Hurst, University of Bath) 
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Figure 4.3 Folliculin while under purifying selection is less constrained 3’ than 5’   
Across four species comparisons, (chicken – Xenopus: black, human – rat: blue, cow – dog: red and human – chimp: green), there is a 
zone (approximately codon 100 to codon 230) with low rates of protein evolution (A) and Ka/Ks (B).  Human chimp comparison Ks is 
generally zero for most windows hence Ka/Ks has no meaning and is omitted.  
(Analysis was undertaken with thanks to Professor Laurence Hurst, University of Bath)  
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4.4.2 Pathogenic missense and inframe deletion mutations significantly affect the 
stability of the folliculin protein 
The folliculin mutation database was reviewed and 6 previously reported non-truncating 
FLCN mutations as well as 1 unreported missense change identified.  In agreement with 
the evolutionary conservation results that suggested deleterious mutations could be 
expected anywhere within the coding sequence, the missense and IFD mutations that 
have been reported in FLCN are relatively well spread out throughout the FLCN coding 
regions (see Figure 4.1). 
To investigate whether the selected missense/IFD FLCN variants were likely to be 
pathogenic and the likely mechanism of pathogenicity, 10 candidate missense/IFD 
mutations were studied in vitro (see Table 4.1). The mutations were introduced into the 
FLCN sequence using a site-directed mutagenesis method, and the mutants and control 
sequences were cloned into the pIRES2-AcGFP1 vector (Clontech) (Figure 4.4).  These 
constructs were then transiently expressed in the FTC-133 cell line (folliculin deficient)  
(Lu, et al., 2011).   
A common mechanism of pathogenicity for non-truncating mutations is to disrupt 
stability of the encoded protein.  The p.His429ProfsX27 frameshift mutation, the 
pAla204X nonsense mutation, and six of the eight missense/IFD mutations impaired 
stability of the folliculin proteins, significantly reducing protein steady state levels.  This 
is consistent with the hypothesis that most of the reported FLCN missense/IFD mutations 
 [136] 
 
are pathogenic by significantly disrupting the stability of the folliculin protein (Figure 
4.5).  
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 Figure 4.4 FLCN mutations introduced using site-directed mutagenesis  
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Figure 4.5  Most FLCN missense and IFD mutations analysed significantly 
disrupted stability of the protein 
The stability of each mutant construct was determined, relative to wild type FLCN, by 
dividing the level of FLCN signal by that of GFP, an indicator of the efficiency of 
transfection.  Experiments were carried out in triplicate.  A: Western blot for FLCN, GFP 
and β-actin for each mutation analysed B: Western blot for the pAla204X mutation C: 
Graphical representation of the stability of each construct from at least 3 independent 
repeats. Error bars represent standard deviation.  One star indicates significance p<0.05, 
two stars indicate p<0.01 (Independent T Test).   
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The putative functional consequences of the FLCN non-truncating mutants were 
evaluated in silico, using predictive computational analyses (SIFT software (Ng and 
Henikoff, 2001) and PolyPhen Web predictive server (Sunyaev, et al., 2001)).  Both 
programmes produced comparable results with four of the proteins that disrupted 
folliculin stability being predicted to be “probably damaging” the other two “possibly 
damaging”.  Both mutations with no effect of folliculin stability were predicted to be 
benign (Table 4.2). 
 
Mutation PolyPhen SIFT  
p.Phe157del Probably damaging  n/a 
p.Arg239Cys Probably damaging not tolerated 
p.His255Pro Probably damaging not tolerated 
p.Arg362Cys Probably damaging not tolerated 
p.Val400Ile Benign Tolerated 
p.Lys508Arg Benign Tolerated 
p.Lys508del Possibly damaging  n/a 
p.Glu510del Possibly damaging  n/a 
 
Table 4.2 In silico analysis predicting the possible functional consequences of missense 
and IFD mutations 
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4.4.3 Analysis of BHD tumour in patient with p.Arg239Cys 
The FLCN mutation p.Arg239Cys was originally identified in a patient presenting with 
inherited susceptibility to RCC but no known causative syndrome (Woodward, et al., 
2008).  In the studies presented in this chapter, the p.Arg239Cys mutation disrupted 
stability of the folliculin protein and was predicted to be “probably damaging” and “not 
tolerated” by PolyPhen and SIFT programs respectively.  In the time since the publication 
of this mutation by Woodward et al. (2008), another patient was identified with the same 
heterozygous p.Arg239Cys mutation.  This patient had developed 3 separate primary 
tumours at a young age (chromophobe RCC, adenocarcinoma of the oesophagus and 
rectal adenocarcinoma).  The patient was confirmed to have fibrofolliculomas and was 
diagnosed with BHD syndrome.  The RCC and a section of normal kidney tissue were 
surgically removed and the DNA and protein extracted from each sample.  Loss of 
heterozygosity was observed in the tumour sample and this correlated with greatly 
reduced folliculin protein levels in the tumour tissue (Figure 4.6). 
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Figure 4.6 Loss of heterozygosity and reduced folliculin expression in p.Arg239Cys 
RCC 
A:  There is a loss of heterozygosity of the wild type allele in the renal tumour of a BHD 
patient with a germline p.Arg239Cys mutation.  B: Reduced folliculin expression in the 
tumour tissue 
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4.4.4 p.Val400Ile and p.Lys508Arg constructs retain anchor independent growth 
suppression  
Two putative FLCN missense mutations, p.Val400Ile and p.Lys508Arg did not seem to 
disrupt the stability of the folliculin protein.  It was postulated that they may be 
pathogenic via an alternative mechanism, or that they might represent non-pathogenic 
polymorphisms.  To determine the likely pathogenicity of these two variants, their impact 
on the ability of folliculin to suppress growth of cells unadhered to a surface, suspended 
in soft agar (in vitro tumour suppressor assay) was investigated.  These mutant proteins 
were also analysed by fluorescence microscopy to investigate any potential alterations to 
folliculin distribution within the cell. 
Stable, mutant folliculin constructs, pVal400Ile and p.Lys508Arg and two further 
mutations (p.His255Pro and p.His429ProfsX27) which were expected pathogenic, were 
transfected into FTC-133 cells as stable mixed populations.  The cell populations were 
grown in soft agar and the number of colonies compared with introducing wild type 
folliculin or empty vector.  Compared to wild type expressing cells, FTC-133 cells 
expressing p.His255Pro and p.His429ProfsX27 produced a significantly larger number of 
colonies (similar to empty vector expressing cells).  However stable mutants, p.Val400Ile 
and p.Lys508Arg exerted a significant suppressive activity on colony formation, 
behaving like wild type folliculin.  It was concluded that neither mutation impaired the 
growth suppressive activity of the foliculin protein (Figure 4.7). 
 [143] 
 
 
 [144] 
 
Figure 4.7 Assessment of the tumour suppressive activity of FLCN mutant proteins. 
p.Val400Ile and p.Lys508Arg variants retain folliculin tumour suppressor activity, and, 
when grown in soft agar, produced a significantly lower number of colonies compared 
with cells transfected with empty vector.  The p.His255Pro and p.His429ProfsX27 
variants have lost this function, and produced a significantly larger number of colonies 
than cells transfected with wild type FLCN, indicating they are pathogenic mutations.  A: 
confirmation of stable transfection by western blot, B: representative picture of soft agar 
plates transfected with each construct, C: Graph of the colony counts for each population 
of cells,from three independent experiments . Error bars represent standard deviation.  
One star indicates significance p<0.05 (Independent T Test). 
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4.4.5 p.Val400Ile and p.Lys508Arg constructs do not affect protein intracellular 
distribution 
To investigate if the p.Val400Ile or p.Lys508Arg mutants might be affecting the 
intracellular distribution of folliculin, FTC-133 cells were transfected with these 
constructs, wild type folliculin and empty vector.  These cells were then stained for 
FLCN and GFP (for identification of successfully transfected cells).  Wild-type folliculin 
is distributed throughout the cytoplasm, and is also present at lower levels in the nucleus.  
Neither p.Val400Ile nor p.Ly508Arg expressing cells displayed any discernible 
difference in localisation pattern compared to wild type folliculin (Figure 4.8 
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Figure 4.8 The cellular localisation of the p.Val400Ile and p.Lys508Arg FLCN 
variants is similar to that of wild type FLCN.   
Transiently transfected cells were co-stained for FLCN and GFP.  The nuclei were 
stained with 4’,6-diamidino-2-phenylindole (DAPI).   In wild type folliculin, pVal400Ile 
and p.Lys508Arg expressing cells, folliculin is distributed throughout the cytoplasm and 
at a reduced level in the nucleus (17.4%, 23.3% and 17.5% compared to the cytoplasm 
level respectively, p=0.53, p=0.97).  Results pooled from three independent experiments 
and tested for significance using independent Student’s T test. GFP signal indicates 
transfected cells. 
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4.4.6 No evidence for a dominant negative effect for pHis429ProfsX27 mutation 
Chapter 3 described that in our cohort, BHD patients harbouring a germline 
p.His429ProfsX27 frameshift mutation were at significantly higher risk of colorectal 
neoplasia than those with a p.Ala204X nonsense mutation.  This could potentially be 
explained if the mutant folliculin protein resulting from the pHis429ProfsX27 frameshift 
is stable and might exert a dominant negative effect, disrupting the function of wild type 
folliculin.  When these mutants were transiently transfected into FTC-133 cells, both 
mutants produced a translated, truncated product, displaying reduced protein stability. 
To further investigate if there was evidence of a dominant negative effect, the 
pHis429ProfsX27 construct was introduced into the DLD-1 colorectal cancer cell line 
(which expresses endogenous levels of folliculin), and the cells grown in soft agar.  
However the number of colonies produced by the empty vector transfected DLD-1 cells 
was not significantly different to those produced in the cells expressing the truncated 
p.His429ProfsX27 mutant construct (p=0.22).  Overexpressing folliculin exerted a 
significant growth suppressive effect compared to empty vector and p.His429ProfsX27 
expressing cells (p=0.0002) (Figure 4.9).   
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Figure 4.9 No evidence of a dominant negative effect associated with the 
p.His429ProfsX27 mutation when introduced into DLD-1 cells 
Wild type folliculin, empty vector and the p.His429ProfsX27 construct were introduced 
into the DLD-1 colorectal cell line.  There was no significant difference in the growth 
suppressor activity of the truncated folliculin protein compared with transfection of 
empty vector providing no evidence of a dominant negative effect in this cell background 
(p=0.23).  A: Conformation of stable transfection by western blot, B: Representative 
picture of soft agar plates transfected with each construct, C: Graph of the colony counts 
for each population of cells, the average of 6 experiments.  Two stars indicate p<0.01.  
Error bars represent standard deviation.  Comparison of colonies between empty vector 
and p.His429Profsx27, (p = 0.23) 
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Folliculin has been reported to impact upon the mTOR signalling pathway (Baba, et al., 
2008), with folliculin loss resulting in increased signalling through both mTORC1 and 
mTORC2 (Baba, et al., 2008; Hasumi, et al., 2009).  In order to gain insights into the 
effects of the FLCN mutants on mTOR signalling, the FLCN mutants were transiently 
and (a subset) stably transfected into FTC-133 cells.  Lysates from these experiments 
were immuno-blotted for phosphorylation of ribosomal protein S6 (indicative of 
mTORC1 activation) and phosphorylation of Akt (indicative of mTORC2 activation).  
However, under neither normal serum conditions, nor in controlled serum free or amino 
acid free media, could robust, repeatable effects on the phosphorylation status of S6 or 
Akt be determined.      
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4.5 DISCUSSION 
This chapter aimed to gain further insights into the way FLCN mutations affect folliculin 
function, and into a potential genotype-phenotype correlation previously identified.  The 
patterns of evolutionary conservation of the FLCN gene investigated in silico by 
Professor Hurst were consistent with the folliculin protein evolving more slowly and 
being under stronger purifying selection compared with the average gene.  Within the 
FLCN gene, the slower evolution and purifying selection was most apparent within the 
first half of the protein, approximately between codons 100 and 230.   
Determining the rate of protein evolution is a powerful tool for quantifying the relative 
importance of a gene and it is a long held view that proteins with a high density of 
important sites are likely to evolve more slowly (Zuckerkandl, 1976).  See review by 
(Pal, et al., 2006). 
Our analysis suggested that such is the conservation across the whole gene, that 
nonsynonymous mutations might be pathogenic throughout the FLCN sequence.  Close to 
90 % of mutations described in FLCN to date prematurely truncate the encoded protein 
(Lim, et al., 2010).  The small number of non-truncating FLCN mutants identified, are 
not constrained to any particular domains and are relatively well spread out throughout 
the sequence, consistent with the in silico analysis.  There is, however, a cluster of three 
putative mutations at amino acid positions 508, 508 and 510 respectively, which were of 
particular interest due to their close proximity.   
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When experimentally modelled in vitro, the majority of missense/IFD mutations analysed 
had a significant impact upon the stability of the folliculin proteins.  This suggests they 
are acting in a similar manner to the effects of truncating mutants (also significantly 
destabilised in this study) by causing a deficiency of the full length FLCN gene product.  
It appears probable that folliculin has multiple functions and that in causing BHD 
syndrome, FLCN mutations compromise multiple aspects of folliculin function.  The 
functions of folliculin are not well characterised, however the  insights to date suggest a 
role for folliculin in mTOR signalling through its interactions with FNIP1 and 
FNIP2/FNIPL and indirectly AMPK (Baba, et al., 2006; Hasumi, et al., 2008; Takagi, et 
al., 2008).  Folliculin binds to FNIP1 and FNIP2 at regions beyond codons 516 and 362 
respectively and therefore these interactions appear unrelated to the domain of strong 
evolutionary selection and strong purifying selection we have identified between codons 
100 and 230.  This region could be particularly crucial for maintaining folliculin 
structural integrity (the only IFD mutation described within this regions p.Phe157del 
significantly alters protein stability), or could represent the binding site for another, yet 
unidentified, folliculin binding partner. 
In collaboration with Dr Ravi Nookala (University of Cambridge), a bioinformatic 
analysis of the structural homologues of the codon 100 to 230 domain of folliculin was 
carried out.  The N-terminus of folliculin carries a KOG3715 domain which spans the 
region of interest identified.  This is not assigned to any domain super family and hence 
the structure of such a domain is yet to be determined.  The only homologous sequence 
for the region which has been annotated is that encoding the Saccharomyces cerevisiae 
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protein LST7 (Lethal with Sec 13 protein 7).  LST7 is only 242 amino acids in size and is 
hence far smaller than the human folliculin, representing the smallest evolutionarily 
functional folliculin protein.  This protein is required for the nitrogen-regulated transport 
of two amino acid permeases (GAP1 and PUT4) from the Golgi to the cell surface 
(Roberg, et al., 1997).   
A range of the missense/IFD mutations that were modelled (p.Phe157del, p.Arg239Cys, 
p.His255Pro, p.Arg362Cys, p.Lys508del and Glu510del) distributed across the folliculin 
protein impaired protein stability.  As aforementioned, this was not necessarily 
predictable despite being consistent with the evolutionary analysis, as we had 
hypothesised that the three putative mutations at codons 508 and 510 may have disrupted 
an interaction with a critical folliculin binding partner (hence maintaining a stable 
structure in this assay).  The ability to determine the pathogenicity of rare polymorphic 
variants is of crucial importance in diagnosing BHD syndrome and the clinical outcomes 
associated with this.  Most of the mutations modelled caused impaired protein stability 
consistent with the interpretation that they are pathogenic. 
However, the assays undertaken only represent one way to identify possible impairment 
of protein stability, by testing effects on steady state levels of foliculin.  To confirm that 
the reduction in folliculin levels caused by introducing the missense mutations is at the 
protein level, it would be important to use real-time quantitative PCR to determine if 
there is any reduction in stability of FLCN mutant constructs at the mRNA level.  It 
would also be interesting to further investigate the mechanism of reduced stability by 
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treating the cells with a proteosome inhibitor such as MG132, to determine if this would 
return the levels of folliculing back to wild-type levels, thus suggesting the mutations are 
cauing foliculin to be degraded more quickly.  Finally, the cells could be treated with a 
protein synthesis inhibitor such as cyclohexamide and cells lysed as a time course, to 
determine if the mutant proteins have a reduced half life, which might be responsible for 
the reduced steady-state levels observed. 
The p.Arg239Cys mutation was previously detected in a patient who presented with 
multicentric clear cell RCC but no other BHD syndrome manifestations (Woodward, et 
al., 2008).  The mutation was predicted to be pathogenic, and the functional analysis 
undertaken in this project confirms this previous interpretation that the p.Arg239Cys 
mutation is responsible for the patient’s condition.  The same mutation has subsequently 
been described in another unrelated BHD patient, presenting with fibrofolliculoma’s and 
three primary tumours.  Analysis of the BHD renal tumour derived from the affected 
patient showed loss of heterozygosity for the second copy of FLCN in the tumour and 
reduced levels of folliculin in the tumour tissue.   
The p.His255Pro mutation is of interest as it is the human equivalent of the mutation 
found in the naturally occurring canine model of BHD syndrome (see section 1.3.5.3 for 
full description) (Lingaas, et al., 2003).  This can also be confirmed as pathogenic.   
Of the other mutations that impaired folliculin stability, the p.Arg362Cys variant was 
identified in the colorectal cell line LoVo (see section 3.4.1).  The p.Lys508del IFD was 
described in a patient with fibrofolliculomas and features of spontaneous pneumothorax 
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(So, 2009). The p.Glu510del IFD has been described in a number of BHD patients 
presenting with at least one of the classical BHD manifestations, although none were 
reported to have renal tumours (Toro, et al., 2008). 
Two of the variants modelled, pVal400Ile and p.Lys508Arg, produced stable folliculin 
proteins.  These were therefore of interest as they could potentially represent stable but 
non-functional folliculin proteins and thus provide insights into important folliculin 
functions.  Folliculin is a tumour suppressor and reintroduction of the protein into null 
cell is able to inhibit tumour growth in nude mice xenografts (Hong, et al., 2010; Vocke, 
et al., 2005).  To test the pathogencity of these two stable variants, the growth 
suppressive effects of the variant proteins were tested by soft agar colony formation 
assay.  Both of the variants produced a strong growth suppressive effect when introduced 
into FTC-133 cells, behaving similarly to wildtype folliculin.  In contrast, the 
p.His255Pro unstable missense mutant and the p.His429ProfsX27 frameshift mutation 
displayed a loss of grow suppressive function.  The possibility that the mutations might 
be having effects on the intracellular distribution of folliculin, was also tested.  Neither of 
the variants were mislocalised compared with wildtype folliculin expressing FTC-133 
cells.  A pathogenic control construct was not included in this assay as all have been 
shown to reduced protein stability, however if a mutation within FLCN were to be 
identified which resulted in a stable protein, this would represent an important control for 
further experiments regarding protein localisation. 
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Both the p.Lys508Arg and the p.Val400Ile mutations were described in a single BHD 
patient.  Since the completion of this chapter, the p.Val400Ile variant was found not to 
segregate with disease status in the affected family and another pathogenic folliculin 
mutation was detected in this family.  This therefore represents a useful control for 
indentifying the pathogenicity of non-truncating FLCN variants.  The BHD family with 
the p.Lys508Arg mutation is still under investigation.  It is unclear whether the mutation 
may affect splicing, which is not tested in the assays reported here, or if the family may 
also harbour another FLCN variant, for example a large deletion or duplication, where 
detection is currently in its infancy (Benhammou, et al., 2011).    
Interestingly, both the in silico methods used to predict pathogenicity using 
computational modelling alone (SIFT and POLYPHEN) predicted both the pLys508Arg 
and p.Val400Ile variants to be benign, consistent with the experimental data.  These 
programs are predicted to be 65% and 70% accurate respectively (Thusberg and Vihinen, 
2009), so while it is can be interpreted that when both programs predict the same 
outcome, they are likely to be correct, the accuracy of these programs is not yet sufficient 
to reliably replace the experimental tests conducted in this chapter.  Studies have shown 
that the performance of variant prediction software can be increased by combining MSA 
information with three-dimensional protein structure (Bromberg and Rost, 2007), 
highlighting that efforts to determine the crystal structure of folliculin may be crucial in 
reliably predicting pathogenic FLCN variants without the need for experimental analysis.    
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Mutations in FLCN are responsible for a range of phenotypes, including those associated 
with BHD syndrome and familial primary spontaneous pneumothorax (Menko, et al., 
2009).  Only few genotype-phenotype correlations have been described to date, and the 
molecular pathogenesis responsible for the variability of BHD phenotype is unclear.  The 
association between BHD syndrome and colorectal cancer is currently unconfirmed.    
Chapter 3 reported a heterozygous, missense variant in the LoVo colorectal cell line 
(c.1084C>T, pArg362Cys).  Although the pathogenicity of this variant was uncertain, the 
evidence presented in this chapter suggests that it is likely to be pathogenic, due to a 
reduction in folliculin stability.  However further investigation is required to identify 
whether the effects of this mutation as a heterozygote in the LoVo cell line are sufficient 
to affect folliculin associated signalling pathways, perhaps as a result of reduced 
folliculin dosage. 
Chapter 3 reported that pHis429ProfsX27 mutation carriers are at significantly increased 
risk of colorectal neoplasia compared with p.Ala204X mutation carriers.  We 
hypothesised that this may be as a result of a dominant negative effect associated with the 
p.His429ProsfsX27 truncated protein.  This chapter demonstrates that both mutations 
result in a translated, truncated protein, although presents no evidence for a dominant 
negative effect when DLD-1 colorectal cells were transfected with p.His429ProfsX27 
mutant expressing vector.  Previous studies had demonstrated the efficacy of using soft 
agar studies to investigate potential dominant negative effects (Kim, et al., 2003), 
however as DLD-1 cells were developed from a late stage colorectal cancer, the 
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possibility that a dominant negative effect may only be exerted by the p.His429ProfsX27 
mutant as an initiating/early stage of colorectal tumourigenesis, cannot be excluded. 
Folliculin is known to bind to two proteins FNIP1 and FNIP2, which interact with 
5’AMP-activated protein kinase (AMPK) an important energy sensor for the cell.   These 
interactions are reported to negatively regulate mTOR, a signalling hub for growth and 
cell proliferation   At the time that this project was undertaken, folliculin loss has been 
reported to upregulate mTOR signalling through both mTORC1 and mTORC2 activation 
in a number of studies (Baba, et al., 2006; Hasumi, et al., 2008; Hasumi, et al., 2009).  
Thus we hypothesised that the effects of expressing the FLCN mutants in our cell lines 
may also lead to an upregulation of mTOR signalling.  However, after many months 
work, investigating a range of cell culture conditions and cell lines, we were unable to 
identify robust, repeatable effects on mTOR signalling associated with each of our FLCN 
mutants.  Subsequent publications reveal the effects of FLCN loss on mTOR signalling to 
be more complicated that initially suggested, appearing to be complex and context-
dependent with both abnormally high and abnormally low levels of mTOR signalling 
reported when functional FLCN is absent (Hartman, et al., 2009; Hudon, et al., 2010).  
This may go some way to explaining the inconsistencies we observed when investigating 
the effects of FLCN mutations on mTOR signalling.     
In summary, the findings reported in this chapter are consistent with the hypothesis that 
the vast majority of FLCN mutations are pathogenic by impairing stability and/or causing 
deficiency of the full length folliculin protein.  Hence it is likely that multiple aspects of 
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folliculin function must be disrupted to cause the associated phenotypes.  Further 
elucidation of folliculin function and description of the protein structure might provide 
novel insights into the significance of the strongly conserved domain (codons 100-230) 
identified.  In addition this chapter demonstrates a practical strategy for establishing the 
likely pathogenicity of putative FLCN variants as they are discovered.   
However, no data was generated from our studies into of the effects of these mutations on 
previously reported FLCN signalling pathways.  It is likely folliculin plays multiple 
molecular roles within the cell which may be more robustly affected by FLCN 
inactivation.  A yeast-2-hybrid screen was undertaken to identify previously unknown 
folliculin binding partners and potential novel functions.  Investigations into a novel 
folliculin binding partner and the associated functional relevance of this interaction are 
discussed in the next chapter.      
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Chapter 5 Investigation of the molecular 
and cellular impact of the 
folliculin/plakophilin-4 interaction 
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5.1 Introduction 
Identification of the molecular functions of folliculin within the cell is crucial for 
understanding the role of its inactivation in renal neoplasia as well as providing clues for 
developing therapeutic agents for the BHD syndrome.  It is anticipated that once the 
major aspects of folliculin function (which drive BHD phenotype when disrupted) are 
well elucidated, targeted therapies may be developed as reported for VHL disease.  
Currently the functions of folliculin are poorly understood; folliculin loss being linked to 
mTOR signalling deregulation through the interaction between folliculin and FNIP1 and 
FNIP2 (discussed in detail in section 1.3.6.1).  However, in the experiments described in 
the previous chapter, I was unable to reliably define the impact of FLCN inactivation on 
the regulation of mTOR signalling and others have also suggested that folliculin 
regulation of the mTOR pathway appears to be variable and context dependent.  It is 
likely that the functions of folliculin are multi-faceted, and identification of novel 
folliculin binding partners might provide further insights into the mechanisms of 
folliculin tumour suppressor function.  A yeast-2-hybrid screen was performed for 
folliculin, with plakophilin-4 (p0071, pkp4) identified as a candidate interacting protein.  
This chapter investigates the interaction between folliculin and p0071 and the potential 
associated relevance for folliculin function.       
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5.1.1 Plakophilin 4 (p0071/pkp4) 
Plakophilin 4 (p0071) is a member of the armadillo-repeat family of cell-adhesion 
proteins of which p120
ctn
 in the prototype.  Members of the p120 family co-localise with 
classical cadherins at adherens junctions, mediated by a direct interaction of classical 
cadherins with the armadillo repeat domain (Hatzfeld, 2005). Interaction of p0071 with 
E-cadherin results in increased E-cadherin stabilisation at cell-cell junctions. p0071 is 
also able to bind desmosomal proteins through its N-terminal head domain (Hatzfeld, et 
al., 2003; Hatzfeld and Nachtsheim, 1996).  p0071 has been reported to function in the 
cross talk between adherens junctions and desmosomes (Hatzfeld, 2005).  A brief 
introduction to the reported functions of p0071 is described below.   
   
5.1.2 Cell-cell adhesion 
In a multicellular organism, cell junctions are required for the adhesion of cells to each 
other and the extracellular matrix in order to maintain tissue form and structure.  
Intercellular junctions also maintain cell and tissue polarity.  The three types of cell 
junction crucial for forming and maintaining barriers are adherens junctions, tight 
junctions and desmosomes (Niessen, 2007).   
 
5.1.2.1 Adherens junctions, Tight junctions and Desmosomes 
Tight junctions are the most apical structure of cell-cell contacts, marking the border 
between apical and basolateral membrane domains.  They are comprised of two types of 
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transmembrane proteins, claudins and occludins and also the cytoplasmic scaffolding 
proteins ZO-1, ZO-2 and ZO-3.  Tight junctions control ion selectivity and permeability 
of the paracellular pathway between adhering cells (Hartsock and Nelson, 2008). 
Adherens junctions are positioned directly below tight junctions (Niessen, 2007).  They 
are made up of proteins of the cadherin superfamily, such as E-cadherin, and catenin 
family members including p120-catenin, β-catenin and α-catenin.  Adherens junctions 
function in initiating and stabilising cell-cell adhesion, regulating the actin cytoskeleton, 
transcriptional regulation and intracellular signalling (Hartsock and Nelson, 2008).  
Junction formation is induced by E-cadherin initiating intercellular contacts through 
trans-pairing with cadherin molecules on adjacent cells, a process which is dependent on 
the presence of calcium ions (Gumbiner, 2005).  It has been reported that the formation 
of the adherens junction leads to the formation of tight junctions, but is not required for 
tight junctional maintenance (Capaldo and Macara, 2007).  Together adherens junctions 
and tight junctions make up the apical junction complex (AJC) complex widely believed 
to be the driving process for the generation of apical basolateral polarity (Nelson, 2003).   
Desmosomes are intercellular junctions that connect intermediate filaments to the plasma 
membrane, and are crucial in tissues which experience mechanical stress such as the 
bladder, gastrointestinal mucosa and the skin (Delva, et al., 2009).  Desmosomes consist 
of transmembrane glycoproteins desmogleins and desmocollins, which are members of 
the cadherin superfamily.  Cytoplasmic associations with desmosomal cadherins are 
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mediated by the armadillo family proteins plakoglobin and plakophilins (Delva, et al., 
2009).   
Plakophilin-4 has been reported to be both present in both desmosomes and adherens 
junctions (Hatzfeld, et al., 2003), and can bind to both classical and desmosomal 
cadherins via its armadillo repeats or N-terminal head domain respectively (Keil, et al., 
2007). 
A schematic of cell-cell contacts and the localisation of p0071 is displayed in Figure 5.1.  
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Figure 5.1 Schematic diagram of the location of p0071 in epithelial cell contacts 
p0071 is localised at both adherens junctions and desmosomes, by binding to classical 
and desmosomal cadherins through its armadillo and head domain respectively 
Figure adapted from (Jefferson, et al., 2004) 
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5.1.2.2 Polarity and the apical junction complex 
The apical-basal polarity of epithelial cells within multicellular organisms is 
characterised by the generation of functionally distinct membrane domains.  The 
basolateral membrane contacts other cells and the underlying connective tissue while the 
apical surface faces the organ lumen.  Polarised cells display an asymmetrical distribution 
of lipids and proteins between both domains, the result of polarised trafficking and the 
presence of the physical barrier of the apical junction complex (Moreno-Bueno, et al., 
2008).   
 
5.1.2.3 Loss of cell polarity and cell junction down regulation lead to cancer 
Metastasis is the most important cause of mortality in human cancers (Moreno-Bueno, et 
al., 2008).  Loss of cell polarity and cell-cell adhesion is a frequent feature of epithelial 
cancers which is strongly linked to tissue invasion and metastasis and can also occur 
early in tumourigenesis (Tervonen, et al., 2011).  The ability of cells to escape the 
primary tumour and migrate to distant sites of metastasis is crucial to cancer progression.  
The epithelial to mesenchymal transition (EMT) is an epithelial process during 
embryogenesis and can be hijacked by a tumour, inducing loss of cell-cell adhesion and 
apical basal cell polarity  as well as increasing cell motility (Thiery, 2003).  One of the 
earliest steps in EMT is loss of E-cadherin, through modulation of transcription factors 
that repress E-cadherin and other similar proteins (Moreno-Bueno, et al., 2008).  A full 
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description of EMT is beyond the scope of this thesis, however for excellent review of 
EMT in the context of all steps of tumour metastasis see (Valastyan and Weinberg, 
2011).   
Understanding of the role of desmosomes in cancer is still in its infancy, however in vivo 
genetic loss of function studies in the mouse, have revealed a causal relationship between 
the downregulation of certain desmosomal genes (Dsp, Dsg2, Dsc2 and Pkp2) and the 
development of cancer (Chun and Hanahan, 2010; Dusek and Attardi, 2011). 
 
5.1.3 RhoA signalling and cancer 
5.1.3.1 Rho GTPases 
P120 protein family members, including p0071, have been previous implicated in the 
regulation of Rho signalling (see section 5.1.3.5).  This is particularly interesting in light 
of the results reported in the chapter, identifying p0071 as a potential folliculin 
interacting protein.  Malignant tumour cells display uncontrolled proliferation, loss of 
epithelial polarity, enhanced cell migration and altered interaction with neighbouring 
cells and the extracellular matrix (Karlsson, et al., 2009).  Rho GTPase family members 
regulate all these processes in cell culture and more recent evidence shows that increased 
Rho signalling correlates with tumour progression in vivo, suggesting the potential 
efficacy of using Rho inhibitors as a feasible new avenue in tumour treatment (Karlsson, 
et al., 2009).  Rho is a member of the Ras superfamily of small GTPase binding proteins.  
The mammalian Rho GTPase family consists of five subfamilies, Rho-like, Rac-like, 
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CDC42-like, Rnd and RhoBTB (Burridge and Wennerberg, 2004).  This chapter focuses 
on RhoA, the best characterised of three members of the Rho-like GTPase family (also 
including RhoB and RhoC) which share the same group of effectors and have similar 
modes of action (Narumiya, et al., 2009).   
 
5.1.3.2 RhoA 
RhoA is a small GTPase which functions as a molecular switch in a wide range of 
cellular processes including cell adhesion, migration and cell cycle progression at 
cytokinesis (Burridge and Wennerberg, 2004; Jaffe and Hall, 2005).  Conversion from 
the GDP-bound inactive form to the GTP-bound active form of Rho is catalysed by 
specific guanine nucleotide exchange factors (Rho GEFs) of the Dbl family (Zheng, 
2001).  Conversion back to the inactive GDP-bound from is due to the intrinsic GTPase 
activity of Rho, stimulated by GTPase activating proteins (Rho GAPs) (Moon and Zheng, 
2003).  An additional level of control is provided by Rho-GDP dissociation inhibitors 
(Rho GDI’s) which bind to inactive Rho and holding it in a complex in the cytoplasm 
away from the site of GTP/GDP exchange at the cell membrane (Garcia-Mata, et al., 
2011) (see Figure 5.2).         
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Figure 5.2 The RhoA GTPase cycle  
The Rho GTPase switches between GDP (inactive) and GTP (active) forms.  Rho 
guanine exchange factors (GEFs) catalyse the conversion from GDP to GTP bound RhoA 
(at the membrane).  Conversion back to GDP bound RhoA occurs by GTP hydrolysis, 
stimulated by Rho GTPase activating proteins (GAPs).   GTP bound RhoA activates 
downstream targets such as ROCK (Rho-dependent kinase), where as the GDP bound 
form binds Rho GDP dissociation inhibitor (GDI) which maintain an inactive state in the 
cytosol.  Pi represents phosphate. 
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RhoA signalling is responsible for the induction of a specific type of actin cytoskeleton in 
the cell and also modulates local dynamics of microtubules  (Narumiya, et al., 2009).  
RhoA induces actin stress fibres and focal adhesions in the interphase cell, and is 
required for contractile ring formation in the mitotic cell (see Figure 5.3).  These actions 
of RhoA are carried out by the effectors activated downstream of Rho; ROCK (Rho-
associated coiled-coil forming kinase) and mDia (mammalian homolog of Drosophila 
diaphanous) (Matsui, et al., 1996; Watanabe, et al., 1997). 
 
  
 [170] 
 
 
 
Figure 5.3 The role of Rho in the interphase and mitotic cell 
Stress fibres and the contractile ring are two actin cytoskeletons induced by Rho, and are 
composed of anti-parallel actin filaments cross linked by myosin II.  Figure adapted from 
(Narumiya, et al., 2009) 
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5.1.3.3 The role of RhoA in invasion and metastasis 
Invasion of malignant tumour cells and formation of metastasis is critically dependent on 
the migratory properties of the cancer cell (Karlsson, et al., 2009).  Cells undergo 
migration by polarising to the direction of migration with extending protrusions at the 
front edge and tail retraction at the rear.  Microtubules and the actin cytoskeleton are 
crucial for this function (Narumiya, et al., 2009). It is well established that in the 
interphase cell, RhoA activation mediates cell migration through retraction at the rear of 
cells, but recent evidence suggests it also actively functions at the protruding edge, with a 
role in the initial events of protrusion (Machacek, et al., 2009; Spiering and Hodgson, 
2011).  As previously mentioned, an early step in the metastatic cascade involves loss of 
cell polarity and disruption of cell-cell contacts (for example during EMT).  Interestingly, 
Rho activation has also been implicated in AJC disassembly, by triggering the formation 
of acto-myosin rings required for disruption of the AJC (Samarin, et al., 2007).  
   
5.1.3.4 The role of RhoA in cytokinesis 
Cytokinesis requires the spatio and temporal control of actin and myosin to cause 
contractile ring assembly and contraction.  In eukaryotes, activation of RhoA is the 
critical step in orchestrating cytokinesis, functioning by binding and regulating specific 
protein effectors which manipulate the actomyosin contractile network (Piekny, et al., 
2005).  Furrow formation is controlled downstream of RhoA, by formin-mediated actin 
polymerisation.  Ingression of the furrow is mediated by ROCK (Rho dependent kinase) 
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activation of mysosin II, another downstream target of RhoA.  Completion of furrow 
ingression and the final stages of cytokinesis are reliant on citron kinase, also activated 
by RhoA (Piekny, et al., 2005).  Cytokinesis is a complex process and requires tight 
spatiotemporal regulation of RhoA activation, for which the Rho GEF, ECT2 is an 
important player (Glotzer, 2005).  Deregulation of RhoA induces cytokinetic defects, 
which can result in polyploidy and increased genome instability, features characteristic of 
the cancer cell (Li, et al., 2010).  Given the important roles of RhoA in cell migration and 
mitosis it is unsurprising that over expression of RhoA has been described in a wide 
variety of human tumours (Karlsson, et al., 2009).   
 
5.1.3.5 P0071 regulates RhoA activity 
P120 family proteins are considered multifunctional and have a signalling role beyond 
their structural role in cell contacts, reflected in their cytoplasmic and nuclear localisation 
(Keil, et al., 2007).  A number of studies have demonstrated a role for p120
ctn 
in 
regulating Rho GTPases, with p120
ctn
 overexpression resulting in a branching phenotype 
and providing evidence for inhibition of RhoA activity by p120
ctn
 (Anastasiadis, et al., 
2000; Reynolds, et al., 1996).  Currently little is known about the role of p0071 in Rho 
signalling in the interphase cell, although it is believed regulation of small GTPases 
might be a common function of all p120 family proteins.  Thus p0071 can induce a 
similar “branching phenotype” albeit to a reduced extent (Hatzfeld, 2005).  However 
insights have been made into the role of p0071 in regulating RhoA in the dividing cell, an 
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important study by Wolf et al. demonstrating that p0071 plays an essential role in 
controlling Rho signalling during mitosis (Wolf, et al., 2006). 
The authors investigated the subcellular localisation of p0071 in the mitotic cell, and 
demonstrated that in the course of mitosis, p0071 was associated with centrosomes, but 
became focussed at the midbody during cytokinesis (see Figure 5.4) (Keil, et al., 2007; 
Wolf, et al., 2006). 
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   Figure 5.4  Localisation of p0071 in the mitotic cell  
During interphase, p0071 is localised at the plasma membrane and centrosomes.  In 
metaphase, it becomes enriched at the spindle poles and retains its membrane 
localisation.  p0071 becomes focused at the midbody region during late anaphase through 
to cytokinesis (Wolf, et al., 2006).  
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The authors demonstrated a functional role for p0071 in cell division with treatment of 
cells with a p0071 siRNA inducing multinucleation due to defects in cytokinesis.  Over-
expression of p0071 produced similar effects.  p0071 knockdown caused a 
downregulation of RhoA, and reduced accumulation of filamental actin at the contractile 
ring.  P0071 was shown to bind RhoA, preferentially to the active GTP-bound form, and 
to modulate the spatio-temporal activity of RhoA by binding to and enhancing the 
activity of the Rho guanine exchange factor Ect2 (Keil, et al., 2007; Wolf, et al., 2006).  
Further light was shed on the subject of p0071-mediated, spatio-temporal control of Rho 
signalling with the motor protein KIF3b being identified as a p0071 binding partner, and 
functioning in targeting p0071 to the midbody at cytokinesis (Keil, et al., 2009).   
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5.2 Aims  
Yeast-2-hybrid analysis identified p0071 as a potential folliculin interacting protein.  This 
chapter aimed to confirm and define the intracellular context of the p0071/folliculin 
interaction, and also the functional effects of cell folliculin status on p0071 associated 
functions.  
 
5.3 Methods   
5.3.1 Co-immunoprecipitation 
Co-immunoprecipitation experiments were undertaken as described in Methods 2.4.3 to 
confirm the interaction between p0071 and folliculin in vitro.  Co-immunoprecipitation of 
folliculin and p0071 was confirmed with pull down of both proteins separately, and 
western blotting for the other protein.  Experiments were carried out with over expression 
of flag-tagged folliculin and also at endogenous levels in Hek293 cells. 
5.3.2 Immunofluorescence analysis 
Immunofluorescence analysis was carried out to define the intracellular context of the 
folliculin and p0071 interaction.  A number of cell lines were fixed and stained for 
folliculin and p0071, both at over-expressed and endogenous levels.  Cell lines 
investigated were Hela, HaCat, MCF-7, ACHN, ACHN Kd1 (FLCN stable knockdown), 
FTC -133 (stable vector control), FTC-133 (Flag tagged folliculin stable expressor). 
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5.3.2.1 Bimolecular fluorescence complementation analysis 
Bimolecular fluorescence complementation analysis enabled the direct visualization of 
the interaction between folliculin and p0071 in living cells.  The assay is based on the 
association of two non-fluorescent proteins (folliculin and p0071 in this case) fused to 
separate halves of YFP (empty Venus constructs kindly provided by Prof M Hatzfeld), 
which when co-expressed, result in the re-formation of the fluorescent protein.  This 
allows the identification of the subcellular localisation the interaction between the two 
proteins.  The principle of the assay is displayed in Figure 5.5.   
 
 
Figure 5.5 Principle of BiFC analysis 
YN = N terminus of YFP, YC = C terminus of YFP 
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Venus constructs expressing p0071 fused to both the N terminal half (Venus 1 - amino 
acids 1-115) and C terminal half (Venus 2 - amino acids 115-238) of YFP respectively, 
were kindly donated by Prof Mechthild Hatzfeld.  Truncation of YFP at amino acid 115 
has been previously shown to produce relatively bright fluorescent signal when two 
proteins are genuine interactors, but produce only nominal fluorescence when fused to 
proteins which do not interact (Kerppola, 2008).  Full length FLCN was amplified from 
human cDNA by PCR, and cloned into both Venus 1 and Venus 2 BiFC vectors (Using 
EcoR1 and BamH1 restriction enzyme site containing primers given in Table 2.14), in 
both N-terminal fusion and C-terminal fusion orientation respectively.  All four 
combinations of FLCN-Venus fusions are displayed in Figure 5.6.  This was to overcome 
any steric constraints that might result from the YFP fusions not being able to collide 
sufficiently frequently with each other to facilitate BiFC complex formation, as a result of 
being too distant from each other when the fusion proteins interact. 
 
Figure 5.6 FLCN Venus constructs cloned for BiFC analysis 
Ven1 = N terminus of YFP, Ven2 = C terminus of YFP.  Flag and HA represent protein 
tags at the N terminus of FLCN  
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All folliculin and p0071 venus construct combinations were co-transfected into Hela cells 
and detection of BiFC signal determined as described in Methods 2.7.1. 
 
5.3.3 Analysis of Rho activity in folliculin isogenic cell lines 
The effect of folliculin status on RhoA cellular levels was tested by western blot in 
Hek293 cells treated with folliculin siRNA compared with control siRNA, in ACHN cells 
stably expressing folliculin specific shRNA or scrambled control, and in FTC-133 cells 
(no endogenous folliculin expressed) stably expressing flag tagged folliculin or empty 
vector.   
 
The effect of folliculin status on RhoA activity was tested using the G-Lisa RhoA 
activation assay, as described in Methods 2.8.  The assay tests the levels of GTP-bound 
RhoA in each cell lysate and hence the level of RhoA signalling in the presence or 
absence of folliculin. 
 
5.3.4 Multinucleation analysis 
Effects of folliculin absence on defects in cytokinesis were determined in FTC-133 cells 
grown on poly-L-lysine coated coverslips.  Cells were grown to 50% confluence, fixed 
and stained for α-tubulin.  The number of multinucleated cells was counted in the 
presence or absence of folliculin and the results of three separate experiments collated. 
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5.3.5 Cell migration analysis 
The potential impact of folliculin on the migratory ability of cells was tested using the in 
vitro cell scratch migration assay.  FTC-133 cells were plated at full confluency, starved 
of serum and a scratch introduced into the cell monolayer.  The migratory ability of cells 
was assessed by quantification of percentage scratch healed every 24 hours. 
To test whether the differences observed in migratory ability of the cells was due to 
differences in Rho signalling, the well characterised Y-27632 ROCK inhibitor was added 
to the cells, at a concentration of 10µM.  For review of the pharmacological properties of 
Y-27632, see (Ishizaki, et al., 2000).  
 
5.3.6 Transepithelial electrical resistance assay and effect of folliulin/p0071 
knockdown on epithelial cell polarisation 
- Cell culture, immunofluorescence in IMCD-3 cells and TEER results calculated 
by Ania Straatman-Iwanowska 
 
To assess the impact of folliculin loss on cell polarity and cell junction formation, IMCD-
3 cells were used.  This cell model was used as it is derived from the murine inner 
medullary collecting duct and thus represents a “normal” kidney cell model, whereas 
cancer cell lines may harbour multiple genetic and epigenetic events that can disrupt 
epithelial polarity.  IMCD-3 cells have been widely used to investigate the physiology of 
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epithelial polarisation, and can be induced to polarise in vitro by growth on Transwell 
permeable supports. 
IMCD-3 cells were treated with either p0071, FLCN or Luciferase siRNA and seeded 
onto Transwell supports.  Trans epithelial electrical resistance (TEER) was measured 
after 8 days using an EVOM AC square wave current resistance meter (World Precision 
Instruments).  TEER measurements were used to assess whether FLCN or p0071 
knockdown affected the integrity of the epithelial monolayer.    
At day 8, filters were mounted between converslips and fixed with 4% formaldehyde.  
Cells were stained for E-Cadherin, Claudin-1 and ZO-1 to assess junctional formation, 
and were visualised using a Leica SP5 Laser Scanning Confocal Microscope.       
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5.4  Results 
5.4.1 Yeast-2-hybrid Screen 
Identification of the proteins that bind to a protein of interest can often provide important 
insights into the functions of that protein, as they are often related.  To identify potential 
novel folliculin binding proteins, a yeast-2-hybrid screen was carried out (DFKZ Cancer 
Research Centre) using full length folliculin as bait against a human fetal brain cDNA 
library.  The screen yielded 17 candidates which were then assessed for their likelihood 
of representing genuine interactors by the number of clones identified to interact with 
foliculin and the promiscuity rating of the protein.  They were then catagorised into one 
of three catagories; likely interactors, uncertain interactors and likely false positive (see 
Table 5.1).   
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Gene 
symbol 
Gene name Number of 
times prey 
isolated 
Promiscuity 
rating 
  
IK IK cytokine, 
down-regulator 
of HLA II 
      
37 2   
      
      
PKP4 plakophilin 4 4 3   
  
ZNF74 zinc finger 
protein 74 
      
4 3  
 
Likely interactors 
NCOR1 nuclear receptor 
co-repressor 1 
 
      
2 3   
ZBTB17 zinc finger and 
BTB domain 
containing 17 
      
2 3   
 
 
 
 
 
CNRIP1 
 
 
 
chromosome 2 
open reading 
frame 32 
      
 
 
 
 
1 
 
 
 
 
1 
  
      
      
      
KIAA1450 KIAA1450 
protein 
      
1 1   
      
LOC644456 similar to RED 
protein 
 
      
1 1   
HS.706042 N/A 
 
1 1   
OTUD1 OTU domain 
containing 1 
 
1  
  
1 
 
 
Uncertain 
interactors 
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SOBP sine oculis 
binding protein 
homolog 
(Drosophila) 
 
      
    Uncertain 
interactors 
1 1   
TRIP4 thyroid hormone 
receptor 
interactor 4 
 
      
1 1  
ZNF251 
 
 
zinc finger 
protein 251 
 
      
1 
 
4 
 
  
 
 
 
 
S100A2 
 
 
 
S100 calcium 
binding protein 
A2 
 
    
 
1 
 
5 
 
 
  
 
 
MAP3K7IP2 
mitogen-
activated protein 
kinase 7 
interacting 
protein 2 
      
      
33   6 Likely false 
positives 
    
      
 
MAP1S 
microtubule-
associated 
protein 1S 
      
5 11   
 
PCBP1 
poly(rC) binding 
protein 1 
      
1 39   
 
Table 5.1Yeast-2-hybrid results for folliculin 
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5.4.2 Folliculin and p0071 interact in vitro 
p0071 was identified as a potential interacting partner of folliculin by a yeast-2-hybrid 
screen, with four independent clones of p0071 encompassing exons 7-10 detected.  This 
region of p0071 corresponds to a section of the p0071 head domain (amino acids 1 – 
509).  To investigate the reliability of the yeast-2-hybrid results, co-immunoprecipitation 
studies were undertaken to confirm the potential interaction in vitro.  Initially flag tagged 
folliculin was transfected into Hek293 cells at high levels and immunoprecipitation 
undertaken for both p0071 and flag.  In both cases the respective binding partner was also 
pulled down as a complex (see Figure 5.7 a and b).   
To confirm the interaction at endogenous levels, untransfected Hek293 cells were lysed 
and immunoprecipitated for folliculin and p0071 respectively.  Consistent with the results 
at over-expressed levels, when p0071 was pulled down folliculin was also detected by 
immuoblotting, and when folliculin was immunoprecipitated p0071 was also detectable 
(see Figure 5.7 c). 
 Immunoprecipitation with control antibody produced no visible folliculin or p0071 
signal.           
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Figure 5.7 P0071 and FLCN interact in vitro 
FLCN and p0071 interact in vitro:  Flag tagged FLCN was stably transfected into Hek293 
cells.  Cell lysates were immunoprecipitated (IP) with flag (A) or p0071 (B) and blotted 
with flag and p0071. (C)  Endogenous interaction was confirmed in Hek293 parental 
cells.  Lysates were immunoprecipitated with FLCN, p0071 or control IgG and blotted 
for p0071 and FLCN.  In both IP’s p0071 and FLCN immunprecipitated together, there 
was no pull down with control IgG.  Arrows indicated size of bands kDa, + and – 
represent presence or absence of transfected construct respectively 
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5.4.3 Folliculin and p0071 colocalise and interact at cell junctions during interphase 
To identify the context of the folliculin and p0071 interaction within the cell, 
comprehensive immunofluorescence microscopic analysis was undertaken.  The 
localisation pattern of p0071 is dependent on cell cycle stage, being located at cell 
junctions in the interphase cell and at the midzone during late anaphase/cytokinesis in the 
mitotic cell. 
Interphase MCF-7 cells were co-transfected with Flag-tagged folliculin and dsRed tagged 
p0071 using lipofectamine transfection reagent.  The cells were fixed and stained for 
folliculin and DAPI.  Microscopic analysis demonstrated a co-localisation of folliculin 
and p0071 at cell contacts and also a more disperse co-localisation pattern throughout the 
cytoplasm (see Figure 5.8a).   
The co-localisation at cell junctions was also observed at endogenous levels in 
untransfected MCF-7 cells in interphase, although the pattern of folliculin signal is more 
consistent with a transient role for folliculin at cell junctions rather than as a major 
structural component (see Figure 5.8b).  Co-localised pixels were identified using ImageJ 
software and a Manders overlap co-efficient was 0.599.  
To confirm folliculin and p0071 were interacting at these sites of co-localisation, 
bimolecular fluorescence complementation (BiFC) analysis was undertaken.  
Microscopic analysis of Hela cells co-transfected with both p.Ven1-p0071-Flag and 
p.Ven2-HA-FLCN-N displayed a strong BiFC signal at cell junctions and also at regions 
within the cytoplasm, indicating interaction in vivo (see Figure 5.8c). 
 [188] 
 
 
 
 
Figure 5.8 Folliculin and p0071 are co-localised and interact at cell junctions  
A)  MCF-7 cells were co-transfected with Flag tagged FLCN and p0071dsRed, fixed and 
stained for Flag and DAPI.  Folliculin and p0071 co-localise at cell junctions and in a 
disperse pattern at certain points within the cytoplasm.  Manders overlap coefficient = 
0.968 (B) Confluent MCF-7 cells were fixed and stained for endogenous folliculin and 
p0071.  Both p0071 and FLCN localised to cell junctions displaying a colocalised 
pattern. FLCN and p0071 colocalised pixels were identified using ImageJ software, and 
are displayed in white on the zoomed images.  Manders overlap coefficient = 0.599 (C) 
Bimolecular fluorescence complementation (BiFC) analysis was used to confirm/identify 
the location of the interaction between FLCN and p0071 in living cells.  Hela cells co-
expressed with pVen-1-flag-p0071 and pVen2-HA-FLCN display clear BiFC signal at 
cell junctions and throughout the cytoplasm. Images displayed are representative of >3 
repeats, in a variety of cell lines  
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5.4.4 Folliculin and p0071 co-localise and interact at the midbody during cytokinesis 
P0071 has been previously reported to become localised in the midzone region in 
anaphase and telophase, then tightly localised at the midbody during cytokinesis (Wolf, et 
al., 2006).  To test whether folliculin also co-localiased with p0071 at this region in the 
mitotic cell, FTC-133 cells stably transfected with flag tagged folliculin were fixed and 
stained for flag, p0071 and tubulin (to identify cells in the late stages of mitosis). A tight 
co-localisation of exogenous folliculin and endogenous p0071 was observed at the 
midbody during cytokinesis (see Figure 5.9a).   
This was also investigated at endogenous levels in the HaCat cell line, which displayed a 
concentrated folliculin and p0071 staining at the midbody with evidence of co-
localisation (see Figure 5.9b).  Co-localised pixels were again identified using imageJ 
software (manders overlap coefficient for FTC-133s = 0.625; for HaCat cells = 0.687). 
Using BiFC analysis, a direct interaction of folliculin and p0071 was observed in dividing 
Hela cells at late telophase/cytokinesis (see Figure 5.9c).    
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Figure 5.9 FLCN and p0071 colocalise and interact at the midbody during 
telophase/cytokinesis  
(A)  FTC-133 cells transfected with FLCN were stained for FLCN, endogenous p0071 
and α tubulin.  Enlargements of midbodies are displayed below the original images with 
only FLCN and p0071 channels displayed.  P0071 and FLCN are concentrated at the 
midbody (stained with α tubulin) at cytokinesis. FLCN and p0071 co-localised pixels are 
displayed in white on the zoomed images.  Manders overlap coefficient = 0.625 (B) 
HaCat cells were fixed and stained for FLCN, p0071 and α tubulin.  Both proteins show 
concentrated localisation at the midbody at endogenous levels.  FLCN and p0071 co-
localised pixels are displayed in white on the zoomed images.  Manders overlap 
coefficient = 0.687. (C) Hela cells were co-expressed with pVen-1-flag-p0071 and 
pVen2-HA-FLCN and fixed after 24 hours.  Cells were stained for HA (to identify 
transfected cells) and α-tubulin (to identify cells in the late stages of cytokinesis).  
Association was detected by BiFC, displaying a focussed signal at the midzone of a 
telophase cell. 
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5.4.5 Loss of folliculin deregulates RhoA signalling/activity 
As described previously, p0071 has been reported to regulate RhoA signalling, a common 
feature of p120 family proteins.  As p0071 was required for correct RhoA signalling 
during cytokinesis and folliculin interacts with p0071 at cell junctions and at the midzone 
during cytokinesis, it was hypothesised that folliculin might also impinge upon RhoA 
signalling.   
The levels of RhoA protein were tested in three different isogenic cell models.  RhoA 
levels were significantly upregulated in FTC-133 cells expressing vector only compared 
to those where folliculin had been stably re-expressed.  Similarly, in the renal cancer cell 
model ACHN, stable knockdown of folliculin also resulted in increased levels of RhoA 
protein.  Furthermore, level of folliculin knockdown by stable shRNA was inversely 
correlated with RhoA levels in a dose-dependent manner.   The same effect was observed 
in HEK293 cells treated with folliculin transient siRNA (see Figure 5.10). 
RhoA is a small GTPase which functions as a molecular switch which is inactive when 
bound to GDP and active when bound to GTP.  This switch is controlled by Rho GEFs, 
GAPs and GDIs as described in Figure 5.2.  It was important to confirm if folliculin 
status influenced cellular RhoA activity as well as cellular levels.  To investigate this 
hypothesis, the G-LISA RhoA activation assay was used, which can be used to determine 
only the levels of RhoA which are GTP-bound.   
In the FTC-133 cell line, the levels of active RhoA were significantly higher (greater than 
2 fold increase) in folliculin deficient cells than in those in which folliculin have been re-
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expressed (see Figure 5.10).  Stable knockdown of folliculin in ACHN cells also caused a 
significant increase in RhoA activation (~30%) (see Figure 5.10).  Results displayed are 
collated from at least three independent repeats.       
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Figure 5.10 Loss of folliculin induces deregulation of RhoA signaling 
(A) 3 BHD cell models were tested for levels of RhoA.  RhoA levels significantly 
increased in FTC133 cells (FLCN negative) compared with FLCN re-expressing clone.  
In both renal cell models Hek293 and ACHN, transient and stable FLCN knockdown 
respectively, caused an increase in RhoA levels. (B)  GTP bound (active) RhoA is 
increased in FLCN null cells (FTC-133) compared with FLCN re-expressing cells (~2 
fold). Results normalised to FLCN expressing FTC-133 cells (C) Active RhoA is 
increased in ACHN cells with stable FLCN knock down (~30% increase). Repeats 
normalised to activation of ACHN scrambled control.  Error bars represent standard 
deviation of at least 3 independent repeats.  Significance tested with independent 
Student’s T test. 
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5.4.6 Loss of FLCN causes cytokinesis defects resulting in multinucleation 
Wolf et al. reported that depletion or overexpression of p0071 resulted in severe 
cytokinesis defects, inducing a multinucleation phenotype correlated with deregulation of 
RhoA signalling (Wolf, et al., 2006).  As folliculin was located at the midbody during 
cytokinesis interacting with p0071 and loss of folliculin increased flux through RhoA 
signalling, it was investigated if folliculin loss might also influence levels of 
multinucleation.  By fixing FTC-133 cells at 50% confluence and staining them with 
tubulin, the numbers of multinucleated cells were counted in cells deficient for and re-
expressing folliculin.  In the folliculin deficient FTC-133 cell line, >16% of cells were 
found to be multinucleated, but reintroduction of folliculin in the FTC-133 cell line 
significantly reduced this number to ~2% multinucleated cells (p<0.005, T test calculated 
from three independent repeats) indicating folliculin is required for cells to complete 
cytokinesis correctly (see Figure 5.11). 
  
 [196] 
 
 
 
 
 
 
       
Figure 5.11 Reintroduction of folliculin rescues multinucleation phenotype in FTC-
133 cells 
A) Representative images of FLCN+/- FTC-133 cells stained with tubulin and DAPI.   
(B) Graph of percentage of multinucleated cells in FTC-133 vector expressing and FLCN 
expressing cells (p<0.01) (at least 400 cells counted from at least 3 independent 
experiments, tested for significance by independent Student’s T test).  Error bars 
represent standard deviation 
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5.4.7 Re-introduction of FLCN into null metastatic cells ameliorates migratory 
phenotype 
As mentioned in the introduction to this chapter, altered expression and activity of RhoA 
has been shown to correlate with a number of metastatic diseases.  The FTC-133 cell 
model used in this project is derived from a metastatic thyroid carcinoma and thus 
provides an interesting model to test whether the dysregulation of RhoA induced by loss 
of folliculin might be associated with a more migratory phenotype.  The in vitro scratch 
assay is a well-developed method for measuring cell migration in culture  (Liang, et al., 
2007).  Cells were grown to full confluence and serum starved (to stop the cells 
proliferating, so that only migration of cells was tested).  A scratch was introduced into 
the monolayer of cells and the scratch photographed at time point 0 and again every 24 
hours until the scratch had healed completely.  Folliculin expressing FTC-133 cells 
migrated significantly more slowly than folliculin deficient (empty vector expressing) 
cells (p<0.05) (see Figure 5.12 a and c). 
The Rho associated kinases ROCK1 and ROCK2 function downstream of RhoA and can 
be specifically targeted by the compound Y-27632, a well characterised ROCK inhibitor 
(Liu, et al., 2009).  To test if inhibiting signalling downstream of RhoA in folliculin 
deficient FTC-133 cells might ameliorate the migratory phenotype and phenocopy re-
expression of folliculin, FTC cells were treated with 10µM Y-27632 every 12 hours.  
Addition of the ROCK inhibitor to folliculin null cells significantly reduced the migratory 
ability of the cells (p<0.005) (see Figure 5.12 b and c). 
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Figure 5.12 FTC-133 cells lacking folliculin are more migratory due to increased 
RhoA signaling. 
A serum starved monolayer of confluent FTC-133 cells was scratched with a sterile 
pipette and left to migrate for 96 hours.  (A) Graph displaying % of scratch healed every 
24 hours for FLCN re-expressing FTC-133 cells (Red line) and FTC-133 empty vector 
expressing cells (Blue line). (B) Graph displaying % of scratch healed for FTC-133 
empty vector expressing cells treated with a 12 hourly, 10 uM dose of Y27632 (Rock 
inhibitor) (Green line) compared with the same cells treated with water control (Blue 
line). Error bars represent standard deviation calculated from 3 independent experiments.  
(C) Representative pictures of migrations at 0, 48 and 96 hours after scratching. 
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5.4.8 Both knockdown of folliculin and p0071 disrupts cell junctional formation 
TEER experiments and staining carried out by Ania Straatman-Iwanowska, University 
College, London 
As shown previously, folliculin and p0071 co-localise and interact at cell junctions.  To 
investigate the functional impact of this interaction, the polarised epithelial cell line 
mIMCD-3 was cultured on Transwell permeable supports.  siRNA oligonucleotides 
designed for FLCN and p0071 produced 46% and 55% transient knockdown respectively 
at day 4, tested by quantitative real-time PCR (Figure 5.13a).  The transepithelial 
electrical resistance of the cell monolayer (TEER), which tests monolayer integrity, was 
taken on day 8 once the control cells had become polarised.  Cells treated with either 
FLCN or p0071 siRNA showed significantly reduced TEER at day 8 (FLCN knockdown, 
52.5% residual TEER p=0.004; p0071 knockdown, 72.1% residual TEER, p=0.005) (see 
Figure 5.13b).  As the correct formation of tight junctions is required to cause a trans-
epithelial resistance, the results suggested a defect in tight junctional formation when 
FLCN or p0071 is knocked down. 
To test the possible cause of the TEER results, the cells were stained for Claudin-1 (an 
inter-cellular tight junction component) and ZO-1 (a tight junctional component located 
on the cytoplasmic surface of intercellular tight junctions).  Claudin-1 staining was 
reduced and disordered in both FLCN and p0071 knockdown cells, however no 
abnormality was detected for either knockdown in the staining pattern of ZO-1 (see 
Figure 5.14).  It is known that the formation of tight junctions is dependent on the correct 
formation of adherens junctions, located just below the tight junctions in cell-cell 
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contacts, so we proceeded to test whether the adherens junction protein E Cadherin was 
located correctly in the FLCN and p0071 knockdowns.  E-Cadherin staining was 
similarly reduced and disordered in both FLCN and p0071 knockdown cells (see Figure 
5.14).   
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Figure 5.13 TEER of cells with FLCN and p0071 
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Figure 5.14 Staining for junctional proteins in IMCD-3 cells treated with FLCN and 
p0071 siRNA 
Cell junctional defects in mIMCD-3 cells with reduced FLCN or p0071.  Cells were 
seeded onto transwell supports to induce cell polarisation. 
(Figure 5.13) (A) Knockdown of FLCN and p0071 was confirmed by quantitative real-
time PCR.  (B)  There is a significantly reduced trans-epithelial electrical resistance in 
cells depleted of FLCN or p0071 at day 8 (p<0.005). Experiments were carried out in 
triplicate and significance tested by independent Student’s T test.  Error bars represent 
standard deviation 
(Figure 5.14) There is a reduced expression of both E-Cadherin and Claudin-1 at cell 
junctions in cells treated with FLCN or p0071 siRNA, however ZO-1 staining appears 
normal.   
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5.5 Discussion 
In order to reveal novel insights into the tumour suppressive mechanisms of folliculin, a 
yeast-2-hybrid screen was undertaken, and plakophilin 4 (p0071) identified as a potential 
folliculin interacting protein.  Given the reported functions of p0071 in cancer related 
functions such as cell junctional maintenance and regulation of RhoA signalling, this 
appeared an interesting interaction to investigate further. 
After confirming the interaction between p0071 and folliculin by co-immunoprecipitation 
analyses, the cellular context of the interaction was defined by immunofluorescence 
analysis.  When both proteins were overexpressed, a co-localisation was clearly observed 
at cell-cell contacts and at the midbody of cells undergoing late mitosis.  The same 
pattern was observed by staining the endogenous proteins in a number of cell types. 
To determine if folliculin and p0071 were indeed interacting at these regions of co-
localisation, bimolecular fluorescence complementation analysis (BiFC) was undertaken.  
BiFC analysis enables direct visualisation of the interaction between folliculin and p0071 
in living cells.  Both folliculin and p0071 were fused to separate halves of yellow 
fluorescent protein (YFP) and co-expressed in Hela cells.  BiFC analysis displayed 
concentrated signal at cell junctions in the interphase cell and at the midbody between 
dividing cells in late telophase/cytokinesis.  BiFC also appeared to show interaction 
(albeit less strong) at certain points within the cytoplasm.  Co-localisation was also 
observed in the cytoplasm in cells in which both p0071 and folliculin had been 
overexpressed.  The cytoplasmic function of p0071 is yet to be elucidated, and thus this 
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represents a potentially significant finding.  However, due to the lack of obvious co-
localisation observed at endogenous levels, it is currently unclear whether these regions 
of interaction may be only apparent when both proteins are overexpressed and thus 
requires further investigation. 
Previous to this study, few studies had investigated the intracellular localisation of 
folliculin.  While folliculin had not previously been linked to the cell junctions, p0071 
and folliculin were found to co-localise and interact at cell-cell contacts.  Loss of cell 
polarity and cell-cell adhesion is a frequent feature of epithelial cancers, linked to both 
tissue invasion and metastasis and also can occur early in tumourigenesis (Tervonen, et 
al., 2011).  Cancer cell lines often harbour mutations and epigenetic changes which can 
disrupt epithelial polarity, thus the IMCD-3 mouse normal kidney cell line was used in 
this study.  These cells are widely used to investigate the physiology of epithelial 
polarisation and are easily polarised by culture on transwell supports.     
Knockdown of FLCN expression in IMCD-3 cells was associated with a significant 
reduction in trans-epithelial electrical resistance (TEER) at day 8, indicating the incorrect 
formation of tight junctions.  This effect was phenocopied by knockdown of p0071, 
suggesting a function role for the interaction between folliculin and p0071 at cell 
junctions.  Consistent with these results, both FLCN and p0071 depleted cells displayed 
reduced expression and disordered patterns of Claudin-1 tight junction staining.  p0071 
binds classical cadherins through its armadillo repeat region, and is known to regulate 
cadherin stability (Hatzfeld, 2005).  As the adhesive activity of E-cadherin is required for 
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the assembly of tight junctions, it was possible that the disruption of Claudin-1 staining 
might be a result of abnormal E-cadherin localisation.  Both FLCN and p0071 depleted 
cells also showed a reduced and abnormal pattern of E-cadherin staining, thus suggesting 
both folliculin and p0071 together are required for the maintenance of adherens junctions.  
This could be an important finding as loss of E-cadherin is frequently observed in 
epithelial cancers and is part of the epithelial to mesenchymal transition cascade which is 
a crucial process in a  tumours progression to metastasis in certain cancers (Moreno-
Bueno, et al., 2008).  Moreover, the major clear cell RCC tumour suppressor gene, VHL, 
is associated with downregulation of E-cadherin expression (Evans, et al., 2007).   
The maintenance of epithelial polarity requires the specific targeting of proteins to the 
apical and basolateral membrane domains (Nelson, 2003).  p0071 contains a PDZ 
domain, placing it in a family of proteins which are implicated in establishing epithelial 
cell polarity (Hatzfeld, 2005).  It is therefore not entirely unexpected that knockdown of 
p0071 induced cell polarity defects.  Folliculin deficiency causes similar defects in cell 
polarity, even in the presence of p0071, thus suggesting the functional importance of the 
folliculin/p0071 interaction in establishing cell polarity.   
As well as interacting at cell-cell contacts, folliculin and p0071 were also found to 
interact at the midzone of mitotic cells.  Disordered cytokinesis is a frequent feature of 
human cancers and RhoA and its regulators have been demonstrated to be critical for 
normal cytokinesis (Piekny, et al., 2005).  The small GTPase RhoA functions as a 
molecular switch in a diverse range of cellular processed including cell adhesion, cell 
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cycle progression and migration (see section 5.1.3).  p0071 has been previously shown to 
regulate RhoA at the midzone, through a direct association with Ect2 (a Rho guanine-
nucleotide exchange factor essential for cytokinesis) (Wolf, et al., 2006).  The results 
presented in this chapter show that, in addition to folliculin co-localising with p0071 at 
the midzone, folliculin deficiency was associated with deregulation of Rho signalling and 
cytokinesis defects with significantly increased numbers of multinucleated cells.  
However, the effects of folliculin status on RhoA activation were studied in cells of 
mixed cell cycle stage.  This therefore suggests the possibility that folliculin impinges 
upon RhoA signalling also in the interphase cell.  Efforts to determine the effect of 
folliculin deficiency on RhoA specifically in mitotic cells was unsuccessful due to 
difficulties in synchronising the isogenic cell models used in this study.  Thus dissection 
of the exact mechanism of folliculin impact on RhoA signalling in both interphase and 
dividing cells represents a potentially interesting area for future research.  
The role of RhoA in the interphase cell is to induce actin cytoskeletal stress fibres and 
facilitate cell migration at both the front edge of cells and inducing retraction at the rear 
edge (Machacek, et al., 2009; Timpson, et al., 2011).  RhoA has thus been found to be 
over-expressed in clinical cancers, being implicated in invasion and metastasis through its 
role in cell adhesion and migration (Narumiya, et al., 2009).  BHD-associated tumours 
have been previously reported to metastasise (Pavlovich, et al., 2005; Toro, et al., 2008), 
and therefore the effects of RhoA deregulation on cell migration was investigated in the 
FTC-133 isogenic FLCN cell model described previously in (Lu, et al., 2011).  Cells not 
expressing folliculin migrated significantly more quickly than those expressing folliculin.  
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To confirm this effect was due to increased RhoA signalling, folliculin null cells were 
also treated with Y-27632 to inhibit ROCK, a downstream effector of RhoA.  Treatment 
with Y-27632 significantly reduced the migratory phenotype of folliculin null cells.  
Inhibition of ROCK has been previously shown to reduce cancer cell motility in vivo 
(Wyckoff, et al., 2006) and such, these findings suggest a novel potential therapeutic 
strategy for treating metastatic BHD renal tumours with deregulated Rho signalling. 
In summary, work presented in this chapter has identified a novel folliculin binding 
partner, plakophilin 4 (p0071), and through investigation of the effects of folliculin loss 
on previously reported p0071 functions, folliculin inactivation has been linked to loss of 
epithelial polarity and normal intercellular junction formation, disordered cytokinesis and 
deregulated RhoA signalling.  It is tempting to suggest that these novel folliculin-related 
cellular pathways are directly implicated in the mechanisms of folliculin tumour 
suppressor function.  These findings also suggest novel potential therapeutic approaches 
for the treatment of cancer in BHD patients and, in view of the frequent overlap between 
the pathways implicated in familial and sporadic forms of cancer, provide new avenues of 
research for both BHD-related and sporadic kidney cancers.   
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Chapter 6 Discussion 
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6.1  Summary of thesis 
Mutations in the FLCN gene are responsible for the Birt Hogg Dubé syndrome of 
fibrofolliculomas, increased susceptibility to lung cysts, pneumothorax and RCC.  Since 
discovery of the causative gene in 2002, research has focused on elucidation of how 
mutations in FLCN compromise aspects of folliculin function and give rise to these 
manifestations.  While mutations in FLCN have now been identified in the vast majority 
of BHD kindreds, links between genotype and BHD syndrome phenotype have proved 
harder to identify.  Similarly, efforts to uncover the role of folliculin in the cell and the 
effects of folliculin loss/mutation on intracellular signaling have arguably not yet 
identified the complete spectrum of folliculin functions. 
Identification of genotype-phenotype correlations is very important in aiding the clinical 
management of “at risk” subgroups of BHD patients.  The findings in Chapter 3 of this 
thesis indicate that patients with a mutation in the mononucleotide tract in FLCN exon 11 
are at increased risk of colorectal neoplasia.  The identification of FLCN mutations at this 
region in sporadic colon cancers adds weight to the argument of an association between 
BHD syndrome and increased risk of colorectal neoplasia.  Further work is required to 
identify a functional explanation for the apparent relationship between FLCN mutations 
at this region and colorectal cancer risk.    
Investigation of the small number of non-truncating FLCN mutations which have been 
reported, aimed to provide insights into functionally important domains of folliculin.  
Results in Chapter 4 of this thesis indicate there is an evolutionarily important region 
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within folliculin, spanning codons 100-230, but that pathogenic, non-truncating FLCN 
mutations spread throughout the gene act by destabilising the protein product.  This is 
consistent with the hypothesis that pathogenic mutations in FLCN result in deficiency of 
the entire folliculin protein and that it is likely multiple facets of folliculin function must 
be compromised to result in BHD syndrome. 
0 detailed the identification of a novel folliculin interacting partner (p0071/plakophilin4) 
and the functional consequences of this interaction.  It is my opinion that it is only 
through unravelling the molecular functions of folliculin within the cell, that the potential 
for targeted therapeutics for BHD syndrome can be realised.  At the start of this project, 
the first insights into potential folliculin functions were provided by the identification of 
the association between folliculin and mTOR signalling (Baba, et al., 2006).  In more 
recent years, a number of other signalling pathways have been described which are 
affected when folliculin in inactivated.  These are described below, in the context of the 
work presented in this thesis. 
 
6.2 Recent breakthroughs in elucidating folliculin function (2008-2012) 
6.2.1 Folliculin and HIF signaling 
Hypoxia inducible factor (HIF) is a transcription factor which controls many cellular 
pathways, including energy  metabolism, angiogenesis, cell survival and proliferation, 
and metastasis (Semenza, 2004).  Under normal conditions, HIF only becomes functional 
when tissues become starved of oxygen.  However, HIF is also central to the tumour 
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formation of renal cancers with tumours from patients with VHL and FH mutations 
displaying higher levels HIF-mediated signaling (see introduction 1.2.2.3) (Isaacs, et al., 
2005; Kaelin, 2005).  Folliculin has also been implicated in regulating HIF signaling in a 
study by (Preston, et al., 2011).  Absence of folliculin in UOK257 cells caused 
upregulation of HIF activity, and increased transcription of HIF target genes.   The 
authors demonstrated that due to the high levels of HIF-mediated gene expression in 
folliculin null cells, the cells display an altered metabolic phenotype, reflecting a 
“Warburg effect”, in which the cells favour glycolytic rather than lipid metabolism 
(Preston, et al., 2011).  This is an interesting finding as there has been some success 
previously in developing targeted therapeutics against HIF targets in VHL disease (see 
introduction), and provides evidence that altered metabolic function may be driving BHD 
tumours.  However the molecular mechanisms by which folliculin influences HIF activity 
are yet to be elucidated.  In agreement with this hypothesis, (Klomp, et al., 2010) found 
BHD tumours to show high expression of mitochondria and oxidative phosphorylation 
associated genes, indicative of mitochondrial dysfunction. 
 
6.2.2 Folliculin and TGF-β signaling     
Transforming growth factor-β (TGF-β) is a cytokine which inhibits cell growth and 
displays apoptotic functions, and thus loss of these effects is often observed in clinical 
cancers.  Interestingly, tumour cells that have lost the growth constraints applied by TGF-
β can then later over-produce it to drive metastatic behavior (Siegel and Massague, 
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2003).  The TGF-β signalling pathway functions by TGF-β binding to its receptors on the 
cell surface and inducing a phosphorylation cascade resulting in the modulation of 
transcription of TGF-β target genes in the nucleus.  Using gene expression microarrays 
on UOK239 (folliculin null) and folliculin re-expressing cells, (Hong, et al., 2010) 
identified several critical genes involved in TGF-β signalling to be differentially 
expressed in the two cell types and also in BHD-associated renal tumours.  The link 
between folliculin and TGF-β was extended by experiments from Cash et al., who 
demonstrated that folliculin deficient cells exhibit defects in apoptosis correlating with 
loss of the pro-apoptotic protein Bim.  This resulted from reduced Bim transcription 
associated with the general loss of TGF-β mediated transcription (Cash, et al., 2011). 
Thus it appears folliulin is also impinging upon TGF-β signalling, however just as with 
the folliculin/HIF relationship, the molecular mechanisms of this impact are unclear.             
 
6.2.3 Further investigations of folliculin and mTOR 
As described in the introduction to this thesis, folliculin has been previously reported to 
interact with AMPK, mediated by interaction with FNIP1 and FNIP2 and is thus involved 
in mTOR signaling (Baba, et al., 2006; Hasumi, et al., 2008).  However in the four years 
since starting the research presented in this thesis, a number of studies have reported 
contradictory impacts of folliculin on mTOR signaling.  In agreement with the research 
of Takagi et al. (which identified FNIP2 as a folliculin interacting protein), a study by 
Hartman et al. showed knockdown of FLCN by siRNA in a human cancer cell line to 
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downregulate signalling through mTORC1 (Hartman, et al., 2009)(Takagi, et al., 2008).  
This is in direct contrast to the earlier publications which reported the binding of 
folliculin to FNIP1, that suggested folliculin loss induced mTORC1 upregulation (Baba, 
et al., 2008; Baba, et al., 2006).  Hartman et al. also observed reduction of p-S6R 
(indicating a reduction in mTORC1 signaling) in the renal cysts of mice that were bred as 
heterozygous knockouts for FLCN.  These findings were in direct contrast to the 
homozygous knockout mice developed by Baba et al. and Chen et al. who reported 
mTOR upregulation in their mouse models.  However another heterozygous knockout 
mouse for folliculin was reported by Hasumi et al.  which similarly displayed activation 
of mTOR signaling in its kidney tumours (Hasumi, et al., 2009)(Baba, et al.,2008; Chen, 
et al., 2008).   
The reasons for these discrepancies are unclear, but a number of explanations have been 
put forward.  It is possible that, in vivo, mTOR activation is not a primary consequence of 
folliculin inactivation, but rather due to activation of kinases upstream of mTOR, for 
example ERK, Akt and Rsk1 (all reported as upregulated in the kidneys of KSP-Cre 
driven inactivation of folliculin by Baba et al. (2008)).  This might also go some way to 
explaining why mTOR signaling appeared lowered in the tumours of the heterozygote 
FLCN mice described by Hartman et al., which represented early lesions, as such kinases 
might only be activated later in tumourigenesis. 
In possible agreement with this hypothesis, a recent study by Hudon et al, demonstrated 
that loss of folliculin expression in their heterozygote FLCN knockout mouse resulted in 
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both upregulation and down regulation of mTORC1 signaling in large polycystic renal 
cysts and smaller single cysts respectively (Hudon, et al., 2010).   
It appears clear that that the impact of loss of folliculin in renal cysts/tumours is more 
complex than affecting the mTORC1 pathway alone, and is likely to be context 
dependent.  In agreement with the findings of Hudon et al, I also found no repeatable 
effects of folliculin re-expression in cell culture (using folliculin null FTC-133 cells) on 
either mTORC1 or mTORC2 signaling.  Neither were there effects associated with the 
expression of a range of pathogenic mutant folliculin proteins (Chapter 4). 
 
6.2.4 Folliculin interacts with p0071 – implications for further research             
In light of these findings, and the failure to identify reliable effects of FLCN mutation on 
the mTOR signaling pathway, further possible folliculin functions were investigated by 
identification of a novel folliculin binding partner plakophilin 4 (p0071).  Folliculin and 
p0071 interact at both cell junctions and at the midzone during late mitosis, and 
deficiency of folliculin impacts upon a number of previously reported functions of p0071.  
Folliulin loss, across a number of cell lines, resulted in dysregulation of RhoA signaling, 
disordered mitosis, cell polarization and junctional formation.  This represents a 
potentially important finding for the field as p0071 is only the third folliculin binding 
partner identified.  Furthermore, these novel, folliculin-related cellular pathways have the 
potential to be directly implicated in the mechanisms of folliculin tumour suppressor 
function. 
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The molecular link for the phenotypes observed through the interaction of folliculin with 
p0071, opens up a new avenue of research for the BHD field.  It is clear that folliculin is 
required for p0071 to carry out its normal functions, however the mechanism by which 
folliculin affects p0071 function is less clear.  Folliculin deficiency induced no reliable 
impact on the cellular levels of p0071, but it remains possible that folliculin is somehow 
working synergistically with p0071.  The molecular basis of this potential synergy 
remains unknown.    
It is currently unclear how folliculin is affecting RhoA signalling, although it appears to 
be at both the level of transcription and activation.  p0071 was reported to affect RhoA 
signalling at the midbody by binding to, and influencing the activity of the Rho guanine 
exchange factor (GEF) Ect2 (Wolf, et al., 2006).  However, the RhoA activation assays 
and cell migration assays presented in this thesis suggest folliculin is affecting RhoA 
activity also in the interphase cell.  In the first instance, it is important to dissect the 
effects of folliculin knockdown on RhoA activity at each stage of the cell cycle, and then  
investigate how folliculin may be affecting RhoA (by influencing a Rho GEF, GAP or 
GDI perhaps).  It is becoming increasingly clear that the dynamics of RhoA activities are 
tightly regulated and highly complex, and that the traditional methods of observing 
activation of Rho GTPases observe only a snap shot of GTP-loading states, while missing 
the dynamic changes in activation which occur in the time-scale of seconds (Spiering and 
Hodgson, 2011).  It is now becoming possible to detect the activity of Rho GTPases in 
living cells using fluorescent biosensors (for review see (Spiering and Hodgson, 2011)).  
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It is possible that by utilising new technologies such as these, the control of RhoA 
activity by folliculin can be more comprehensively dissected.    
The stable knockdown of folliculin in the ACHN line is far from optimal, and such 
induces only a 30% increase in RhoA signalling (compared to ~130% increase in the 
FTC-133 null cells compared with folliculin re-expressers).  The ACHN cells (kindly 
donated by Professor Arnim Pause, McGill University, Montreal) are derived from a 
cancer cell and display multinucleation even in the scrambled control.  To determine 
whether the induction of multinucleation that was observed in the FTC-133 cell model is 
reliant on folliculin loss alone or if the phenotype requires the background of other 
alterations present in a cancer cell, it is crucial to develop optimal folliculin knockdowns 
in normal cells. 
The data presented in this thesis shows folliculin to localise to cell contacts and that both 
folliculin and p0071 together are required for the correct induction of cell junctions in 
polarised IMCD3 cells.  The reduced levels and disordered pattern of E-cadherin and 
Claudin-1 staining in both p0071 and folliculin deficient cells demonstrate a functional 
role for folliculin at the cell junction.  It is tempting to suggest that disruption of E-
Cadherin when folliculin is deficient might relate to the increased metastatic potential of 
BHD tumour cells described in previous reports (Claessens, et al., 2010a; Pavlovich, et 
al., 2005; Toro, et al., 2008).  VHL loss has been previously linked to epithelial to 
mesenchymal transition (EMT), largely dependent on HIF-α induced NF-kappaB 
(Pantuck, et al., 2010), and it thus should be investigated whether folliculin loss also 
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affects other proteins involved in EMT, and through which pathways it might be exerting 
its effect.  Such pathways would represent novel therapeutic targets for BHD renal 
tumours.     
Folliculin null FTC-133 cells display a more migratory phenotype compared to those re-
expressing folliculin.  I have demonstrated a potential therapeutic impact of treating 
folliculin null cells with a ROCK inhibitor, rescuing this phenotype.  It would be 
intriguing to investigate the effects of folliculin and/or p0071 loss in an in vivo mouse 
model, testing Rho pathway inhibition on the metastatic potential of tumour cells which 
develop.  However there is currently no reported evidence of metastasis in any of the 
BHD mouse models described to date.  Rho inhibitors are not currently in clinical trials 
for treating cancer; however they are currently being researched in mouse models as a 
proof-of-principle (For Example the Rho inhibitor RhostatinTM and ROCK inhibitor 
BA-1049 (BioAxone)).  In addition, Fasudil (the only clinically available inhibitor of 
ROCK at present) demonstrates no severe side effects when administered to patients with 
acute ischemic stroke or stable effort angina, thus highlighting the possiblility of safely 
using ROCK inhibition as a cancer therapy in humans (Kubo, et al., 2008).       
  
6.3 Conclusions 
Identifying the molecular mechanisms by which folliculin exerts its tumour suppressor 
function has proved a challenging task, particularly due to the lack of sequence homology 
between folliculin and any other known protein.  This thesis extends the knowledge of 
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the functions of folliculin in a number of interesting areas, with the next step for the field 
being the identification of the precise biochemical functions for this protein, and the 
mechanisms by which is exerts its reported functions.  
In my opinion, these next steps in BHD syndrome research should be to identify and 
investigate all potential interacting partners and to search for possible patterns in the 
cellular effects, which might link these interactions.  This may provide a clue as to the 
molecular function of the folliculin protein.  Also, it is hoped that ongoing work to 
identify the crystal structure of folliculin might provide important insights into the 
biochemical function of this protein within the cell. 
Familial cancer syndromes have not provided an attractive target for large-scale drug 
development programs due to their rare nature; however developments in genomic 
technologies in the last decade have provided an opportunity for exerting a real impact on 
the management and treatment of these patients.  This can be achieved through a 
concerted effort of clinicians, geneticists and functional biologists.  Clinical studies 
provide the proper definitions of the syndrome phenotype, which is crucial for informing 
clinical management and providing better surveillance of affected families. In the case of 
BHD syndrome where tumours are generally slow developing, this could arguably have 
singly the greatest impact on reducing BHD mortality.  These studies also provide the 
framework for genetic modelling studies (as described in Chapter 4) by identifying 
causative mutations, which can provide important insights into how certain genotypes 
relate to BHD syndrome phenotype, with the potential for the results to directly feed back 
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into the clinic.  Also, the availability of next generation sequencing and whole genome 
array studies on tumour material has the promise to define the crucial factors driving 
tumour progression at the genetic level.  The extension of genetic studies into molecular 
biological investigations that provide functional explanations of how the folliculin 
tumour suppressor exerts its effects and thus how FLCN mutations cause increased risk 
of cancer, make up another crucial facet of BHD syndrome research.  It is by 
understanding the cellular functions of the folliculin protein that a real idea of the factors 
causing this syndrome can be developed, with the hope that they will provide 
opportunities for treatment with already available therapeutics.  A good example of this is 
that since the identification of mTOR dysregulation in follciulin deficient cells by Baba et 
al. 2006 and Chen et al. 2008, a clinical trial is currently underway investigating the 
possible effects of rapamycin application on fibrofolliculoma development.  Over the 
next decade, it is a realistic hope that information obtained from functional studies will 
also translate back into the clinic, to the benefit of BHD syndrome patients. 
We are currently at a very interesting period of time in the history of research into cancer.  
With previously unforeseen technologies, now within the financial grasp of the vast 
majority of laboratories, the data pooled from next generation sequencing projects will 
give ever increasing insight into the landscape of the cancer genome in the next decade.  
It is my opinion that despite such technical advance, it is only through identifying and 
understanding the cellular pathways which are disrupted in the development of cancer 
that the enormous power of next generation technologies can really impact upon cancer 
treatment.  Once the mutations identified in these deep sequencing studies can be linked 
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to deregulation of a specific cellular function/s, the potential for true personalised therapy 
can be realised. 
A key component of these investigations will lie in the identification of the driving 
factors of tumours caused by inherited mutations within the germline.  Research into rare 
syndromes provides us with not only the syndrome-associated factors driving 
tumourigenesis, but can also inform research into sporadic forms of the disease, as 
exemplified by the disruption of VHL associated pathways in a large proportion of 
sporadic kidney cancers.  The findings presented in this thesis provide a number of 
insights into the pathogenesis of the clinical manifestations of Birt Hogg Dubé syndrome, 
but also contribute a small but novel impact upon the general mechanisms of renal 
tumourigenesis, which has the potential to prove relevant to the wider cancer field. 
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7.1 Plasmid Maps 
 
 
Figure 7.1 p.Flag-CMV plasmid map 
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Figure 7.2 p.IRES2-AcGFP1 plasmid map 
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Figure 7.3 p.Ven1-flag-C plasmid map 
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Figure 7.4 p.Ven1-flag-N plasmid map 
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Figure 7.5 p.Ven2-HA-N plasmid map 
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Figure 7.6 p.Ven2-HA-C plasmid map 
 
 
 [230] 
 
7.2 Site-directed mutagenesis primers 
 
Mutation Primer sequence F Primer sequence R Tm 
Phe157del CAGCCACACCTTCATCAAGGACAGCC GGCTGTCCTTGATGAAGGTGTGGCTG 79.3 
Val400IIe CCCGTGGGCTGCATCCGCATCATCCC GGGATGATGCGGATGCAGCCCACGGG 80.1 
Lys508del CCTCGTCTGCCTCGAGGAGTGGATG CATCCACTCCTCGAGGCAGACGAGG 80.9 
Glu510del GTCTGCCTCAAGGAGTGGATGAACAAAGTG CACTTTGTTCATCCACTCCTTGAGGCAGAC 79.5 
His429ProfsX27 CACGTGCAGATCCCCCCCCCACGTGCTCTC GAGAGCACGTGGGGGGGGGATCTGCACGTG 87.0 
Ala204X GATGAGCTCCAGGGCAAGTAGCTCAAGGTGTTTGAGGC GCCTCAAACACCTTGAGCTACTTGCCCTGGAGCTCATC 81.3 
Arg362Cys GGGTGCCCCTTCTTTCTGCATGCTGGCCTGGC GCCAGGCCAGCATGCAGAAAGAAGGGGCACCC 84.5 
His255Pro GTGGGCGTGCCTGCCCACCTCCTTTGCC GGCAAAGGAGGTGGGCAGGCACGCCCAC 82.5 
Table 7.1 Site-directed mutagenesis primers 
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